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1. OVERVIEW 
 
“Catalysis lies at the heart of modern synthetic chemistry: 90% of all commercial chemicals are 
produced by methods that involve at least one catalytic step.”[1]  
 
Those words from Q.-L. Zhou point out that, over the last 30 years, the development of metal-
catalyzed cross-coupling reactions has revolutionized the way carbon-carbon and carbon-
heteroatom bonds are formed. These methods have deeply changed the protocols for the synthesis 
of natural products[2], building blocks for supramolecular chemistry[3] and self-assembly, organic 
materials and polymers, as well as for lead compounds in medicinal chemistry[4] from simpler 
entities.[5] 
 
In particular, the platinum-group metals — ruthenium, rhodium, palladium, osmium, iridium and 
platinum — are extensively used as catalysts in industries that produce compounds such as 
agrochemicals, dyes or pharmaceuticals.[6] But as demand for these relatively scarce metals 
increases, their future availability is a cause for concern.[7] 
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2. PALLADIUM- AND NICKEL-CATALYZED CROSS-COUPLING AND AMINATION 
REACTIONS 
2.1 PALLADIUM- AND NICKEL-CATALYZED CROSS-COUPLING REACTIONS 
 
After decades of intensive research, transition metal-catalyzed cross-coupling reactions are 
nowadays playing a crucial role in organic synthesis.[8] Among them, the very general and selective 
palladium-catalyzed Stille (involving organotin reagents) and Suzuki (involving boronic acids or 
esters) cross-coupling reactions have been particularly popular. Other cross-couplings, using 
different metal species have been developed, offering chemists new methods to achieve C-C bond 
formations. For instance, the palladium-catalyzed Hiyama (organosilicon reagents), Sonogashira (in 
situ copper acetylides), or the palladium- or nickel-catalyzed Negishi (organozinc reagents), and 
Kumada reaction (organomagnesium reagents) have proven to be highly valuable tools in organic 
chemistry (Scheme 1).[9a, 5, 9b] Last but not least, the palladium-catalyzed Heck cross-coupling allows 
the reaction of an organohalide with an alkene, leading to substituted olefins.[10] 
 
 
Scheme 1: Representative palladium- and nickel-catalyzed cross-coupling reactions. 
 
These palladium- or nickel-catalyzed cross-coupling reactions have the characteristic to share a 
common mechanism pathway (Scheme 2). The first step usually involves the in situ reduction of the 
catalyst precursor M1(II)L4 to the reactive species M
1(0)L2. This step is followed by an oxidative 
addition to the C-X bond of the electrophile R2X, affording the cis palladium complex. Subsequent 
transmetalation of the trans isomer followed by reductive elimination of the cis isomer, provides the 
   A. INTRODUCTION 
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cross-coupling product R1-R2, and regenerates the active catalyst M1(0)L2. Alternatively, M(0) 
complexes, such as Pd(PPh3)4 or Ni(COD)2 can also be used. In this case, no preliminary reduction is 
required. Among the factors influencing the catalysis efficiency, the nature of the ligand L plays an 
essential role. For instance, electron-rich ligands facilitate the oxidative addition step, whereas 
electron-poor ligands enhance both the transmetalation and the reductive elimination steps. Thus, 
when the determining-rate step is the oxidative addition (aryl chlorides used as electrophiles for 
example), electron-rich ligands are more advantageous and enhance the reaction rate.[5]  
 
 
Scheme 2: Catalytic cycle of the palladium- and nickel-catalyzed cross-coupling reactions. 
 
The most important and elegant application of cross-coupling reactions is probably the synthesis of 
pharmaceuticals.[11]  
An interesting application is the well-designed total synthesis of the anti-tumor antibiotic 
(±)-streptonigrin by Donohoe via the use of different metal-catalyzed couplings as key reactions 
(Scheme 3).[12] After few steps including a challenging ring-closure metathesis, the desired 
pentafunctionalized pyridine could be coupled with the stannylquinoline within a Stille cross-
coupling, providing the B-C core of the desired product in 77% yield.[13] Thereafter, Suzuki reaction 
with activation of the bromine substituent provided the C-D bond formation leading to the 
tetracyclic compound in 74% yield.  
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Scheme 3: Key steps in the synthesis of (±)-streptonigrin. 
 
2.2 PALLADIUM-CATALYZED AMINATION REACTIONS 
 
Syntheses of amino-substituted heterocycles are of the utmost importance for pharmaceutical and 
agrochemical industry due to their high biological activity.[14] These molecules are generally prepared 
by nucleophilic aromatic substitution[15] but transition metal catalysts for aminations have also been 
intensively studied.[16]  
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During the 1980s, few preliminary results suggested that a general metal-catalyzed method to form 
arylamines from aryl halides could be feasible. In 1983, Migita et al. performed the coupling of aryl 
bromides with tin amides in the presence of a palladium catalyst.[17] Treatment of bromobenzene 
with an amino-tin compound in the presence of a palladium catalyst provided N,N-diethyl-aniline  
(Scheme 4).  
 
 
Scheme 4: First Pd-catalyzed aryl amination using tributyltin amides. 
 
In 1995, the groups of Buchwald[18a, 18b, 14c, 18c] and Hartwig[19] independently realized a tremendous 
improvement by using free amines. Both groups reported the palladium-catalyzed amination of aryl 
bromides derivatives with secondary amines using a base, such as NaOt-Bu or LiHMDS, affording the 
tertiary arylamines in good to excellent yields (Scheme 5).[20] 
 
 
Scheme 5: Palladium-catalyzed aryl amination of aryl bromides with secondary amines. 
 
Since then, they have revolutionized this field by developing new classes of ligands and highly active 
palladium catalysts. Indeed, fine tuning of the ligand has shown the biggest effect and led to two 
main and complementary classes of ligands: bulky biaryl monophosphine ligands and chelating 
bisphosphine ligands, such as X-Phos and John-Phos or the Josiphos-type ligand CyPF-t-Bu (Figure 1). 
 
 
Figure 1: Phosphine ligands for palladium-catalyzed amination reactions. 
 
This new Pd-catalyzed C-N coupling reaction is known today as the Buchwald-Hartwig amination.[21] 
It now allows a broad range of amination reactions of aryl halides and sulfonates in combination not 
only with amines, but also with hydrazines, amides, imines, nitrogen-containing heterocycles or 
ammonia (Scheme 6).[22a, 22b, 18b, 22c, 14d] 
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Scheme 6: Palladium-catalyzed amination reactions. 
 
Apart from academic interests, the Buchwald-Hartwig amination reaction is also in focus of industrial 
chemists, since it fulfills the different requirements of modern synthetic methods by its versatility, its 
reliability and its applicability both on small and large scale syntheses.[16c, 18b] As an illustration, 
scientists from GlaxoSmithKline used palladium acetate in combination with JohnPhos as a ligand in 
order to couple cyclopentylamine with the 8-chloroimidazopyridine derivative. This led to the 
production of novel imidazo[1,2-a]pyridines, which have demonstrated potent activity against the 
herpes virus (Scheme 7).[23] 
 
 
Scheme 7: GSK synthesis of an anti-herpes agent. 
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On the other hand, nickel-catalyzed amination reactions have received less attention. Buchwald has 
reported the amination of aryl chlorides in the presence of Ni(COD)2 and DPFF  
(1,1'-bis(diphenylphosphino)ferrocene) or 1,10-phenanthroline.[24] This methodology was extended 
by using a heterogeneous Ni(0)/C catalyst[25] or employing 2,2’-bipyridine[26] or N-heterocyclic 
carbenes (NHC)[27] as ligands. However, these reactions required high amounts of nickel catalysts (5-
10 mol%) and either unstable or expensive Ni(0) sources like Ni(COD)2 or Ni(II)-precursors and 
reducing agents like NaH or MeMgBr were required, which are incompatible with several functional 
groups. 
 
Blackwood, Buchwald and Hartwig have reported a detailed mechanistic study of the amination of 
aryl halides in the presence of palladium complexes.[28]  
Like most Pd-catalyzed reactions, the Buchwald-Hartwig amination requires a Pd(0) or Pd(II) 
precursor, a ligand to increase the electron density at the metal center, which facilitates the 
oxidative addition step, a base to deprotonate the amine substrate, and a suitable solvent. Notably, 
in situ palladium systems are used, but as user-friendly alternative, isolated and mostly air-stable 
palladium complexes are also used. Whereas Pd2(dba)3 or Pd(dba)2 serve as Pd(0) source, Pd(OAc)2 is 
the most versatile Pd(II) source in addition to [η3-C3H5PdCl]2 or Pd(acac)2. Unfortunately, the most 
commonly available PdCl2 is only rarely used.
[29]  
The first step is the oxidative insertion of the electrophile R1X to the active metal(0) complex, prior to 
the amine addition. The base-assisted ligand exchange of the [RML2X]-complex with the amine 
follows. Reductive elimination of the resulting amido-complex provides the desired amine, and 
regenerates the active M(0)-complex. If M(+2)-salts are used, the active M(0)-complex has to be 
generated via reduction from the M(+2)-precursor M(II)L4 (Scheme 8).
[30] 
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Scheme 8: Buchwald-Hartwig amination mechanistic studies. 
 
For the corresponding nickel-catalyzed amination reaction no detailed mechanistic studies have 
been reported so far, although a similar mechanism is presumed.[27, 31] 
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3. IRON-CATALYZED CROSS-COUPLING AND AMINATION REACTIONS OF 
AROMATICS AND HETEROAROMATICS 
 
Although, palladium- and nickel-catalyzed cross-couplings have by far the largest synthetic scope, 
alternative cross-coupling methods have to be considered.[32] Indeed, with an average price of 
18.5 k€/kg,[33] palladium is the bull of any synthesis employing it, especially in the context of 
manufacturing on larger scales. On the other hand, even though cheaper (8.0 €/kg),[33] the use of 
nickel-catalyzed processes is tainted by various toxicity aspects undesired for consumer goods and 
healthcare products.[34] Furthermore, both palladium and nickel catalyst systems usually require the 
addition of structurally complex and costly ligands of high molecular weight. These practical issues 
have to be taken into account for industrial applications. 
 
Iron-salts represent ideal alternative precatalysts. Firstly, iron being the most abundant metal in the 
universe and the second-most abundant metal in the earth´s crust, no supply issue should occur, 
such as in the case of palladium complexes. Moreover, iron is the most abundant transition metal in 
the human body (4 g/person) and it is an essential metal in the life cycle of all living organisms. This 
factor actually represents a big advantage for using iron catalysts in health-care related chemistry, 
since no severe toxicity and side effects are existing.   
The environmentally friendly properties and low price (0.04 €/kg)[33] make iron a catalyst of the 
future and therefore provide ample motivation for further developments in the field of iron-
catalyzed cross-coupling. 
 
3.1 IRON-CATALYZED CROSS-COUPLING REACTIONS OF AROMATIC AND HETEROAROMATIC 
ELECTROPHILES 
 
Although the pioneer work of Kochi et al. reporting the first iron-based catalyst for cross-coupling 
reactions appeared already in 1971,[35] which is within a year of the initial reports using palladium 
and nickel, the progress towards a practical and general protocol for iron-catalyzed cross couplings 
has not been as rapid as for the development of analogous palladium and nickel-based 
methodologies. This progress has been partly weakened by a lack of mechanistic understanding for 
these reactions.[32c] 
However, with the central contributions of Cahiez’s, Nakamura’s and Fürstner’s research groups, 
attention has returned to the use of iron for cross-coupling reactions between alkyl, alkenyl, alkylnyl 
and (hetero)aryl Grignard reagents with alkyl,[36] alkenyl,[37]  alkylnyl[37am, 38] and (hetero)aryl halides, 
triflates, tosylates, sulfones, and phosphates. This rebirth is partly due to the emergence of detailed 
mechanistic studies aiming the understanding these processes.[39, 36c, 37ai, 32c] 
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3.1.1 Substrate scope generalities 
 
Additionally to its environmentally friendly properties, iron catalysts presents a large application 
scope, which is complementary to those of Pd- and Ni-species. Indeed, a wide range of chlorinated 
electrophiles, as well as a broad variety of alkyl halides, react well within an iron-mediated Kumada-
type cross-coupling, areas in which palladium catalysis shows limitations. 
 
In 2002, Fürstner et al. studied the relative cross-coupling rates of aromatic chlorides, bromides and 
iodides with Grignard reagents.[40] Iron-catalyzed cross-coupling reactions proved to proceed at best 
with chlorinated aryl electrophile, and led to the least amount of the reduced electrophile side-
product (Scheme 9). In the case of bromo- and iodobenzoate, the cross-coupling of 
n-hexylmagnesium bromide led to respectively 46 and 50% GC yields of the reduced byproduct, 
whereas only 27 and 38% of the desired alkylated coupling product was obtained. On the other 
hand, methyl-4-chlorobenzoate reacted in virtually quantitative yield in only a few minutes to yield 
the coupled product, which was obtained in 91% yield after purification. Additionally, the 
corresponding triflate and tosylate reacted similarly affording the desired product in respectively 87 
and 83% yields. 
 
 
Scheme 9: Comparison of aromatic halides, triflate and tosylate in iron-catalyzed cross-couplings. 
 
Functional group tolerance of iron-catalyzed cross-coupling reactions is quite broad. Indeed, 
organomagnesium reagents proved to undergo the desired cross-coupling faster than they reacted 
with other electrophilic sites present in the substrate. A wide range of electrophiles bearing ketones, 
aldehydes, esters, ethers, nonaflates, nitriles or trialkylsilyloxy groups were successfully coupled  
(Scheme 10).[41] This very interesting compatibility showed by versatile iron-mediated couplings is 
very important for synthetic utility, making this methodology useful for more complex products, such 
as natural products.  
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Scheme 10: Fe(acac)3-catalyzed cross-coupling of functionalized aryl Grignard reagents. 
 
Different iron-catalyzed cross-coupling reactions of aromatics and heteroaromatics will be further 
discussed by the type of nucleophiles used.  
 
3.1.2 Iron-catalyzed cross-coupling of aromatics and heterocycles with alkyl metal 
nucleophiles 
 
In the field of iron-catalyzed cross-couplings of aryl electrophiles with alkyl metal nucleophiles, 
Pridgen et al. realized pioneer experiments in 1989 (Scheme 11).[42] Ortho-halobenzaldimines were 
be successfully coupled, and the corresponding substituted imines were obtained in good yield. 
 
 
Scheme 11: Coupling of halobenzylidene cyclohexylamine with alkyl Grignard reagent. 
 
Fürstner et al. developed later general conditions for cross-coupling reactions of alkyl metal species 
with various aromatic and heteroaromatic halides, triflates and tosylates (Scheme 12).[43a, 43b, 39c, 43c] 
Noteworthily, alkylmagnesium substrates containing alkene or alkyne moieties could be successfully 
engaged in such a process. 
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Scheme 12: Iron-catalyzed aryl-alkyl cross-coupling reactions. 
 
3.1.3 Iron-catalyzed cross-coupling of aromatics and heteroaromatics with aryl metal 
nucleophiles 
 
Additionally, the use of aryl metal species with aryl electrophiles was also explored.  
 
In 2002, Fürstner et al. reported the first iron-catalyzed unsymmetrical biaryl formation. Under  
5 mol% Fe(acac)3 catalysis, a wide range of heteroaromatic halides were successfully coupled with 
various (hetero)aryl organomagnesium reagents (Scheme 13).[43b]  At -30 °C in THF, only 10 min 
reaction time was required for this ligand-free procedure, showing the high activity of the iron 
catalyst. However, 2.3 equivalents of Grignard reagent proved to be necessary. This high excess was 
necessary due to the formation of large amounts of homo-coupling side-product.  
 
 
Scheme 13: Iron-catalyzed heteroaryl-(hetero)aryl cross-coupling. 
 
Supporting the involvement of reduced ferrate species in the mechanism, Knochel et al. described in 
2003 the use of iron powder for the cross-coupling of 2-chloroquinoline with phenylmagnesium 
bromide (Scheme 14).[44] 
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Scheme 14: 2-chloroquinoline cross-coupling catalyzed by iron powder. 
 
Knochel et al. further studied Fe-catalyzed aryl-aryl cross-coupling reactions. The undesired homo-
coupling byproduct formation could be suppressed by using organocopper reagents resulting from 
the transmetallation of Grignard reagents (Scheme 15). This relatively mild cross-coupling proceeded 
at best with aryl iodides in the presence of Fe(acac)3 in THF/DME at 80 °C and showed a broad 
functional group tolerance.[45] 
 
 
Scheme 15: Iron-catalyzed cross-coupling reactions of organocopper reagents with aryl iodides. 
 
Another major discovery in iron-catalyzed cross-coupling was made by Nakamura et al. in 2007, 
describing a novel catalytic system for the hetero-biaryl coupling based on FeF3·3H2O and SIPr·HCl  
(1,3-bis-(2,6-diisopropylphenyl)-4,5-dihydroimidazolium chloride).[46] The iron salt, while treated with 
the NHC ligand and EtMgBr led to the active iron species, which proved to be critical for high 
selectivities. The (hetero)aromatic halides and the aryl Grignard reagents were then added to this 
reaction mixture and stirred at 60-120 °C for 24 h. The desired biaryl coupling products were 
obtained in high yields with negligible traces of homo-coupling side-product (Scheme 16). 
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Scheme 16: Biraryl cross-coupling usind FeF3/NHC as catalytic system. 
 
As a conclusion, various reaction conditions could be set up and a wide range of organomagnesium, 
organozinc and organomanganese reagents react with aryl and heteroaryl chlorides, triflates and 
tosylates (Scheme 17).[47a, 37d, 43a, 43b, 47b, 44, 47c-e, 45a, 47f, 47g, 46a, 45b] Unlike aryl chlorides, the corresponding 
bromides and iodides were prone to reduction of the C-X bonds. The wide substrate scope involved 
functionalized aromatic compounds bearing ether, sulfonate, nitrile, or heterocycle substituents. 
 
 
Scheme 17: Non exhaustive reaction conditions for the iron-catalyzed cross-coupling reaction of (hetero)aryl 
electrophiles with (hetero)aryl metal nucleophiles. 
 
Even though the scope of iron-catalyzed aryl-aryl cross-coupling reactions was considerably 
extended through the work of Fürstner,[43a, 43b, 39c, 43c, 48] Figadère,[47b] Plé,[47c] Knochel,[44-45] Cahiez,[37p, 
44, 47d, 47g] Nakamura[46] and co-workers, it is worth noting that these cross-coupling reactions present 
a bigger challenge in respect to the corresponding alkyl-aryl, alkyl-alkenyl, aryl-alkenyl or alkynyl 
cross-coupling reactions that are now well documented. The obstacle to overcome is generally the 
insufficient catalytic activity of the iron-catalyst, as well as the formation of undesired homo-
coupling side-reaction of the organometallic species.[47a, 37d, 47e, 47d, 47f, 49a, 47g, 49b, 49c] 
 
3.1.4 Iron-catalyzed Suzuki and Sonogashira cross-coupling reactions of aromatics 
 
Interestingly, iron-catalyzed Suzuki and Sonogashira cross-coupling reactions are at their infancy. 
 
On the one hand, Young et al. developed the first iron-catalyzed liquid-phase Suzuki cross-coupling 
of aryl halides and aryl boronic acids under high pressure and in the presence of  
2-(diphenylphosphino)pyridine (DPPY) as ligand (Scheme 18).[50]  
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Scheme 18: Iron-catalyzed Suzuki-Miyaura at high pressure. 
 
On the other hand, Bolm et al. showed the use of iron-catalysts in the coupling of various terminal 
alkynes with various electron-withdrawing and -donating aryl iodides. The desired arylacetylenes 
were obtained in good yields under iron(III) chloride-catalysis in combination with N,N’-dimethyl-
ethylenediamine (DMEDA) as ligand (Scheme 19).[51] 
 
 
Scheme 19: Iron-catalyzed arylation of terminal alkynes. 
 
3.1.5 Use of iron-catalysis in total synthesis 
 
Due to the versatility of these iron-catalyzed cross-coupling procedures, they are nowadays more 
and more applied in the total synthesis of natural products. For instance, the highly regioselective 
and efficient aryl-alkyl cross-coupling methodology developed by Fürstner and co-workers could be 
highlighted by the synthesis of (R)-(+)-Muscopyridine, a natural alkaloid (Scheme 20).[52] The key 
steps in this synthesis exploited the higher reactivity of triflates over chlorides in Fe-catalyzed aryl-
alkyl cross-coupling reactions. In the first step, the difunctional 6-chloropyridin-2-yl 
trifluoromethanesulfonate was reacted with the appropriate vinyl Grignard reagent to yield 
predominantly mono-coupling product and the dicoupled product in a ratio of 4:1. This reaction 
mixture was reacted with a second Grignard reagent to obtain the crude product of the decoupled 
pyridine precursor in 80% yield. Finally, ring closing metathesis followed by hydrogenation furnished 
(R)-(+)-Muscopyridine. 
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Scheme 20: Key steps in the synthesis of (R)-(+)-Muscopyridine. 
 
3.2 IRON-CATALYZED AMINATION REACTIONS OF (HETERO)AROMATIC ELECTROPHILES WITH 
NITROGEN-NUCLEOPHILES 
 
The metal-catalyzed reaction of a nitrogen-nucleophile and an aryl or heteroaryl halide, commonly 
known as N-arylation, is recognized as one of the most powerful means for the C-N bond formation 
due to the industrial value of the resulting substituted aromatics and heterocycles. 
 
Early attempts of iron-catalyzed C-N bond formation relied on a co-catalysis of iron and copper 
salts.[53]  
 
In 2006, Wakharkar et al. described the N-arylation of amines with iodo- and bromoarenes using Cu-
Fe-hydrotalcite as catalyst (Scheme 21).[54] A series of arylamines bearing electron-withdrawing and  
-donating groups were obtained in very good yields under theses simple reaction conditions. The 
main advantages of this methodology are that no expensive catalyst or ligand is required, as well as 
any use of base or amine in excess. 
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Scheme 21: Cu-Fe-hydrotalcite-catalyzed N-arylation. 
 
Few months later, the group of Taillefer reported the iron-copper cooperative catalysis for the  
N-arylation of several heterocycles with aryl halides (Scheme 22).[55] The combination of 10 mol% 
copper(I) oxide and 30 mol% Fe(acac)3 catalyzed the arylation of pyrazole, imidazole, pyrrole, 
triazoles, indole and pyrrolidinone with electron-deficient and -rich aryl iodides and bromides. 
Activated aryl chlorides compounds reacted at higher temperatures (140 °C). A solvent-free 
alternative methodology was developed by Li and co-workers.[56] 
 
 
Scheme 22: Fe/Co co-catalyzed N-arylation of heterocycles. 
 
The major drawback of the previously described methodologies is the requirement of a copper salt 
as second metal source for the catalysis.  
In 2007, Bolm et al. described the first iron-catalyzed N-arylation.[57] Aryl bromides and iodides 
reacted well with N-nucleophiles using iron(III) chloride in combination with DMEDA as catalytic 
system. This versatile protocol not only allowed the use of N-heterocycles, but could also be 
extended to other nitrogen nucleophiles such as primary amides[58] and sulfoximine derivatives 
(Scheme 23).[59] Unfortunately, the authors showed that the use of ultrapure FeCl3 (>99.99%) led to 
only traces of the coupling products. Addition of 5 ppm CuO restored the yields obtained with the 
original iron catalyst. This indicates that copper is in fact playing a crucial role in this catalysis and 
that copper impurities are necessary for the arylation to proceed. 
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Scheme 23: Iron(III) chloride-catalyzed N-arylation. 
 
Rao introduced the use of a recyclable heterogeneous graphite-supported iron catalyst for the  
N-arylation of aromatic amines, benzamide, thiobenzamide, pyrazole, imidazole, benzimidazole, and 
indole with aryl iodides and bromides (Scheme 24).[60] The developed catalyst could be recycled and 
reused at least five times without notable decrease of efficiency. 
 
 
Scheme 24: Graphite-supported iron-catalyzed N-arylation. 
 
In 2009, Teo and Kwong reported the N-arylation of pyrazole in aqueous medium (Scheme 25).[61] 
Pyrazoles, indole, 7-azaindole, and benzamide reacted well with aryl iodides under Teo’s developed 
reaction conditions and the N-arylated nucleophiles were obtained in moderate to high yields. While 
Teo uses a combination of FeCl3 and DMEDA, Kwong treated the same heterocycles with FeCl3 and  
N,N’-dimethylcyclohexane-1,2-diamine (L). The yields in the desired N-arylated heteroarenes are 
comparatively higher with the second method. 
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Scheme 25: Teo’s and Kwong’s iron-catalyzed N-arylation methodologies in aqueous conditions. 
 
Furthermore, a co-catalysis methodology using iron(III) oxide and copper(I) iodide in a solution of 
aqueous ammonia in ethanol was developed by Darcel et al. in 2009.[62] This ligand-free N-arylation 
of aryl iodides with anilines required the use of sodium hydroxide as base (Scheme 26). 
 
 
Scheme 26: Fe2O3/CuI-catalyzed N-arylation. 
 
Not only diaryl- but also triarylamines could be synthesized by iron-catalyzed N-arylation. In 2012, 
Nakamura et al. reported the amination of aryl and heteroaryl bromides with magnesium amides 
under iron(II) chloride catalysis (Scheme 27).[63] The triarylamines were obtained in high yields, in the 
presence of lithium bromide in xylene at 140 °C. Investigations with stoichiometric amounts of the 
newly synthesized iron(II) diamide complex and DFT calculations enabled the authors to propose a 
non-conventional Fe(II)-Fe(IV) mechanism for this reaction. 
 
 
Scheme 27: Iron-catalyzed aromatic amination for nonsymmetrical triarylamine synthesis. 
 
A direct iron-catalyzed coupling of aryl- and alkylamines, as well as N-heterocycles with aryl halides 
has been described by Liu et al. in 2008 (Scheme 28).[64] Under the catalysis of Fe2O3 and L-proline as 
ligand, a wide range of amines was successfully arylated, mainly with aryl iodides. A microwave-
assisted alternative procedure was also developed by the authors. The reaction times were 
shortened but the use of Cu(acac)2 as co-catalyst proved to be necessary.
[65] 
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Scheme 28: Fe2O3-catalyzed N-arylation using L-proline as ligand. 
 
In 2007, Li et al. reported the use of aryl- and vinyl(trimethoxy)silanes as coupling partner in the 
iron(III) chloride/copper-catalyzed arylation of imidazoles and triazoles (Scheme 29).[56] 
 
 
Scheme 29: Solvent-free copper/iron co-catalyzed N-arylation reactions of nitrogen-containing heterocycles 
with trimethoxysilanes in air. 
 
As a conclusion, starting with an iron/copper cooperative catalysis, few iron-catalyzed N-arylation 
methodologies have been developed since 2006. However, these results are tainted by further 
experiments performed by Buchwald and Bolm in 2009.[66] They could show that the “iron-catalyzed” 
C-X/N-H coupling reactions of pyrazole, benzamide and (thio)phenol were in fact triggered by copper 
impurities. While using ultrapure FeCl3 (>99.99%), the yields of those N-arylations dropped 
drastically. The addition of trace amounts of Cu2O (5-10 ppm) restored the original yields, showing 
the decisive role of copper salts in this catalysis. One should then keep this observation in mind for 
many iron-catalyzed aminations, since not all new developed methodologies have been tested using 
copper-free iron salts. 
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4. COBALT-CATALYZED CROSS-COUPLING AND AMINATION REACTIONS OF 
AROMATICS AND HETEROAROMATICS 
 
Although there have been striking breakthroughs in the development of iron catalysts for the 
formation of C-C and C-N bonds, cobalt salts have to be truly considered as an alternative to costly 
palladium and toxic nickel salts. Cobalt is not only relatively cheap (20.7 €/kg),[55] it also shows in 
some cases a higher reactivity than the corresponding iron-catalyzed cross-coupling reactions. 
 
4.1 COBALT-CATALYZED CROSS-COUPLING REACTIONS OF AROMATIC AND HETEROAROMATIC 
ELECTROPHILES 
 
Since the pioneering work of Kharasch and Fields on the metal-catalyzed homo-coupling reaction of 
aromatic Grignard reagents,[47a] cobalt-catalyzed cross-coupling reactions have received  growing 
attention.  
 
4.1.1 Cobalt-catalyzed cross-coupling of aromatics and heterocycles with aryl metal 
nucleophiles 
 
The first cobalt-mediated cross-coupling reaction was reported by Gilman and Lichtenwalter in 
1939.[67] Nearly quantitative yields of homo-coupling product were obtained by treating aromatic 
organomagnesium reagents with stoichiometric amount of cobalt halides. In 1941, Kharasch et al. 
developed the first cobalt-catalyzed symmetrical aryl-aryl homo-coupling, using 2.5 mol% of CoCl2 
and a stoichiometric amount of oxidant, allowing the oxidation of the reduced cobalt(0) species into 
the active Co(II) complex after reductive elimination (Scheme 30).[47a] 
 
 
Scheme 30: First cobalt-catalyzed aryl-aryl cross-coupling. 
 
One had to wait four decades to see the development of the first unsymmetrical cobalt-catalyzed 
biaryl formation by Uemura et al. (Scheme 31).[68] Diaryltellurides could be moderately coupled with 
aromatic Grignard reagents under 5 mol% CoCl2(PPh3)2 catalysis. However, because of the formation 
of a significant amount of homo-coupling side product, the purification of the desired unsymmetrical 
product proved to be difficult. 
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Scheme 31: Cobalt-catalyzed cross-coupling of organotellurides. 
 
In 2003, a collaborative work between the groups of Knochel and Cahiez led to the publication of an 
efficient cobalt-catalyzed cross-coupling methodology between activated heteroaryl chlorides with 
(hetero)aryl Grignard reagents (Scheme 32).[44] Even though 2 equivalents of organomagnesium 
reagents were necessary, the desired coupling products were obtained in excellent yields. Steric 
hindrance did not show any big influence in these reactions conditions, since Grignard reagents such 
as mesitylmagnesium bromide could also react well. Interestingly, the authors could demonstrate 
the use of cobalt powder as catalyst for particular cases (Scheme 33). Furthermore, Oshima et al. 
reported a similar but alternative protocol using cobalt(II) acatylacetonate in diethylether one year 
later.[69] 
 
 
Scheme 32: Cobalt-catalyzed cross-couplings of heteroaryl chlorides and (hetero)aryl Grignard reagents. 
 
 
Scheme 33: Cobalt powder-mediated heteroaryl-aryl cross-coupling reaction. 
 
Moreover, Knochel et al. described the cobalt-catalyzed cross-coupling of aryl- and 
heteroarylcyanocuprates with various halogenated aromatic carbonyls (Scheme 34). Ortho-bromo, 
chloro, fluoro and tosyl aromatic ketones, esters and aldehydes reacted well under these reaction 
conditions, and a wide range of polyfunctional biaryls were obtained in high yields. The use of 
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1 equivalent tetrabutylammonium iodide and 20 mol% 4-fluorostyrene, as well as 3 equivalents 
organocuprate proved to be essential for the reaction with the halide. Interestingly, the use of a 
THF/DME/DMPU mixture instead of THF as solvent greatly decreased the reaction time (15 min 
instead of 21 h). It is also worth to note that meta- and para-aromatic halides showed only moderate 
conversion due to the position of the activating carbonyl group.[70] 
 
 
Scheme 34: Co-catalyzed cross-coupling of cyanocuprates with (hetero)aryl halides. 
 
In parallel with the development of the corresponding iron-catalyzed cross-coupling, Nakamura et al. 
reported in 2009 the alternative cobalt-catalyzed cross-coupling of heroaromatic halides and non-
activated aryl halides with aryl Grignard reagent (Scheme 35).[46b] The catalytic system was based on 
the use of FeF3·3H2O and SIPr·HCl (1,3-bis-(2,6-diisopropylphenyl)-4,5-dihydroimidazolium chloride). 
Interestingly, the two described methodologies seem complementary, since better results were 
obtained with aromatic iodides and bromides under Co-catalysis, whereas higher yields were 
obtained with aromatic chlorides under FeF3-catalysis. 
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Scheme 35: Co-catalyzed cross-coupling between non-activated (hetero)aryl halides and aryl Grignard 
reagent. 
 
A cobalt/titanium co-catalysis was reported by Duan et al. in 2013, enabling the cross-coupling of 
aryl halides not only with aryl Grignard reagents, but also with aromatic organolithium compounds  
(Scheme 36).[71] The use of 0.4 equivalents Ti(OEt)4 proved to have a beneficial effect, since no homo-
coupling byproduct was formed from the organometallic reagent. This methodology showed a wide 
functional group tolerance as carboxylic acid, alcohol or amide could be present on the electrophile. 
 
 
Scheme 36: Co/Ti cooperative catalysis towards the synthesis of biaryls. 
 
4.1.2 Cobalt-catalyzed cross-coupling of aromatics and heterocycles with alkyl metal 
nucleophiles 
 
The first example of cobalt-catalyzed cross-coupling of heteroaromatics with alkyl metal nucleophile 
was reported by Hey et al. in 1969.[72] He discovered that the reaction between 2-bromopyridine and 
methylmagnesium iodide could be dramatically improved by the presence of catalytic amounts of 
cobalt(II) chloride (Scheme 37). However, these reaction conditions were not very general, since low 
yields were obtained in other cases. 
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Scheme 37: First cobalt-catalyzed cross-coupling of heterocycles with alkyl Grignard reagents. 
 
Until today, the only efficient cobalt-catalyzed cross-coupling methodology between aryl halides and 
aliphatic Grignard reagents has been developed by Oshima et al. in 2008 (Scheme 38).[73] This very 
interesting alternative to the corresponding palladium and nickel protocols used aromatic bromides 
as electrophiles with primary alkyl Grignard reagents. The desired biaryls are obtained in good to 
excellent yield, exploiting CoCl2 and the NHC IMes·HCl as catalytic system, and in the presence of 
N,N,N’,N’-tetramethyl-1,3-propadiamine (TMPDA).  
 
 
Scheme 38: Cobalt-catalyzed aryl-alkyl cross-coupling reactions. 
 
4.2 COBALT-CATALYZED AMINATION REACTIONS OF (HETERO)AROMATIC ELECTROPHILES 
WITH NITROGEN-NUCLEOPHILES 
 
The field of cobalt-catalyzed amination reaction, as an alternative to the Pd-catalyzed Buchwald-
Hartwig amination, is nowadays at its infancy. 
 
The very first report of cobalt-catalyzed N-arylation was published by Teo et al. in 2009 (Scheme 39). 
This cross-coupling of nitrogen heterocycles with electrophilic aryl iodides was performed under 
10 mol% CoCl2 catalysis used in combination with 20 mol% of the chelating 
N,N’-dimethylethylenediamine (DMEDA), and in the presence of 2 equivalents K3PO4 as base. It is 
worth to note that these N-arylations proceeded in water and without the need for any other 
reducing agent or electrochemical methods.[74] 
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Scheme 39: Cobalt-catalyzed N-arylation of N-nucleophiles in water. 
 
Teo et al. further extended this methodology to the use of both aliphatic and aryl amides with a wide 
range of aryl and heteroaryl iodides (Scheme 40).[75] Contrary to the previously described method, 
the amide-coupling required Co(C2O4) as catalyst instead of CoCl2. The amine ligand DMEDA has 
remained but the preferred base was in this case Cs2CO3. Good to excellent yields in the desired 
substituted amides were obtained under those aqueous conditions. Moreover, they could 
successfully apply this protocol to the synthesis of prostate anticancer drug flutamide and 
derivatives. 
 
 
Scheme 40: Cobalt-catalyzed amination of aryl iodides by aliphatic and aryl amides in water. 
 
In 2009, Toma et al. reported the cobalt(II) chloride-catalyzed amination of secondary amines with  
N-aromatic 2-chlorides (Scheme 41).[76] Using potassium carbonate as base and 1,3-bis(diphenyl- 
phosphanyl)propane (DPPP) as ligand, this cobalt-catalyzed approach led to the desired tertiary 
amines in high yields. These N-aromatic-containing tertiary amines should be of interest for further 
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use as building blocks for bioactive molecules. 
 
Scheme 41: Cobalt-catalyzed C-N bond forming reaction between N-aromatic 2-chlorides and secondary 
amines. 
 
One year later, a new methodology for the preparation of nitro-substituted tertiary amines was 
described by these authors under similar reaction conditions (Scheme 42).[77] The combination of 
CoCl2 and the phosphane ligand DPPP was maintained, as well as the use of p-xylene at 140 °C. 
However, the authors preferred exploiting KHCO3 as base, which showed better results than the 
previously used K2CO3. Interestingly, these N-arylations were completely ortho- and para-selective, 
since meta-substituted halides showed to be unreactive in these reaction conditions. An analog 
methodology was developed by Chatterjee et al. using alumina-supported cobalt(II) bromide.[78] 
 
 
Scheme 42: Cobalt-catalyzed C-N bond forming reaction between chloronitrobenzenes and secondary 
amines. 
 
Finally, an intramolecular Co-catalyzed amination protocol was reported towards the synthesis of 
substituted benzimidazoles (Scheme 43). A combination of Co(acac)2·2H2O and 1,10-phenanthroline 
proved to catalyze the cyclization of (Z)-N’-(2-halophenyl)-N-phenylamidines in the presence of 
K2CO3 at 110 °C. This simple and air-stable methodology furnished the desired benzimidazoles in high 
yields.[79] 
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Scheme 43: Cobalt-catalyzed intramolecular amination towards the synthesis of substituted benzimidazoles. 
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5. CHROMIUM-CATALYZED TRANSFORMATIONS 
 
Even though chromium ranks among the most abundant elements on earth,[80] chromium-catalyzed 
transformations remain under-developed compared to other transition-metal catalysts, such as 
palladium, nickel, iron or cobalt salts. 
 
In 1919, Hein et al. pioneered the field by preparing the first organochromium reagent. The 
treatment of chromium(III) chloride with phenyl Grignard led to the formation of a 
bis(arene)chromium species.[81] It took not less than four decades to finally clarify the correct 
structure of this complex.[82] 
 
In 1977, Nozaki and Hiyama and co-workers reported the first carbonyl addition of allyl halides by 
means of chromous salt.[83] The authors, in parallel of Kishi’s independent work, improved the 
synthesis of (homo)allylic alcohols in 1986 by discovering that traces of nickel salts enhance the 
catalytic effect on the formation of the C-Cr(III) bond.[84] This finding led to the development of the 
so-called Nozaki-Hiyama-Kishi reaction,[85] especially useful for less reactive substrates, such as 
alkenyl and aryl halides or triflates, in Barbier-type addition reactions (Scheme 44). This standard 
tool using stoichiometric or excess amounts of chromium salts has found many applications and 
various coupling reactions were published.[86] 
 
 
Scheme 44: Chromium-mediated and nickel-catalyzed Nozaki-Hiyama-Kishi reaction. 
 
A significant progress in this chromium-mediated methodology was done by Fürstner et al.  in 1996, 
who reported the use of catalytic quantities of chromium salt.[87] The developed catalytic system 
involved 7-15 mol% of chromium(II) or (III) chloride doped with nickel(II) chloride and manganese 
powder as stoichiometric reductive agent. Chlorosilane served as essential additive for ligand 
exchange, helping the dissociation of the product from the chromium (Scheme 45). It was noted that 
other chromium salts such as Cp2Cr or CpCrCl2THF could be used as well as precatalyst. 
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Scheme 45: Chromium-catalyzed Nozaki-Hiyama-Kishi reaction. 
 
The mechanism of the chromium(II)-catalyzed Nozaki-Hiyama-Kishi, in contrary to its nickel(II)-
mediated analogue, relies on both the use of Mn(0) and a chlorosilane (Scheme 46). First, the 
proposed catalytic cycle starts with the reaction of two equivalents CrY2 with the organic halide. Cr
+2 
being a one-electron donor, 2 equivalents of complex are necessary for the formation of the 
organochromium complex R1CrX2 and CrX2Y. R
1CrX2 adds then to the carbonyl, forming the chromium 
alkoxide. The high stability of the O-Cr+3 bond hampering the formation of the (homo)allylic alcohol, 
the necessary chlorosilane realizes the ligand exchange with the chromium alkoxide, leading to the 
desired alcohol after deprotection. A second equivalent of CrX2Y is then released and reduced by 
manganese(0), enabling its further re-use in the catalytic cycle. 
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Scheme 46: Mechanism of the chromium-catalyzed Nozaki-Hiyama-Kishi reaction. 
 
The development of further chromium-catalyzed processes needed to wait till 2007. Oshima et al. 
described the arylmagnesiation of unfunctionalized alkynes in the presence of pivalic acid and 
catalytic amounts of chromium(III) chloride (Scheme 47).[88] The alkenylmagnesium intremediates 
reacted with various electrophiles, leading to the desired tetrasubstituted olefins in good yields and 
high cis-stereoselectivity. 
 
 
Scheme 47: Chromium-catalyzed arylmagnesiation of alkynes. 
 
Since the development of the first organochromium reagent, chromium catalysis has attracted high 
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interest. Various useful chromium-mediated synthetic methods have been developed, such as the 
Takai-Uchimoto olefination,[89] ethylene oligomerization[90] and polymerization,[91] alcohol and 
carbonyl oxidation,[92] aldol[93] and Diels-Alder[94] reactions. These common tools in organic chemistry 
generally show good functional group compatibility and high selectivity, and are of widespread use in 
total synthesis as key steps for the preparation of sophisticated natural products.  
As an illustration, one can for instance cite the use of the Nozaki-Hiyama-Kishi reaction as key 
macrocyclisation in the total synthesis of cytotoxic cembranolide uprolide F diacetate (UFD) 
performed by Tong and co-workers (Scheme 48).[95] 
 
 
Scheme 48: Enantioselective total synthesis of Uprolide F acetate using Nozaki-Hiyama-Kishi 
macrocyclization. 
 
Despite these achievements, chromium-catalyzed organic reactions still remain underdeveloped in 
comparison to other transition metal catalysts, and considerable more effort should be dedicated to 
discover new transformations and broaden the reaction scope of this field. Until now, no chromium-
catalyzed cross-coupling methodology has been described yet. This possible expansion of the 
chromium catalysis palette would represent an extension to the use of alternative metal salts in 
cross-coupling reactions.[96] 
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6. SYNTHESIS OF PYRIDONAPHTHYRIDINES 
 
Nitrogen heterocycles, and particularly pyridines as well as pyridine-based compounds play diverse 
roles in organic chemistry. As ligands, solvents or catalysts, they facilitate reactions; thus the 
description of new cores and applications abound each year.[97]  
Additionally, pyridine-based molecules are also used in material science, where their optical and 
physical properties are highly valued (e.g. fluorescent probe or organic solar cells). Moreover, the 
medical potential of six-membered N-heteroaromatics remains an area of intense research, as 
pyridines are frequent subunits of medicinally relevant compounds.[98, 14d] 
Among those scaffolds, not only substituted pyridines[99] but also a number of privileged ring systems 
have been extensively studied, such as quinolines,[100] isoquinolines,[101] acridines[102] or diazines. 
Annelated six-membered N-heteroaromatics bearing one nitrogen atom per ring such as 
naphthyridines[103] are much less investigated, and the corresponding triazaanthracenes[104] and 
triazaphenanthrenes[105] are almost unknown. Pyridonaphthyridines, a particular type of 
azaphenanthrenes, result from the fusion of three pyridines without any bridged nitrogen (Figure 2).  
 
 
Figure 2: Pyridonaphthyridines. 
 
The first pyridonaphthyridine synthesis was reported by Case and Brennan in 1959 (Scheme 49).[106] 
After amination of 4-chloro-1,5-naphthyridine, the key step of this synthesis was the cyclization of 4-
amino-1,5-naphthyridine in the presence of ethyl ethoxymethylenemalonate, leading to the 3-ring 
intermediate in 78% yield over 2 steps. Further decarboxylation, chlorination and reduction led to 
pyrido[3,2-c][1,5]naphthyridine in 15% overall yield in 6 synthetic steps. 
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Scheme 49: Synthesis of pyrido[3,2-c][1,5]naphthyridine by Case and Brennan. 
 
Furthermore, in 1975, Hamada et al. described the synthesis of the same regioisomer via a Skraup-
type reaction.[107] 4-Amino-1,5-naphthyridine reacted with oleum, iron(II) sulfate and boric acid in 
glycerol, using nitrobenzene as oxidizing agent. This one-step synthesis provided the desired 
pyrido[3,2-c][1,5]naphthyridine in 26% yield (Scheme 50). 
 
 
Scheme 50: Skraup-synthesis towards pyrido[3,2-c][1,5]naphthyridine. 
 
Pyrido[3,4-c][1,8]naphthyridine and pyrido[3,4-c][1,7]naphthyridine were prepared by Nutaitis and 
Brennan in 2004.[108] Condensation and subsequent reduction of 5-bromonicotinaldehyde with an 
excess of either 2- or 3-aminopyridine afforded the cyclisation precursor, which led after treatment 
with LDA at -78 °C and MnO2-mediated aromatization to the desired azaphenanthrenes in 11 and 
13% overall yield (Scheme 51). 
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Scheme 51: Formation of pyrido[3,4-c][1,8]naphthyridine and pyrido[3,4-c][1,7]naphthyridine. 
 
Moreover, Rault et al. reported the first multi-step synthesis towards the formation of 
pyridonaphthyridines including a metal-catalyzed cross-coupling step.[109] Indeed, the Pd-catalyzed 
Suzuki cross-coupling of 2-chloro-3-fluoropyridine with 3 different ortho-cyanopyridylboronic esters 
provided the required bipyridines in 60-88% yield (Scheme 52). After KOH-mediated anionic ring 
closure, pyridonaphthyridinone intermediates were obtained in 78-81% yield. Chlorodehydroxylation 
and dehalogenation furnished the final pyrido[4,3-c][1,5]naphthyridine, pyrido[3,4-c][1,5]naphthy-
ridine and pyrido[2,3-c][1,5]naphthyridine in 30-44% overall yield. 
 
 
Scheme 52: 4-Step synthesis of pyrido[4,3-c][1,5]naphthyridine, pyrido[3,4-c][1,5]naphthyridine and 
pyrido[2,3-c][1,5]naphthyridine. 
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7. OBJECTIVES 
 
With the increasing pressure to reduce energy consumption, to protect the environment, and to 
conserve natural resources, catalysis is clearly a mean towards this goal for synthetic chemists. Late 
transition-metal catalysts, particularly in cooperation with organometallic species, have become an 
indispensable tool to accomplish efficient and selective multiple syntheses. In particular, palladium- 
and nickel-catalyzed cross-couplings have been widely used for the introduction of various functional 
groups into unsaturated substances such as aromatic rings, alkenes or alkynes. However, on one 
side, the constantly increasing price of palladium complexes as well as its declining availability, and 
on the other side, the toxicological concerns linked with nickel salts, are encouraging the quest for 
alternative metals. Those metal substitutes should fit different requirements: they should be 
ecologically-friendly, readily available, as well as relatively cheap, and should show high catalytic 
activity and chemical selectivity to be applicable in both total syntheses and modern industrial 
manufacturing processes.  
 
In this context, relatively low-cost and low-toxic iron and cobalt salts are viable alternatives. Even 
though iron- and cobalt-catalyzed alkyl-aryl, alkyl-alkenyl, aryl-alkenyl, and alkynyl-coupling reactions 
are well documented, the corresponding aryl-aryl cross-coupling methodologies still need to be 
improved.  
 
Hence, the first goal of this work was to extend the scope and search for better ligands for the 
(iso)quinoline-accelerated CoCl2-catalyzed methodology for the coupling of (hetero)aryl halides and 
(hetero)aryl Grignard reagents (Scheme 53).[110] 
 
 
Scheme 53: Attempted cobalt-catalyzed cross-coupling reactions. 
 
In order to find alternative complexes for the use in Csp2-Csp2 cross-coupling reactions also other 
metals than the widely used ones like palladium should be investigated. For this reason, the 
application of Cr-salts was investigated in the C-C bond formation of (hetero)aromatics with 
(hetero)aryl magnesium reagents (Scheme 54).[111] 
 
 
Scheme 54: Attempted chromium-catalyzed cross-coupling reactions. 
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Moreover, the methodology described above should then be further extended to the replacement of 
palladium in Buchwald-Hartwig amination reactions. Hence, the Cr-catalyzed C-N bond formation 
was intensively studied.[112] 
 
Scheme 55: Attempted Cr-catalyzed Buchwald-Hartwig aminations. 
 
Due to the potential applications of N-heterocycles in medicinal chemistry and material science, the 
preparation of almost unknown annelated six-membered N-heteroaromatics was investigated. 
Attention was paid in particular to the synthesis and the functionalization of  
pyrido[3,2-f][1,7]naphthyrdine using metal-catalyzed cross-coupling and amination reactions as key 
steps (Figure 3).[113] 
 
 
Figure 3: Metal-catalyzed multi-step synthesis of pyrido[3,2-f][1,7]naphthyrdine and derivatives. 
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1. COBALT(II)-CATALYZED CROSS-COUPLING REACTIONS BETWEEN  
N-HETEROCYCLIC HALIDES AND ARYL OR HETEROARYL MAGNESIUM 
REAGENTS 
 
Knochel et al. demonstrated in 2013 the ability of quinoline and isoquinoline to act as efficient ligand 
for the iron- and cobalt-catalyzed cross-coupling of N-heteroaryl halides with aryl Grignard reagents 
(Scheme 56).[114] 
 
 
Scheme 56: Ligand-accelerated Fe- and Co-catalyzed cross-coupling reactions. 
 
The following work presents an extension of the scope of the cobalt-catalyzed cross-coupling 
methodology, as well as a study of other N-heterocycles used as potential ligands for this procedure. 
 
1.1 COBALT-CATALYZED CROSS-COUPLING REACTIONS UTILIZING ISOQUINOLINE AS LIGAND 
 
Preliminary experiments were showing that the reaction of 1-chloroisoquinoline (1a) and PhMgCl 
(2a) in presence of 3% FeBr3 took only 5 min in the solvent mixture t-BuOMe/THF, and provided the 
cross-coupling product 1-phenylisoquinoline (3a) in 90% yield. In comparison, the cross-coupling of 
2-chloropyridine (1b) required 1.5 h under the same conditions until completion and gave 
2-phenylpyridine (3b) in 82% yield (Scheme 57). The reactivity difference of these substrates led us 
to postulate that the catalytically active iron species, generated in situ, may contain an isoquinoline 
fragment as ligand.[115, 114a] A similar accelerating effect of isoquinoline (4a) was observed in  
Co-catalyzed cross-coupling reactions.  
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Scheme 57: Iron-catalyzed cross-coupling reactions of 1-chloroisoquinoline (1a) or 2-chloropyridine (1b) with 
PhMgCl (2a). 
 
The reaction scope of cobalt-catalyzed cross-coupling reactions in the presence of isoquinoline 4a as 
key ligand in the solvent mixture t-BuOMe/THF was further investigated. Various N-heterocycles 
have successfully been coupled with both aromatic and heteroaromatic Grignard reagents under 
cobalt(II) chloride catalysis. 
 
This way, 2-bromopyridine (1c) could be readily coupled with the methyl-indole magnesium reagent 
2b, providing the desired pyridine 3c in 61% isolated yield (Table 1, entry 1). TMS-substituted 
2-bromopyridine 1d underwent the Co-catalyzed coupling with the thiophene organomagnesium 
reagent 2c to furnish the respective 2,3-disubstituted bis-heteroaromatic compound 3d in 49% yield 
after 15 min at 25 °C (entry 2). The 2,3- and 2,4-disubstituted pyridines 1e and 1f reacted with 
electron-rich (2d) and -poor (2e) Grignard reagents, resulting in the corresponding 2,3- and 
2,4-bisarylated pyridines 3e and 3f in good yield (69-70% yield, entries 3 and 4). 
Also the arylated 2-bromopyrimidine 1g could be used in such cross-coupling reaction, enabling the 
access to the naphthalene-substituted pyrimidine 3g in 57% yield (entry 5). Another N-heterocycle, 
2,6-dichloroquinoline (1h), reacted with (4-fluorophenyl)magnesium bromide (2e) and provided the 
desired quinoline 3h in 63% after 15 min at 25 °C (entry 6). 
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Table 1: Room-temperature Co-catalyzed cross-coupling reactions between N-heterocyclic halides and 
arylmagnesium reagents. 
 
Entry Starting material Grignard reagent Producta 
 
 
 
 
1 1c 2b 3c: 61% 
 
  
 
2 1d 2c 3d: 49% 
 
 
 
 
3 1e 2d 3e: 69% 
 
 
 
 
4 1f 2e 3f: 70% 
 
 
 
 
5 1g 2f 3g: 57% 
 
  
 
6 1h 2e 3h: 63% 
a
Isolated yields of analytically pure product.  
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quinolines, but also the 6-position can be functionalized using cobalt(II) chloride as catalyst in 
combination with isoquinoline (4a) as ligand (Scheme 58). 6-Chloro-2-phenyl-quinoline 1i underwent 
a cross-coupling reaction with 4-fluorophenylmagnesium bromide (2e) in a moderate yield of 55%. 
Interestingly, the formation of the diarylation products from 1i was not observed (Table 1, entry 6), 
probably due to the fact that the cross-coupling at position 2 is faster than at position 6.  
 
 
Scheme 58: Co-catalyzed cross-coupling reaction between 6-chloroquinoline 1i and organomagnesium 
reagent 2e. 
 
1.2 LIGAND SCREENING FOR THE COBALT-CATALYZED CROSS-COUPLING OF CHLOROPYRIDINES 
 
During the scope investigation of this cobalt-catalyzed cross-coupling methodology, it was observed 
that the accelerating effect of isoquinoline (4a) was extremely depending on the nature of the 
substrate (Scheme 59). 
For instance, 2-chloropyridine (1b) reacted with phenylmagnesium chloride (2a) in 46% yield in the 
absence of ligand. This cross-coupling was greatly improved by addition of 10 mol% isoquinoline (4a) 
and led to the desired 2-phenylpyridine (3b) in 90% yield after 15 min at 25 °C. The catalytic activity 
of isoquinoline (4a) in the cross-coupling of 2-chloro-5-(dimethylamino)pyridine is even more 
remarkable: whereas only 19% of the desired phenylated pyridine 3j is achieved without additive, 
78% product could be isolated after 15 min by using isoquinoline (4a) as ligand. 
Interestingly, an erosion of the efficiency occurred when more electron-withdrawing substrates were 
present: 2-phenyl-5-(trifluoromethyl)pyridine 3k could only be obtained with 17% yield. 
Unfortunatelly, only an minor improvement was achieved by the use of 10 mol% isoquinoline (4a). 
This observation led to the search for a more universal ligand, which could accelerate the cobalt-
catalyzed cross-coupling reaction of substrates bearing either electron-donating or  
-withdrawing substitutents. 
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Scheme 59: Substituent effect on Co-catalyzed cross-couplings leading to pyridines 3b, 3j and 3k. 
 
The screening of various quinoline- and isoquinoline-related heterocycles, as well as other nitrogen-
containing additives was then performed systematically on the three previously discussed pyridine 
systems. The comparison of the 2-chloropyridine 1b with the electron-rich 2-chloro-5-
(dimethylamino)pyridine 1j and the electron-poor 2-chloro-5-(trifluoromethyl)pyridine 1k was 
chosen to get a better insight into the reactivity differences. 
 
The screening of various additives for the cobalt-catalyzed cross-coupling reaction of 
2-chloropyridine (1b) with phenylmagnesium chloride (2a) is shown in Table 2. A negative effect was 
observed by addition of 10 mol% pyridine (4b), 2,2’-bipyridine (4c), 1,10-phenanthroline (4d) or the 
bis-imine and bis-oxazoline compounds 4e and 4f as ligand, leading to the desired product only in 
unsatisfactory yields (28-37%, entries 1-5). Interestingly, Pybox ligand (4g), usually known for 
enhancing Ni-catalyzed cross-couplings[116] suppressed the reaction of the substrate with the 
Grignard reagent, probably due to the strong chelation of the cobalt with the ligand (entry 6). In 
contrary, a significant improvement of the reaction was detected with all quinolines and 
isoquinolines that were tested. The 8-substituted quinolines 4i and 4j (entries 8 and 9) showed a 
slight decrease of the catalytic activity in comparison with quinoline (4h, entry 7), since 65% yield of 
2-phenylpyridine (3b) was observed, whereas 71% yield was achieved with the latter one. The ligand 
of choice for this cross-coupling proved to be isoquinoline (4a) with its 90% yield (entry 10). An 
erosion of the rate enhancement occurred when the isoquinoline core was bearing electron-
donating substituents (4k, entry 11). 
 
Table 2: Screening of various additives for the Co-catalyzed cross-coupling reaction of 2-chloropyridine (1b) 
with PhMgCl (2a). 
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Entry Additive Yield (%)a Entry Additive Yield (%)a 
 
 
  
 
 
1 4b 28 7 4h 71 
 
 
  
 
 
2 4c 30 8 4i 65 
 
 
  
 
 
3 4d 29 9 4j 65 
 
 
  
 
 
4 4e 37 10 4a 90 
 
 
  
 
 
5 4f 34 11 4k 68 
 
 
  No additive  
6 4g 0 12  49 
a
Yield determined by integration of a gas chromatogram and comparison against undecane as a calibrated internal 
standard. 
 
A similar trend was observed for the cobalt-catalyzed cross-coupling of electron-rich 2-chloro-5-
(dimethylamino)pyridine (1j) with phenylmagnesium chloride (2a, Table 3). The use of 2,2’-bipyridine 
(4c), 1,10-phenanthroline (4d), the bis-imine 4e, the bis-oxazoline 4f or Pybox 4g as additive 
significantly decelerated the cross-coupling, leading to conversions up to 13% only (entries 1-5). 
Contrary to the cross-coupling of 2-chloropyridine 1b, the use of pyridine 4b as ligand showed a 
positive effect on the reaction of the pyridine 1j with the organomagnesium reagent 2a (entry 6). 
Whereas all the quinolines 4h, 4i and 4j and isoquinoline 4k showed an improvement in the desired 
product formation (27-54%, entries 7-9 and 11), only isoquinoline (4a) appeared to largely increase 
the yield of this reaction. Indeed, 80% of the pyridine 3j was formed under these reaction conditions 
(entry 10).  
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Table 3: Screening of various additives for the Co-catalyzed cross-coupling reaction of 2-chloro-5-(dimethyl-
lamino)pyridine (1j) with PhMgCl (2a). 
 
Entry Additive Yield (%)a Entry Additive Yield (%)a 
 
 
  
 
 
1 4c 9 7 4h 54 
 
 
  
 
 
2 4d 12 8 4i 32 
 
 
  
 
 
3 4e 13 9 4j 27 
 
 
  
 
 
4 4f 10 10 4a 80 
 
 
  
 
 
5 4g 1 11 4k 40 
 
 
  No additive  
6 4b 41 12  22 
a
Yield determined by integration of a gas chromatogram and comparison against undecane as a calibrated internal 
standard. 
 
Remarkably, the cross-coupling of 2-chloro-5-(trifluoromethyl)pyridine (1k) with phenylmagnesium 
chloride (2a) in the presence of 3 mol% CoCl2 showed a very different trend (Table 4). Except of the 
bis-oxazoline compound 4f (entry 5), all tested additives showed either no effect or a positive one on 
the studied reaction, compared to the corresponding cross-coupling in absence of ligand (entry 12). 
Interestingly, 2,2’-bipyridine (4c) and 1,10-phenanthroline (4d) furnished the desired product in 
respectively 64 and 52% yield (entries 3 and 4). The substituted isoquinoline 4k showed a similar 
effect on the cross-coupling reaction as isoquinoline (4a), and only 21% of the product 3k was 
observed (entries 10 and 11). Quinoline (4h) and its electron-donating substituted derivatives had a 
positive influence on the cross-coupling reaction (entries 7-9). The use of 10 mol% 
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8-dimethylaminoquinoline 4j showed an impressive rate-acceleration in this case, and 2-phenyl-5-
(trifluoromethyl)pyridine (3k) was produced in 84% yield after 15 min at 25 °C (entry 9). 
 
Table 4: Screening of various additives for the Co-catalyzed cross-coupling reaction of 2-chloro-5-
(trifluoromethyl)pyridine (1k) with PhMgCl (2a). 
 
Entry Additive Yield (%)a Entry Additive Yield (%)a 
 
 
  
 
 
1 4b 35 7 4h 59 
 
 
  
 
 
2 4c 64 8 4i 47 
 
 
  
 
 
3 4d 52 9 4j 84b 
 
 
  
 
 
4 4e 25 10 4a 22 
 
 
  
 
 
5 4f 14 11 4k 21 
 
 
  No additive  
6 4g 19 12  16 
a
Yield determined by integration of a gas chromatogram and comparison against undecane as a calibrated internal 
standard. 
b 
79% isolated yield. 
  
In conclusion, the comparison of the different ligand screenings showed that none of the tested 
additives presented a general rate-enhancement in the studied cobalt-catalyzed cross-coupling 
reactions. Indeed, in the case of 2-chloropyridine (1b, Table 2) and electron-rich 2-chloro-5-
(dimethylamino)-pyridine (1j, Table 3), the best catalytic system proved to be 3 mol% cobalt(II) 
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chloride in combination with 10 mol% isoquinoline (4a). In contrary, this ligand showed only a 
modest activity for the cross-coupling of electron-poor 2-chloro-5-(trifluoromethyl)pyridine (1k, 
Table 4) whereas electron-rich 8-dimethylaminoquinoline 4j greatly contributed to a positive 
coordination with the cobalt center and led to a high yield in the product formation. 
 
A study on the effect of 8-dimethylaminoquinoline 4j on the cobalt-catalyzed cross-coupling of 
various 2-chloropyridines bearing at least one electron-withdrawing substituent was performed 
(Table 5). Subsequently, 3-bromo-2-chloropyridine (1l) was first coupled with phenylmagnesium 
chloride (2a) under the developed conditions (entry 1). Due to the selectivity lack of this reaction, 
only 11% yield in the desired 2-arylated pyridine was observed. Better result could be achieved with  
2-chloro-3-fluoropyridine (1m), leading to 91% of the desired product. However, it is worth 
mentioning that this product was obtained in 72% yield without any ligand (entry 2). The cross-
coupling of very electron-poor 2,3-dichloro-5-(trifluoromethyl)pyridine (1n) showed the same 
problem as  
3-bromo-2-chloropyridine (1l): only 13% of the desired 2-arylated pyridine was produced by the 
unselective cross-coupling (entry 3). However, 2-chloro-3-(trifluoromethyl)pyridine (1o) was 
successfully cross-coupled in 83% yield under these reaction conditions. This shows a real 
improvement compared to the cross-coupling performed in the absence of ligand, which led only to 
9% yield, or to the 13% yield obtained if isoquinoline (4a) was used as additive (entry 4). The cobalt-
catalyzed cross-coupling reactions of both 2-chloronicotinonitrile (1p) and ethyl 2-chloronicotinate 
(1q) were unsuccessful due to the addition of the Grignard reagent respectively to the cyano and 
ester functions of the pyridine scaffold (entries 5 and 6). 
 
Table 5: Co-catalyzed 8-dimethylaminoquinoline-assisted cross-coupling reaction of electron-poor pyridines. 
 
Entry Starting material Yield (%)a 
 
 
 
1 1l 11 
 
 
 
2 1m 91b 
 
 
 
3 1n 13 
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4 1o 83c 
 
 
 
5 1p 0 
 
 
 
6 1q 0 
a
Yield determined by integration of a gas chromatogram and comparison against undecane as a calibrated internal 
standard. 
b
72% yield of the desired cross-coupling product was obtained if no ligand was added to the reaction mixture. 
c
13% product was obtained if 10 mol% isoquinoline was added instead, and 9% yield was observed if no ligand was added 
to the reaction mixture. 
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2. CHROMIUM(II)-CATALYZED CROSS-COUPLING REACTIONS BETWEEN CSP2 
CENTERS 
 
In the search for alternative metal catalysts having a suitable low toxicity, the potential use of 
chromium salts have was studied. [117a-g, 86b, 117h-l] Although CrVI is highly toxic (ORL-RAT LD50 = 50-150 
mg/kg), CrII has a much lower toxicity (ORL-RAT LD50 = 1870 mg/kg), also compared to other metals: 
ORL-RAT LD50(NiCl2) = 105 mg/kg, (PdCl2) = 2700 mg/kg, (CoCl2) = 766 mg/kg, (MnCl2) =1480 mg/kg, 
(FeCl2) = 450 mg/kg.
[118] 
 
2.1 PRELIMINARY EXPERIMENTS 
 
Preliminary experiments showed that chromium-catalyzed cross-coupling reactions between Csp2-
centers proceed quite smoothly and led to significantly lower amounts of homo-coupling side-
products compared to iron or cobalt.[119] Thus, the reaction of 2-chloropyridine (5a, 1.0 equiv) with 
PhMgCl (6a, 2.3 equiv) in THF in the presence of 3 % CrCl2 (purity 99.99%) was complete within 
15 min at 25 °C, affording the desired cross-coupling product 7a in 90% yield (Scheme 60). GC-
analysis of the crude reaction mixture indicated that less than 1% of homo-coupling product 
(biphenyl) was obtained. Performing the same reaction with 3% FeBr3 or 3% CoCl2 led to ca. 15% of 
homo-coupling product under optimized conditions.[115, 120] For all subsequent reactions, standard 
grade CrCl2 (purity 97%) was used, since no difference was observed with CrCl2 (purity 99.99%). 
Interestingly, performing the cross-coupling with 5% MnCl2 led, under optimum conditions, to only 
58% yield of 7a[121] compared to 90% yield obtained with 3% CrCl2. The performance of the cross-
coupling using CrCl3 instead of CrCl2 was also possible, although a significant yield drop was observed 
(74% instead of 90 %), therefore CrCl2 has been used for all further experiments. 
 
 
Scheme 60: Chromium-catalyzed cross-coupling between 2-chloropyridine 5a and PhMgCl 6a. 
 
A solvent screening (THF, n-hexane, toluene and t-BuOMe) indicated that THF was the optimal 
solvent. The optimization of the reaction stoichiometry showed that only a small excess of Grignard 
reagent (1.2 equiv) was required. 
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2.2 CROSS-COUPLING REACTIONS OF 2-HALOGENATED N-HETEROCYCLES WITH ARYL 
GRIGNARD REAGENTS 
 
The reaction scope of this new cross-coupling proved to be quite broad. Thus, a range of N-
heterocyclic chlorides and bromides could be readily used as electrophiles (Table 1). PhMgCl (6a) 
underwent a smooth cross-coupling with 2-bromo-3-(but-3-en-1-yl)pyridine (5b; 25 °C, 15 min), 
leading to the  
2,3-disubstituted pyridine 7b in 95% yield (entry 1 of Table 6). Interestingly, no radical cyclization 
product was observed in this cross-coupling (similar iron and cobalt cross-couplings produced 20% of 
radical cyclization product).[120]  
Both electron-rich and electron-poor Grignard reagents could be used for such cross-couplings.[122] 
Thus, the sterically hindered bromopyridine 5c reacted with 4-N,N-dimethyl-aminophenylmagnesium 
bromide (6b) within 1.5 h at 25 °C, producing the 2,3-diarylated pyridine 7c (80% yield; entry 2). 
Moreover, the electron-poor Grignard reagent 6c reacted with 2-bromo-3-chloropyridine (5d) in 
15 min at 25 °C, leading to the pyridine 7d in 76% yield (entry 3). The similar cross-coupling 
performed with 3% of FeBr3 gave only traces of product and significant amounts of homo-coupling. 
2-Chloro-5-fluoropyridine (5e) also underwent the cross-coupling reaction with the sensitive ester-
substituted Grignard reagent 6d to give the pyridine 7e in 66% yield (entry 4).  
Further N-heterocyclic halides, such as the 2-chloroquinoline (5f) and the 4-chloroquinoline 5g, 
reacted well with Grignard reagents 6e and 6b, affording the expected products 7f and 7g (74-78%; 
entries 5 and 6). In contrast, the corresponding iron-catalyzed cross-coupling with 4-chloroquinoline 
5g failed, indicating that this Cr(II)-catalyzed cross-coupling may have a broader reaction scope than 
the corresponding Fe- and Co-catalyzed cross-couplings.[115, 120] Halogenated diazenes, such as the  
2-chloropyrimidines 5h-i and the 2-chloropyrazine 5j, rapidly reacted with the magnesium 
organometallics 6f-h to provide the substituted diazenes 7h-j in 71-85% yield (entries 7-9). 
 
Table 6: Cr-catalyzed cross-coupling reactions between N-heterocyclic halides and arylmagnesium reagents 
at room-temperature. 
 
Entry Starting material Grignard reagent Producta 
 
  
 
 
1 5b 6a 7b: 95%; 15 min 
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2 5c 6b 7c: 80%; 90 min 
 
  
 
3 5d 6c 7d: 76%; 15 min 
 
  
 
4 5e 6d 7e: 66%; 15 min 
 
 
 
 
5 5f 6e 7f: 74%; 1 h 
 
 
 
 
6 5g 6b 7g: 78%; 15 min 
 
 
 
 
7 5h 6f 7h: 71%; 2 h 
 
 
 
 
8 5i 6g 7i: 85%; 15 min 
 
  
 
9 5j 6h 7j: 72%; 30 min 
a
Isolated yields of analytically pure products.  
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2.3 CROSS-COUPLING REACTIONS OF 2-HALOGENATED (HETERO)ARYL SUBSTITUTED KETONES 
WITH (HETERO)ARYL GRIGNARD REAGENTS 
 
Remarkably, 2-halogenated aromatic ketones also underwent the chromium-catalyzed cross-
coupling at room temperature within a time range of 15 min up to 2 h (Table 2).[123] Interestingly, the 
organomagnesium reagent did not attack the keto-function. Thus, 2-chlorobenzophenone (8a) 
reacted with a range of aryl- and heteroarylmagnesium reagents (6b, 6c, 6i-k) yielding the 
corresponding polyfunctional ketones 9a-e (71-94%; entries 1-5 of Table 7). 
 
Table 7: Cr-catalyzed cross-coupling reactions between 2-chlorobenzophenone (8a) and phenylmagnesium 
reagents. 
 
Entry Grignard reagent Product Time Yielda 
 
 
 
 
 
1 6i 9a 15 min 79% 
 
 
 
 
 
2b 6j 9b 2 h 71% 
 
 
 
 
 
3 6c 9c 15 min 93% 
 
 
 
 
 
4 6b 9d 15 min 94% 
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5 6k 9e 2 h 89% 
a
Isolated yields after purification by flash column chromatography. 
b
0.7 equiv of 2j was used. 
c
Reaction run at 50 °C for 2 h.  
 
Interestingly, the (2-bromophenyl)(6-chloropyridin-3-yl)-methanone (8b) reacted with the Grignard 
reagent 6a under complete regioselectivity (no chloride-substitution occurs) and furnishes the 
pyridylketone 9f in 72% yield (Scheme 61). 
Heterocyclic ketones, such as 8c, also cross-coupled well with 3-thienylmagnesium chloride 6l, 
affording the new ketone 9g in 90% yield (Scheme 61). These reactions showed a remarkable 
functional group tolerance, since ester, nitriles and ketones were compatible with this Cr-catalyzed 
cross-coupling methodology.[124] 
 
 
Scheme 61: Cr-catalyzed cross-coupling reactions between heteroaryl-substituted ketones and Grignard 
reagents. 
 
2.4 CROSS-COUPLINGS BETWEEN IMINE-PROTECTED ALDEHYDES AND ORGANOMAGNESIUM 
REAGENTS 
 
Interestingly, also the imine-protected 2-chlorobenzaldehyde 10 reacted readily under the CrCl2-
catalysis with various Grignard reagents (6a, 6h, 6l) at 25 °C. Acidic work-up provided the aldehydes 
11a-c in 69-84% yield (Scheme 62). The thiophene Grignard reagent 6l required a considerably longer 
reaction time. After 16 h, 11c was obtained in 75% yield. Thus, this cross-coupling constitutes a 
simple way for functionalizing aromatic aldehydes in ortho-position. 
S
MgBr Ph
O
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Scheme 62: Cr-catalyzed cross-coupling reactions between imine-protected aldehyde 10 and different 
Grignard reagents (6a, 6h, 6l). 
 
2.5 CROSS-COUPLING REACTIONS OF ALKENYL IODIDES WITH ARYL GRIGNARD REAGENTS 
 
Furthermore, alkenyl iodides, such as (E or Z)-12, underwent a stereoselective chromium-catalyzed 
arylation with a range of aryl Grignard reagents (6b, 6g, 6h, 6m), affording in all cases the 
functionalized styrenes 13a-e in 69-80% yield (Scheme 63). For the alkenyl iodide (E)-12, the 
reactions were completed in 15 min at 25 °C (E:Z ratio > 99:1), whereas a reaction time of 14 h was 
required for the coupling of (Z)-12 (Z:E ratio = 99:1). Since no loss of stereochemistry was observed, a 
single electron transfer mechanism implying radical intermediates could be excluded, confirming the 
results obtained with the radical clock substrate (6b, entry 1 of Table 6). 
 
 
Scheme 63: Cr-catalyzed cross-coupling reactions between alkenyl iodide (E or Z)-12 and Grignard reagents 6. 
 
2.6 REGIOSELECTIVE CROSS-COUPLING REACTIONS OF DICHLORINATED HETEROAROMATICS 
 
An effective strategy to obtain highly functionalized heteroaromatic structural motifs involves the 
use of polyhalogenated starting materials that can be subsequently functionalized. Challenges in 
product selectivity with such systems have been addressed by utilizing differentially halogenated 
rings.  
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Indeed, regioselective differentiation of a wide range of dichloropyridines, -quinolines, 
and -isoquinolines was studied in the context of biaryl coupling due to the prevalence of such motifs 
in drug discovery programs.  
 
2.6.1 Regioselective Csp2-Csp2 cross-coupling reactions between dichlorinated pyridines 
and (hetero)aryl Grignard reagents 
 
Initial work showed that the reaction of 2,4-dichloropyridine (14a) with PhMgCl (6a) via a previously 
optimized Fe-catalysis protocol[125, 114a] exclusively gave the 2-arylated product (15a) in 58% yield. In 
comparison, the chromium(II) chloride-catalyzed reaction using lower amount of 6a (1.2 instead of 
2 equiv) selectively furnished pyridine 15a in even higher yield (80%; Scheme 64) with only trace 
amounts of the homocoupled product.[126] 
 
 
Scheme 64: Cross-coupling of 2,4-dichloropyridine (14a) with PhMgCl (6a): Fe versus Cr.
 
 
Evaluation of the scope of the regioselective chromium-catalyzed cross-coupling led to the arylation 
of a range of dichloro-N-heterocycles at room temperature (Table 8). Both 2,3-dichloropyridine (14b) 
and 2,5-dichloropyridine (14c) reacted with Grignard reagent 6a within minutes to selectively form 
the 2-arylated products 15b (76% yield, entry 1) and 15c (87% yield, entry 2) respectively. Methyl 
substitution on the pyridine ring also led to high levels of selectivity. Therefore, 2,4-dichloropyridines 
14d-e reacted rapidly with 6a to afford phenylated products 15d-e in high yields (85% for 15d and 
88% for 15e, entries 3-4). The sterically more demanding and coordinating acetal-containing 2,4-
dichloropyridines 14f-g also reacted rapidly to furnish products 15f-g in 67% and 76% yield, 
respectively (entries 5-6). 
 
Table 8: Regioselective Csp
2
-Csp
2
 cross-coupling reactions between dichlorinated pyridines (14b-g) and 
PhMgCl.
a 
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Entry Grignard reagent Product Time (min) Yield 
 
  
  
1 14b 15b 15 76% 
 
  
  
2 14c 15c 15 87% 
 
  
  
3 14d 15d 15 85% 
 
  
  
4 14e 15e 15 88% 
 
  
  
5 14f 15f 30 67% 
 
  
  
6 14g 15g 30 76% 
a
Reaction conditions: PhMgCl (6a; 1.2 equiv), dichlorinated pyridine (1 equiv), CrCl2 (3 mol %) in THF at 25 °C.  
 
To further evaluate the utility of the regioselective chromium(II)-catalyzed cross-coupling reaction, 
various aromatic Grignard reagents were employed (Table 9).[127] Electron-rich Grignard reagents 
such as 3-(methoxyphenyl) magnesium bromide 6n and methylenedioxyarylmagnesium bromide 6c 
reacted with dihalogenated pyridines 14c and 14a resulting in the formation of the coupled products 
15h-i in 71-77% yield (entries 1 and 2).  Notably, complete control in site-selectivity was obtained in 
these cross-coupling reactions. Heteroaromatic nucleophile 5-magnesiated indole 6o reacted with 
2,3-dichloro-5-(trifluoromethyl)pyridine (14h) within 1 h to give the 2-arylated coupling product 15j 
in 56% yield (entry 3). Silyl-protected 3-hydroxyphenyl magnesium bromide 6g and acetal-
substituted arylmagnesium derivative 6p participated in the CrCl2-catalyzed cross-coupling reaction 
with dichlorinated pyridines 14b, 14h and 14g selectively on C2 affording the desired products in 66-
82% isolated yield (entries 4-6).  
Electron-poor Grignard reagent 4-(trifluoromethyl)phenyl magnesium bromide (6c) was particularly 
effective in the Cr-catalyzed cross-coupling reaction.  When this substrate was treated with pyridine 
14a in the presence of 3 mol% CrCl2, the formation of heterocycle 15n occurred in 92% yield (entry 
7). Chloro-substituted Grignard reagent 6q coupled with trifluoromethylated 2,3-dichloropyridine 
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14h and furnished the desired product 15o in 66% yield (entry 8).  
 
Table 9: Regioselective Csp
2
-Csp
2
 cross-coupling reactions between dichlorinated pyridines and various 
Grignard reagents.
a 
 
Entry Substrate Grignard reagent Product 
 
   
1 14c 6n 15h: 71%; 30 min 
 
 
 
 
2 14a 6c 15i: 77%; 15 min 
 
 
 
 
3b 14h 6o 15j: 56%; 1 h 
 
   
4 14b 6g 15k: 82%; 15 min 
 
  
 
5 14h 6p 15l: 71%; 15 min 
 
 
 
 
6 14g 6p 15m: 66%; 30 min 
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7 14a 6c 15n: 92%; 30 min 
 
   
8 14h 6q 15o: 66%; 30 min 
a
Reaction conditions: Grignard reagent (1.2 equiv), dichlorinated heterocycle of type 14 (1 equiv), CrCl2 (3 mol %) in THF at 
room temperature. 
b
The reaction was performed at 50 °C.  
 
The ability to conduct these experiments at room temperature is a significant advantage. Thermally 
sensitive Grignard reagents, such as those containing an ester (6i) or 4-fluorophenylmagnesium 
bromide 6r, underwent rapid cross-coupling reactions leading to trisubstituted pyridines 15p-q in 
70-79% yield (Scheme 65). It turned out that 14h was particularly reactive in Cr-catalyzed arylations 
with electron-poor aromatic Grignard reagents, such as 6i, probably due to the electron deficiency of 
this starting material. Ester 6i has previously been used in Pd-catalyzed cross-coupling reactions on 
monohalogenated systems. Therefore, this method proves to be very practical to access 
heterobiaryls that are commonly found in bioactive pharmaceuticals. 
 
 
 
Scheme 65: Regioselective Cr(II)-catalyzed cross-coupling reactions of pyridines 14h and 14f with thermally 
sensitive Grignard reagents 6i and 6r. 
 
To rationalize the site-selectivity in this Cr-catalyzed cross-coupling methodology, a mechanism 
where the nitrogen of the pyridine ring directs the attack of the low-valent phenyl-chromium 
organometallic onto the dihaloaromatic was postulated.[128] To support the notion of a directed 
delivery of the aryl nucleophile, treatment of 3,4-dichloropyridine 1i (where a ring nitrogen is not 
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proximal to the C–Cl bond) with Grignard reagent 6a in the presence of 3 mol% chromium chloride 
led to the exclusive formation of biphenyl, and no cross-coupled product was observed (Scheme 66). 
The formation of a chromium-aryl species is proposed in analogy to recent studies on the formation 
of an iron-aryl species that can oxidatively add into 2-chloropyridine.[129] Furthermore, high 
selectivity for aryl incorporation proximal to the nitrogen with various 2,4- and 2,5-dichloropyridines 
supports the hypothesis of an  
N–directed addition. 
 
 
 
Scheme 66: Evidence for N-directed site selectivity. 
 
2.6.2 Use of cyclopentyl methyl ether as solvent for the Cr(II)-catalyzed cross-coupling 
reactions of chloroquinolines and -isoquinolines 
 
Chromium-catalyzed biaryl formation on 1,3-dichloroisoquinoline 14j and 2,4-dichloroquinoline 14k 
proved to be very challenging. Although selective, the optimal conditions illustrated in  
Table 9 resulted in attenuated reactivity. Evaluation of coordinating and non-coordinating solvents 
with these fused aromatics revealed the superiority of CPME (cyclopentyl methyl ether) in the CrCl2-
catalyzed cross-coupling reaction. The desired coupling product 15r was obtained in 71% yield after 
only 1 h reaction time at room temperature, using 3 mol% of CrCl2 in CPME as solvent. The 
phenylation regioselectivity of 14j at C1 can be explained by formation of the more stable 
intermediate A that retains aromaticity. The competing arylation at C3 does not occur because of 
loss of aromaticity in intermediate B. Analogously, the regioselective coupling between quinoline 14k 
and Grignard reagent 6a afforded the desired 2-arylated quinoline 15s in 70% yield using CPME 
(Scheme 67). 
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Scheme 67: Cr(II)-catalyzed cross-coupling reactions using CPME as solvent and mechanistic aspects. 
 
Regioselective cross-coupling reactions of other chlorinated quinolines could also be improved by 
the use of CPME as solvent. 2,7-Dichloroquinoline 14l reacted well with the electron-rich Grignard 
6n, leading to the 2-substituted desired quinoline 15t in 72% yield after 2 h (Table 10, entry 1). Both 
electron-rich and -poor Grignard reagents (6e, 6b and 6q) could be successfully coupled with  
2,6-dichloro-quinoline 14m under chromium(II)-catalysis in 71-87% yield (entries 2-4). 
 
Table 10: Regioselective Csp
2
-Csp
2
 cross-coupling reactions between dichlorinated quinolines and various 
aryl Grignard reagents.
a 
 
Entry Substrate Grignard reagent Product 
 
   
1 14l 6n 15t: 72%; 2 h 
 
  
 
2 14m 6e 15u: 82%; 1 h 
  
 
 
3b 14m 6b 15v: 71%; 3 h 
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4 14m 6q 15w: 87%; 1 h 
a
Reaction conditions: Grignard reagent (1.2 equiv), dichlorinated heterocycle of type 14 (1 equiv), CrCl2 (3 mol %) in CPME 
at room temperature. 
b
The reaction was performed in THF.  
 
2.7 REMOVAL OF THE CHROMIUM CATALYST 
 
After demonstrating the wide substrate scope, the removal of the chromium salt needed to be 
investigated. Despite the low toxicity of chromium(III) picolinate,[37q] the reduction of the overall 
chromium content from the reaction mixture prior to chromatography was considered. Employing 
2,4-dichloropyridine 14a as a prototype, treatment with PhMgCl 6a in the presence of 3 mol% CrCl2, 
quenching unreacted Grignard reagent with an aqueous solution of ammonium chloride, separation 
and treatment of the organic layer using various solid supports was evaluated. Chromium 
concentration of the untreated organic layer after aqueous work-up was 34 ppm. As illustrated in 
Figure 4, several scavengers resulted in high recovery of arylated pyridine 15a with remarkably low 
levels of chromium thereby enhancing the utility of this methodology for pharmaceutical 
applications where low levels of concerning metals are crucial. 
 
 
Figure 4: Scavenger treatment to evaluate recovery and chromium levels prior to chromatography.  
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3. CHROMIUM(II)-CATALYZED AMINATION OF N-HETEROCYCLIC CHLORIDES 
WITH MAGNESIUM AMIDES  
 
With the objective of replacing cost-intensive palladium and sensitive phosphine ligands generally 
used in the Buchwald-Hartwig amination methodoly, economic, low toxic and readily available 
transition metal catalysts for amination reactions were considered.  
Therefore, a chromium(II)-catalyzed amination of N-heterocyclic chlorides with magnesium amides 
was studied, affording a range of aminated pyridines, quinolines and quinoxalines.  
 
3.1 OPTIMIZATION OF THE REACTION CONDITIONS 
 
In preliminary experiments, the transition metal-catalyzed amination of 2-chloropyridine (16a) with 
magnesium chloride pyrrolidin-1-ide (17a) was investigated. 17a was prepared by deprotonation of 
pyrrolidine (18) with i-PrMgCl in THF at 0 °C and subsequently warmed up to 23 °C over 1 h (Table 
11). The resulting magnesium amide showed a high thermic stability and a good solubility under the 
reaction conditions.  
In absence of any catalyst, only 13% of the aminated product (19a) was observed at 23 °C after 20 h 
reaction time (entry 1). However, when the Grignard reagent was prepared with an equimolar 
amount of lithium chloride as additive (by using i-PrMgCl·LiCl),[127a, 130]  the conversion was increased 
and 27% of the pyridine 19a was detected by calibrated GC analysis (entry 2).  
The use of 3% FeBr3 or 3% CoCl2 under the same conditions did not improve the amination (14–12%, 
entries 3 and 4). Interestingly, in the presence of 3% CrCl2, 19a was obtained in 72% yield, which 
could be improved to 77% by using 10% of catalyst (entries 5 and 6). Performing the latter 
experiment without lithium chloride led to the formation of noticeably less product (64%, entry 7). In 
an attempt to further accelerate the reaction, the amination was then performed at 50 °C with 10 
mol% of chromium(II) chloride. In the presence of 2.0 equivalents of LiCl, the aminated product 19a 
was isolated in 95% yield, whereas 19a was obtained in only 60% yield without additive (entries 8 
and 9). Other chromium catalysts [CrCp2,
[131] Cr(acac)3, CrBr2
[132]] led to somewhat lower yields (45–
81%, entries 10–12). Indeed, the air-stable and cheap Cr(acac)3 could be used in these aminations 
but led to either similar or, in most cases, to lower yields and/or longer reaction times. The 
mechanism of this amination method may be a result of the Lewis-acidity of Cr(II) as well as the 
higher ligand rate exchange of Cr(II)-complexes compared to Cr(III)-salts. 
 
Performing this reaction at 50 °C for three hours without catalyst in the presence of LiCl produced 
the aminated pyridine 19a in 43% yield and, without LiCl, in 27% yield, confirming the importance of 
this salt (entries 13 and 14). However, it is worth mentioning that a longer reaction time (20 h at 
50 °C) also led to full conversion. Replacing 2-chloropyridine with the corresponding 2-
bromopyridine led to slower substitution rates and incomplete conversion. 
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Table 11: Optimization of the reaction conditions.
a 
 
Entry Catalyst Amount (mol%) Additive Temp. (°C) Time (h) Yield (%)b 
1 - - - 23 20 13 
2 - - LiCl 23 20 27 
3 CoCl2 3 LiCl 23 20 14 
4 FeBr3 3 LiCl 23 20 12 
5 CrCl2 3 LiCl 23 24 72 
6 CrCl2 10 LiCl 23 20 77 
7 CrCl2 10 - 23 20 64 
8 CrCl2 10 LiCl 50 3 95 
9 CrCl2 10 - 50 3 60 
10 CrCp2 10 LiCl 50 3 45 
11 Cr(acac)3 10 LiCl 50 3 81 
12 CrBr2 10 LiCl 50 3 70 
13 - - LiCl 50 3 43 
14 - - - 50 3 27 
a
Reaction conditions: deprotonation of pyrrolidine 18 (2.0 mmol) with i-PrMgCl (with or without LiCl; 2.0 mmol) in THF at 0 
to 23 °C in 1 h. Amination of 2-chloropyridine (16a; 1.0 mmol) with the prepared magnesium amide 17a in THF at 23 or 50 
°C with or without CrCl2. 
b
Yield determined by integration of a gas chromatogram and comparison against undecane as a 
calibrated internal standard. 
 
3.2 CHROMIUM-CATALYZED AMINATION OF SUBSTITUTED 2-CHLOROPYRIDINES 
 
The reaction scope of this amination was studied by using various magnesium amides (Table 12). 
First, 2-chloropyridine (16a) underwent an amination with magnesium chloride morpholin-4-ide 
(17b) or magnesium chloride dibutylamide (17c), respectively leading to the formation of the 
aminated pyridines 19b and 19c in 75% yield after 5-12 h reaction time (entries 1-2). Substituted 
pyridines such as 2-chloro-5-methylpyridine (16b) usually reluctantly undergo amination with 
magnesium chloride pyrrolidin-1-ide (17a) and full conversion was not observed even after 3 d at 50 
°C without catalyst. In the presence of 10% CrCl2, the aminated product 19d was isolated in 96% 
after 24 h (entry 3). A selective monoamination of 2,6-dichloropyridine (16c) with magnesium 
chloride pyrrolidin-1-ide (17a) was selectively achieved after 7 h to give the pyridine 19e in 81% yield 
(entry 4). 2,4-Dichloropyridine (16d) showed complete regioselectivity for the C2 position of the 
pyridine ring. Performing this amination reaction either with magnesium chloride dibenzylamide 
(17d) or with magnesium chloride indolin-1-ide (17e) led to the corresponding aminated pyridines 
19f and 19g in 50-54% yield after 3 h (entries 5-6), showing the limits of this chromium-catalysis. 
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In the same way, 2,3-dichloropyridine (16e) underwent the desired selective amination with a range 
of aliphatic (17c), allylic (17f), benzylic (17g) and saturated heterocyclic (17b, 17h) magnesium 
amides to provide the aminated pyridines 19h-l in 71-86% yield (entries 7-11). In any case, no 
diamination product was observed in the aminations involving 16c, 16d, and 16e. 
 
Table 12: Cr(II)-catalyzed amination of the 2-chloropyridines (16a-i) with magnesium amides (17a-k).
a 
 
Entry Substrate Magnesium amideb Product 
 
  
 
1 16a 17b 19b: 75%; 12 h 
  
  
2 16a 17c 19c: 75%; 5 h 
 
   
3 16b 17a 19d: 96%; 24 h 
 
  
 
4 16c 17a 19e: 81%; 7 h 
 
 
 
 
5 16d 17d 19f: 50%; 3 h 
  
 
 
6 16d 17e 19g: 54%; 3 h 
 
   
7 16e 17c 19h: 71%; 5 h 
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8 16e 17f 19i: 82%; 5 h 
  
 
 
9 16e 17g 19j: 83%; 3 h 
  
 
 
10 16e 17b 19k: 86%; 4 h 
  
 
 
11 16e 17h 19l: 71%; 5 h 
a
Reaction conditions: CrCl2 (10 mol%), chlorinated heterocycle (16a-e, 1.0 equiv), magnesium amide (2a-h, 2.0 equiv) in THF 
at 50 °C. 
b
LiCl was omitted for clarity. 
 
3.3 CHROMIUM-CATALYZED AMINATION OF SUBSTITUTED 2-CHLOROQUINOLINES, 
1-CHLOROISOQUINOLINE AND 2,3-DICHLOROQUINOXALINE 
 
The amination of various other 2-chlorinated N-heterocycles was also examined. 2-Chloroquinoline 
(16f) was aminated with diverse saturated cyclic (17i) or heterocyclic (17b) magnesium amides, as 
well as with the magnesiated substituted benzylic amide 17j, to afford the desired N-substituted 
quinolines 19m-o in 85-95% yield after 6-23 h (Table 13, entries 1-3). Also, the use of chromium(II) 
chloride dramatically increased the reaction rate and efficiency of 2-chloroquinoline (16f) with 
magnesium chloride pyrrolidin-1-ide (17a). Without catalyst, only 65% of the aminated quinoline 19p 
was obtained after 2 d whereas 95% of 19p was isolated after 10 h in the presence of 10% CrCl2 
(entry 4).  
 
Regioselective amination of 2,4-dichloroquinoline (16g) with the benzylic magnesium amide 17g led 
selectively to the aminated heterocycle 19q (50 °C, 5 h) in 54% yield (entry 5).  
 
Table 13: Cr(II)-catalyzed amination of the 2-chloroquinoline 16f-g with magnesium amides 17.
a
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Entry Substrate Magnesium amideb Product 
 
 
  
1 16f 17i 19m: 85%; 23 h 
  
 
 
2 16f 17b 19n: 85%; 8 h 
  
 
 
3 16f 17j 19o: 95%; 6 h 
  
 
 
4 16f 17a 19p: 90%; 10 h 
 
 
 
 
5 16g 17g 19q: 54%; 5h 
a
Reaction conditions: CrCl2 (10 mol%), chlorinated heterocycle (16, 1.0 equiv), magnesium amide (17, 2.0 equiv) in THF at 
50 °C. 
b
LiCl was omitted for clarity. 
 
The amination on the C1 position of 1-chloroisoquinoline (16h) could be realized efficiently by using 
the saturated heterocyclic magnesium amides 17a and 17b, which led to the isoquinolines 19r and 
19s after 2 h at 50 °C in 89-93% yield (Scheme 68). 
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Scheme 68: Cr(II)-catalyzed amination of 1-chloroisoquinoline 16h with magnesium amides (17a-b).
a 
 
Noteworthy, the annelation of the quinoxaline scaffold was achieved by diamination of  
2,3-dichloroquinoxaline (16i) with the bis-magnesium amide 17k leading to the hydropyrazino[2,3-
b]quinoxaline 19t in 80% (Scheme 69). 
 
 
Scheme 69: CrCl2-catalyzed diamination of 2,3-dichloroquinoxaline (16i). 
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4. SYNTHESIS OF PYRIDO[3,2-F][1,7]NAPHTHYRIDINE AND RELATED 
HETEROCYCLES 
 
Six-membered N-heterocyclic molecules have found numerous applications due to their biological or 
physical properties. Annelated six-membered N-heteroaromatics bearing one nitrogen atom per ring 
such as naphthyridines 20, triazaanthracenes 21 and triazaphenanthrenes 22 are much less studied. 
In particular, the applications of pyridonaphthyridines – azaphenanthrenes resulting from the fusion 
of three pyridines – could be of high interest due to their favorable geometry for coordination  
(Figure 5). 
 
 
Figure 5: Fused six-membered N-heteroaromatics. 
 
In total, among the 16 possible regioisomers, the syntheses of only 6 different pyridonaphthyridines 
have been reported so far. The methodologies developed for their synthesis appear to be inefficient, 
inconvenient and not very general. Except of the method described by Rault et al.,[109] none of them 
are applicable in medicinal chemistry.  
 
A general synthesis of new pyrido[3,2-f][1,7]naphthyridine 23 using Negishi cross-coupling with 
polyfunctional zinc intermediates, as well as the study of their reactivity was envisioned (Figure 6).  
 
 
Figure 6: New pyrido[3,2-f][1,7]naphthyridine 23. 
 
4.1 RETROSYNTHETIC ANALYSIS 
 
The retrosynthesis proposed involved as final ring closure an intramolecular N-arylation of bis-
pyridine 24 possibly catalyzed by transition metals.[18a, 53a, 16g, 14c] This aminopyridine 24 could be 
readily prepared from the bis-pyridine 25 by selective halogenation and amination of the methyl 
substituent. The polyfunctional bis-pyridine 25 would be finally synthesized via a Negishi cross-
B. RESULTS AND DISCUSSION 
   71 
coupling of the  
3-zincated 2-chloropyridine 26 with the 3-halogenated 2-picoline 27 (Scheme 70). 
 
Scheme 70: Retrosynthetic analysis. 
 
4.2 MULTI-STEP SYNTHESIS OF PYRIDO[3,2-F][1,7]NAPHTHYRIDINE AND DERIVATIVES 
 
First, the polyfunctional zinc reagents of type 26 required from the retrosynthetic analysis were 
prepared from the corresponding 3-bromo-2-chloropyridines 28a-b by a bromine/magnesium 
exchange using i-PrMgCl·LiCl followed by transmetallation with ZnCl2. These pyridylzinc reagents 
underwent a Negishi cross-coupling with the iodopicolines 27a-b in THF in the presence of 2% 
Pd(PPh3)4. Interestingly, a number of catalyst systems were screened and Pd(PPh3)4 gave the best 
results in most cases. However, for the cross-coupling of 26a with 27b, better yields were obtained 
by using 2% Pd(OAc)2/4 % SPhos. These cross-couplings were usually completed within 1-5 h at 50 °C. 
As expected, the presence of electron-withdrawing substituents on the pyridylzinc reagents 26 
lowered significantly the cross-coupling efficiency (Scheme 71). 
 
 
Scheme 71: Negishi cross-coupling towards the synthesis of the bis-pyridines (25a-c). 
 
Subsequently, the introduction of an amino function was achieved by the convertion of the 2-methyl 
substituent into a chloromethyl group, followed by a Gabriel reaction.[133] This chlorination was 
achieved by two methods. The most convenient procedure consisted of the treatment of the  
bis-pyridines 25a-b with trichloroisocyanuric acid in chloroform in the presence of 3% PhCONH2 
(60 °C, 4-12 h), leading to the chloromethyl bis-pyridines 29a-b in 78-81% yield.[134] This electrophilic 
substitution did not proceed if the methyl substituent was attached to a pyridyl ring bearing an 
electron-withdrawing chlorine substituent. In this case, the intermediate trimethylsilylmethyl 
derivative 30 was prepared by deprotonation with LDA (1.2 equiv, -78 °C, 2 h), followed by trapping 
with TMSCl. Intermediate 30 was smoothly chlorinated by the method of Fraser,[135] using C2Cl6 and 
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CsF in acetonitrile (reflux, 3 h), affording the chloromethyl derivative 29c in 62% yield (Scheme 72).  
 
Scheme 72: Chlorination of the picolyl derivatives (25a-c).  
 
Gabriel reaction using potassium phthalimide (DMF, 100 °C, 2-5 h) provided the phthalimides (31a-c) 
in 69-92% yield. Deprotection of the phthalimides 31a-c using hydrazine hydrate in ethanol gave 
aminomethyl intermediates of type 24. Unexpectedly, those aminated compounds underwent a 
spontaneous ring closure under the reaction conditions, providing the dihydrotriazaphenanthrenes 
(32a-c). Treatment with chloranil in DMF (25 °C, 2 h) led to the aromatized target molecules (23a-c) 
in 75-89% yield (Scheme 73). 
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Scheme 73: Gabriel substitution and corresponding deprotection leading to the azaphenanthrenes (23a-c). 
 
4.3 FUNCTIONALIZATION OF PYRIDO[3,2-F][1,7]NAPHTHYRIDINE BY ORGANOLITHIUMS 
ADDITION 
 
Additionally, the reactivity and further functionalization of these new N-heterocycles was studied. 
 
Although metalations using various TMP-bases (TMPLi, TMP2Mg·2LiCl, TMPMgCl·LiCl, TMP2Zn·2LiCl, 
TMPZnCl·LiCl)[136] led to complex mixtures, the treatment of 23a with a range of organolithiums 
at -60 °C for 0.5 h followed by a rearomatization with chloranil (DMF, 25 °C) furnished the 
functionalized triazaphenanthrenes (33a-j) in 34-93% yield (Table 14).  
 
A range of aryllithium reagents (34a-d) bearing electron-donating (34b) and -withdrawing groups  
(34c-d) react well with 23a, leading to the azaphenanthrenes (33a-d) in 62-93% yields after 
rearomatization (entries 1-4). Also, heterocyclic lithium derivatives smoothly added to the 
pyridonaphthyridine (23a). Thus, 2-lithiofuran (34e), 2-lithiothiophene (34f), as well as  
2-lithiobenzofuran (34g) and 2-lithiobenzothiophene (34h), led to azaphenanthrenes (33e-h) in  
32-80% yield (entries 5-8). Interestingly, 1-lithio-1-ethoxyethene (34i) reacted well with 4a under 
these reaction conditions, and the keto-azaphenanthrene derivative (33i) was produced in 90% yield 
(entry 9). Surprisingly, alkyllithium reagents such as n-BuLi (34j) underwent a similar addition on the 
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azaphenanthrene core without competitive metalation, affording the butyl-substituted 
azaphenanthrene (33j) in 76% yield (entry 10). 
 
Table 14: Functionalization of azaphenanthrene (23a) with organolithium reagents leading to substituted 
pyridonaphthyridines of type 33. 
 
Entry Organolithium reagent Producta 
 
 
 
1 34a: R = H 33a: 93% 
2 34b: R = p-OMe 33b: 87% 
3 34c: R = p-CF3 33c: 68% 
4 34d: R = m-F 33d: 62% 
 
 
 
5 34e: X = O 33e: 80% 
6 34f: X = S 33f: 46% 
 
 
 
7 34g: X = O 33g: 32% 
8 34h: X = S 33h: 51% 
 
 
 
9 34i 33i: 90% 
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 n-BuLi 
 
10 34j 33j: 76% 
a
Isolated yields of analytically pure product.  
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5. SUMMARY AND OUTLOOK 
 
Nitrogen-containing heterocyclic compounds are of significant interest for the pharmaceutical and 
agrochemical industry. Transition-metal-catalyzed cross-coupling reactions have become a 
cornerstone in the functionalization of such compounds, and are among the most used C-C bond 
forming reactions in organic chemistry. In general, cross-coupling reactions employ Pd- or Ni-salts as 
catalyst, while palladium is certainly by far the most used metal. However, the high cost of palladium 
and the comparable high toxicity of nickel salts have motivated the development of new cross-
coupling methods employing economically reasonable, environmentally friendly, and readily 
available less toxic transition metals. 
This work focused on the search for alternative metals to replace palladium- and nickel-catalysts by 
the development of new cobalt(II)- and chromium(II)-catalyzed cross-coupling methodologies. 
Furthermore, an effective strategy to obtain highly functionalized structural heterocyclic motifs 
involves the use of polyhalogenated starting materials that can be subsequently functionalized. For 
this purpose, the use of CrCl2 in highly regioselective cross-coupling reactions of dichlorinated 
heteroaromatics was demonstrated. Attention was also paid to the effective purging of chromium 
salts from the desired product by demonstrating the use of various solid supports for the removal of 
remaining metal traces. Besides the C-C bond formation, this work focused on the replacement of 
the cost-intensive palladium salt associated with sensitive phosphine ligands in the Buchwald-
Hartwig amination reaction. Therefore, the chromium(II)-chloride catalyzed amination of N-
heterocyclic chlorides with a range of magnesium amides was developed. 
Besides, particular attention was paid to the synthesis and functionalization of unexplored annelated 
six-membered N-heterocycles having potential use in medicinal and/or material applications: 
pyrido[3,2-f][1,7]naphthyrdine.  
 
5.1 COBALT(II)-CATALYZED CROSS-COUPLING REACTIONS BETWEEN N-HETEROCYCLIC 
HALIDES AND ARYL OR HETEROARYL MAGNESIUM REAGENTS 
 
The reaction scope of cobalt-catalyzed cross-coupling reactions in the presence of isoquinoline in the 
solvent mixture t-BuOMe/THF was further investigated.  
Various 2-halogenated pyridine, pyrimidine, and quinoline derivatives were arylated under mild 
reaction conditions in high yields (Scheme 74).  
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Scheme 74: Cobalt(II)-catalyzed cross-coupling reactions of 2-halogenated N-heterocycles.  
 
The developed catalytic system of the cobalt(II) complex associated with isoquinoline allows, not 
only to perform cross-coupling reactions at the 2-position of the haloquinoline, but also to achieve 
the more challenging cross-coupling at the 6-position of 6-chloro-2-phenylquinoline with electron 
poor  
4-fluorophenylmagnesium bromide (Scheme 75). 
 
 
Scheme 75: CoCl2-catalyzed cross-coupling of 6-chloro-2-phenylquinoline with 4-fluorophenylmagnesium 
bromide. 
 
Furthermore, it was found that the use of 10% 8-dimethylaminoquinoline increases greatly the yields 
of some Co-catalyzed cross-coupling reactions with chloropyridines bearing electron-withdrawing 
substituents, e.g. for 2-chloro-5-(trifluoromethyl)pyridine (Scheme 76). 
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Scheme 76: Co-catalyzed cross-coupling reaction between 2-chloro-5-(trifluoromethyl)pyridine and PhMgCl 
utilizing 8-dimethylaminoquinoline as ligand. 
 
Upcoming work could focus on the optimization of this ligand system, since it is lacking from 
generality. Future heterocyclic ligands should involve the following features: 
1. General catalysis with all different types of halogenated heterocycles, regardless the 
electron-withdrawing or -donating nature of its substituents. 
2. Easily accessible, either by a very short synthesis or, in best case, an inexpensive 
commercially available compound. 
Future extensions could involve cross-coupling reactions with non-activated aromatic halides instead 
of N-heterocyclic halides. 
 
5.2 CHROMIUM(II)-CATALYZED CROSS-COUPLING REACTIONS BETWEEN CSP2 CENTERS 
 
Against common wisdom, toxicological data has proven the low toxicity of CrCl2, in contrary to high-
valent Cr(VI) complexes. It is worth noting that, analogous to other commonly used salts such as 
PdCl2, NiCl2 or even CoCl2, chromium(II) chloride exhibits a lower toxicity. Therefore, CrCl2 is sold as a 
low-toxic chemical by major international suppliers.  
 
In this work it was shown that, unexpectedly, CrCl2 can undergo very efficiently cross-coupling 
reactions of C–X bonds with a wide range of Grignard reagents, which allow the effective 
construction of C–C bonds with a fast conversion rate under ambient conditions. 
The simple procedure does not require any additional ligand or additive for coupling reactions to 
proceed at room temperature in the presence of 3 mol% of chromium(II) chloride.  
 
Remarkably, much lower amounts of homo-coupling side products are obtained compared to related 
iron, cobalt, or manganese cross-couplings. 
 
Using this novel methodology, various unsymmetrical (hetero)biaryls can be formed from 
(hetero)arylmagnesium reagents with N-heterocyclic halides and aromatic halogenated ketones 
(Scheme 77). Imino-protected 2-chlorobenzaldehyde, as well as alkenyl iodides, are also suitable 
partners for the efficient coupling with a range of (hetero)aromatic Grignard reagents. A variety of 
functionalities, such as electron-withdrawing halogens, ester, trifluoromethyl or cyano groups, as 
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well as electron-donating methoxy and amino group, are compatible with this catalytic system. 
 
 
Scheme 77: Cr-catalyzed cross-coupling reaction at room-temperature. 
 
Moreover, a further study of this cross-coupling method led to a broadened substrate scope by 
regio- and chemoselectively coupling of a wide range of substituted dichloropyridines to aromatic 
Grignard reagents (Scheme 78).  
Furthermore, it was found that previously challenging electron-rich quinolines and isoquinolines 
undergo the selective Cr-catalyzed cross-coupling much faster in CPME (cyclopentyl methyl ether) 
than in THF as solvent. 
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Scheme 78: Regioselective Cr-catalyzed cross-couplings of dichlorinated heteroaromatics. 
 
The unexpected discovery that CrCl2 can catalyze cross-coupling reactions led to various studies as 
extension for the scope of this methodology.  
The cross-coupling methodology was pushed further by demonstrating the chromium(II)-catalyzed 
direct C-H arylation of pyridines, aryl oxazolines, and imines with arylmagnesium reagents.[137] 
Furthermore, also aryl alkyl ethers in the presence of aryl and alkyl Grignard reagents could 
successfully provide the desired regioselective Cr-catalyzed cross-coupling products.[138] 
 
5.3 CHROMIUM(II)-CATALYZED AMINATION OF N-HETEROCYCLIC CHLORIDES WITH 
MAGNESIUM AMIDES  
 
After studying the effect of chromium(II) salts in cross-couplings, its possible use in amination 
reactions as an alternative to the palladium-catalyzed Buchwald-Hartwig reaction was investigated.   
 
For this reason, the ligand-free chromium(II)-catalyzed amination reaction of various N-heterocyclic 
chlorides was found. CrCl2 regioselectively catalyzes the reaction of chloro- and 
dichloropyridines, -quinolines, -isoquinolines and -quinoxalines with a range of aliphatic, allylic, 
benzylic and saturated (hetero)cyclic magnesium amides in the presence of lithium chloride as 
additive (Scheme 79). The reactions have been performed at 50 °C in THF and led to the desired 
aminated products in 56-96% yield. 
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Scheme 79: Cr(II)-catalyzed amination of N-heterocyclic chlorides with magnesium amides. 
 
Using chromium(II) salts, future work could focus on extending the scope of chromium-catalysis to 
other potential reactions like carbometalation, borylation or trifluoromethylation reactions. 
5.4 SYNTHESIS OF PYRIDO[3,2-F][1,7]NAPHTHYRIDINE AND RELATED HETEROCYCLES 
 
N-heterocycles play an important role in medicinal chemistry and material science. However, the 
synthesis of complex six-membered N-heteroaromatics still remains an under-explored field. Due to 
their great potential as ligand, drug or fluorescent probe for instance, pyrido[3,2-
f][1,7]naphthyridines were studied. A general synthesis based on metal-catalyzed cross-coupling and 
amination reactions was envisioned (Scheme 80). 
First, Negishi cross-coupling of polyfunctional pyridylzinc reagents furnished the desired bis-pyridines 
in moderate to excellent yields under tetrakis(triphenylphosphine)palladium-catalysis, and no 
expensive ligand was needed in most cases. 
Furthermore, in order to generate the required amino-pyridine, selective halogenation and further 
amination was envisioned. Chlorination was performed using two different methods depending on 
the electron-density of the substrate. Whereas electrophilic chlorination was achieved using 
trichloroisocyanuric acid, metalation by LDA, followed by TMS trapping and halogenation led to the 
chloromethyl intermediates in good yield. 
Gabriel substitution and subsequent deprotection under Manske-Ing conditions furnished the 
desired amino-pyridines, which underwent spontaneous ring closure. Hence, the final substituted  
pyrido[3,2-f][1,7]naphthyridines were obtained in high yield after aromatization. 
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Scheme 80: General synthesis of pyrido[3,2-f][1,7]naphthyridines. 
 
Furthermore, the reactivity of pyrido[3,2-f][1,7]naphthyridines was also studied. It could be shown 
that these molecules are readily functionalized by the addition of organolithium reagents. A wide 
range of aryl-, heteroaryl- and alkyllithiums could add successfully and led to the 6-substituted 
azaphenanthrene after smooth rearomatization (Scheme 81). 
 
 
Scheme 81: Functionalization of azaphenanthrene with organolithium reagents. 
 
At the moment, the potential application of these complex N-heterocycles as fluorescence markers is 
investigated. 
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Furthermore, upcoming work should continue with the functionalization of the 
pyridinonaphthyridines in order to generate a broader variety of interesting new molecules. Besides 
metalations, also other methods such as C-H-functionalization or amination reactions could be 
considered. 
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1. GENERAL CONSIDERATIONS 
 
All reactions were carried out with magnetic stirring and, if the reagents were air or moisture 
sensitive, in flame-dried glassware under argon. Syringes, which were used to transfer reagents and 
solvents, were purged with argon prior to use.  
 
1.1 SOLVENTS 
 
Solvents were dried according to standard procedures by distillation over drying agents and stored 
under argon. 
t-BuOMe was continuously refluxed and freshly distilled from sodium benzophenone ketyl under 
nitrogen. 
CPME was pre-dried over CaCl2 and distilled from CaH2. 
n-Hexane was continuously refluxed and freshly distilled from sodium benzophenone ketyl under 
nitrogen. 
THF was continuously refluxed and freshly distilled from sodium benzophenone ketyl under nitrogen. 
Toluene was pre-dried over CaCl2 and distilled from CaH2. 
Solvents for column chromatography were distilled prior to use. 
 
1.2 REAGENTS 
 
All reagents were obtained from commercial sources and used without further purification unless 
otherwise stated.  
CoCl2 was dried under high vacuum at 200 °C for 2 min prior to reactions (until the color turned 
blue). 
CrCl2 was dried under high vacuum at 200 °C for 2 min prior to reactions (until the color turned 
white-grey). 
i-PrMgCl·LiCl solution in THF was purchased from Rockwood Lithium GmbH. 
PhMgCl solution in THF was purchased from Rockwood Lithium GmbH. 
ZnCl2 solution (1.0 M) was prepared by drying ZnCl2 (100 mmol, 13.6 g) in a Schlenk-flask under 
vacuum at 140 °C for 5 h. After cooling, 100 mL dry THF were added and stirring was continued until 
the salt was dissolved. 
(i-Pr)2NH was distilled under Ar prior to use. 
n-BuLi was purchased as a solution in hexane from Rockwood Lithium. 
 
1.3 CONTENT DETERMINATION OF ORGANOMETALLIC REAGENTS 
 
Organzinc and organomagnesium reagents were titrated against I2 in THF. 
[139] 
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Organolithium reagents were titrated against i-PrOH using 1,10-phenanthroline as indicator in 
THF.[140] 
 
1.4 CHROMATOGRAPHY 
 
Flash column chromatography was performed using silica gel 60 (0.040-0.063 mm) from Merck.  
Thin layer chromatography was performed using SiO2 pre-coated aluminium plates (Merck 60, F-
254). The chromatograms were examined under UV light at 254 nm and/or by staining of the TLC 
plate with one of the solutions given below followed by heating with a heat gun: 
- KMnO4 (3.0 g), 5 drops of conc. H2SO4 in water (300 mL). 
- Phosphomolybdic acid (5.0 g), Ce(SO4)2 (2.0 g) and conc. H2SO4 (12 mL) in water (230 mL). 
- Ninhydrin (0.3 g) and AcOH (3.0 mL) in butanol (100 mL).  
 
1.5 ANALYTICAL DATA 
 
1H-NMR and 13C-NMR spectra were recorded on VARIAN Mercury 200, BRUKER ARX 300, VARIAN 
VXR 400 S and BRUKER AMX 600 instruments. Chemical shifts are reported as -values in ppm 
relative to tetramethylsilane. The following abbreviations were used to characterize signal 
multiplicities: s (singlet), d (doublet), t (triplet), q (quartet), qn (quintet), spt (septet), m (multiplet) as 
well as br (broadened). 
Mass spectroscopy: High resolution (HRMS) and low resolution (MS) spectra were recorded on a 
FINNIGAN MAT 95Q instrument. Electron impact ionization (EI) was conducted with an ionization 
energy of 70 eV.  
For coupled gas chromatography/mass spectrometry, a HEWLETT-PACKARD HP 6890/MSD 5973 
GC/MS system was used. Molecular fragments are reported starting at a relative intensity of 10%. 
Infrared spectra (IR) were recorded from 4500 cm-1 to 650 cm-1 on a PERKIN ELMER Spectrum BX-
59343 instrument. For detection a SMITHS DETECTION DuraSamplIR II Diamond ATR sensor was 
used. Wavenumbers are reported in cm-1 starting at an absorption of 10%. 
Melting points (m.p.) were determined on a BÜCHI B-540 melting point apparatus and are 
uncorrected. Compounds decomposing upon melting are indicated by (decomp.). 
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2. COBALT(II)-CATALYZED CROSS-COUPLING REACTIONS BETWEEN 
N-HETEROCYCLIC HALIDES AND ARYL OR HETEROARYL MAGNESIUM 
REAGENTS 
2.1 STARTING MATERIALS SYNTHESIS 
 
Grignard reagents were prepared according to a literature procedure.[122] 
 
Starting materials 1a, b, c, f, 1k are commercially available. 
Starting material 1d was prepared according to a procedure described in the literature.[141] 
Starting material 1e was prepared according to a procedure described in the literature.[142] 
Starting material 1g was prepared according to a procedure described in the literature.[114a] 
Starting material 1h was prepared according to a procedure described in the literature.[143] 
Starting material 1j was prepared according to a procedure described in the literature.[144] 
 
Ligand 4a-h are commercially available. 
Ligand 4i was prepared according to a procedure described in the literature.[145] 
Ligand 4j was prepared according to a procedure described in the literature.[146] 
Ligand 4k was prepared according to a procedure described in the literature.[147] 
 
2.2 GENERAL PROCEDURES 
2.2.1 Typical procedure for the Co-catalyzed cross-coupling reaction with isoquinoline as 
ligand (TP1) 
 
A solution of the appropriate Grignard reagent (concentration in THF varying depending on the 
identity of the Grignard reagent, 1.0 mmol, 2.0 equiv) was added dropwise to a suspension of CoCl2 
(1.9 mg, 0.015 mmol, 0.03 equiv), isoquinoline (6.5 mg, 0.05 mmol, 0.10 equiv), and the aryl halide 
(0.5 mmol, 1.0 equiv) in t-BuOMe (2.5 mL) at 25 C. The suspension was stirred at 25 C for the 
indicated time before being quenched with sat. aq. NaHCO3. The mixture was diluted with CH2Cl2 and 
an EDTA (1.0 M, H2O) solution was added. The mixture was stirred at 25 C for 15 min, before being 
filtered through a pad of Celite®. After washing the pad of Celite® with CH2Cl2, sat. aq. NaCl was 
added, and the mixture was extracted with CH2Cl2. The organic layer was dried with MgSO4, filtered, 
and concentrated in vacuo to yield the crude compound, which was purified by column 
chromatography, leading to the final compound as an analytically pure substance. 
 
2.2.2 Typical procedure for the ligand screening of the Co-catalyzed cross-coupling 
reaction of chloropyridines (TP2) 
 
A solution of the appropriate Grignard reagent (concentration in THF varying depending on the 
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identity of the Grignard reagent, 1.0 mmol, 2.0 equiv) was added dropwise to a suspension of CoCl2 
(1.9 mg, 0.015 mmol, 0.03 equiv), the appropriate ligand (0.05 mmol, 0.10 equiv), and the aryl halide 
(0.5 mmol, 1.0 equiv) in t-BuOMe (2.5 mL) at 25 C. The suspension was stirred at 25 C for 15 min 
before being quenched with sat. aq. NaHCO3 and extracted with ethyl acetate. The organic phase 
was injected to a gas chromatography apparatus and the yields were determined by integration of 
the gas chromatogram and comparison against undecane as a calibrated internal standard. 
 
2.3 PREPARATION OF THE SYNTHESIZED N-HETEROCYCLIC COMPOUNDS 
 
Synthesis of 1-methyl-5-(pyridin-2-yl)-1H-indole (3c) according to TP1: 
 
According to TP1, the substituted pyridine 3c was prepared from 0.5 mmol of 1c with 1.0 mmol of 2b 
at 25 °C for 15 min. Flash column chromatography (i-hexane/ethyl acetate 3:1 + 0.5% NEt3) furnished 
3c as brown solid (64 mg, 61%).  
 
m.p.: 66.8 – 68.3 °C. 
1H NMR (300 MHz, CDCl3) ppm: 3.82 (s, 3 H), 6.58 (d, J=3.04 Hz, 1 H), 7.09 (d, J=3.04 Hz, 1 H), 7.14 - 
7.20 (m, 1 H), 7.41 (d, J=8.57 Hz, 1 H), 7.68 - 7.82 (m, 2 H), 7.94 (dd, J=8.57, 1.66 Hz, 1 H), 8.29 (d, 
J=1.11 Hz, 1 H), 8.71 (d, J=4.70 Hz, 1 H). 
 13C NMR (75 MHz, CDCl3) ppm: 32.9, 101.9, 109.4, 119.7, 120.3, 120.9, 121.0, 128.8, 129.6, 131.0, 
136.6, 137.3, 149.5, 158.8. 
MS (70 eV, EI) m/z (%): 209 (13), 208 (100), 207 (26), 166 (4), 104 (5), 43 (10). 
IR ATR  (cm-1): 3084, 2998, 2923, 1615, 1584, 1558, 1513, 1461, 1420, 1339, 1304, 1271, 1245, 
1184, 1149, 1104, 1081, 968, 884, 819, 775, 760, 729, 686. 
HRMS (EI) for C14H12N2 (208.1000) [M]
+: 289.0993. 
 
Synthesis of 2-(thiophen-2-yl)-3-(trimethylsilyl)pyridine (3d) according to TP1: 
 
According to TP1, the substituted pyridine 3d was prepared from 0.5 mmol of 1d with 1.0 mmol of 2c 
at 25 °C for 15 min. Flash column chromatography (i-hexane/ethyl acetate 4:1 + 0.5% NEt3) furnished 
3d as brown oil (81 mg, 49%). 
 
1H NMR (300 MHz, CDCl3) /ppm: 0.18 (s, 9 H), 7.07 (dd, J=4.84, 3.73 Hz, 1 H), 7.17 - 7.28 (m, 2 H), 
7.41 (d, J=4.98 Hz, 1 H), 7.91 (dd, J=7.60, 1.80 Hz, 1 H), 8.61 (dd, J=4.84, 1.80 Hz, 1 H). 
13C NMR (75 MHz, CDCl3) /ppm: 0.1, 121.6, 126.6, 126.8, 127.4, 133.9, 143.4, 145.6, 149.2, 158.3. 
N
N
Me
N
TMS
S
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MS (70 eV, EI) m/z (%): 233 (22), 220 (15), 219 (23), 218 (100), 202 (9), 188 (14). 
IR ATR  (cm-1): 3028, 2953, 2897, 1560, 1548, 1439, 1391, 1264, 1249, 1214, 1129, 1044, 972, 835, 
781, 749, 697, 658. 
HRMS (EI) for C12H15NSSi (233.0694) [M]
+: 233.0684. 
 
Synthesis of 3-(2-methoxyphenyl)-2-(4-methoxyphenyl)pyridine (3e) according to TP1: 
 
According to TP1, the substituted pyridine 3e was prepared from 0.5 mmol of 1e with 1.0 mmol of 
2d at 25 °C for 15 min. Flash column chromatography (i-hexane/ethyl acetate 7:1) furnished 3e as 
colourless oil (100 mg, 69%). 
 
1H NMR (300 MHz, CDCl3) /ppm: 3.42 (s, 3 H), 3.75 (s, 3 H), 6.61 - 6.86 (m, 3 H), 6.95 (t, J=7.46 Hz, 
1 H), 7.14 (dd, J=7.46, 1.66 Hz, 1 H), 7.17 - 7.42 (m, 4 H), 7.66 (dd, J=7.74, 1.66 Hz, 1 H), 8.65 (dd, 
J=4.70, 1.66 Hz, 1 H). 
13C NMR (75 MHz, CDCl3) /ppm: 55.1, 111.2, 113.0, 120.8, 121.3, 129.1, 129.3, 130.1, 131.2, 132.5, 
133.6, 139.1, 148.2, 156.2, 157.6, 159.1. 
MS (70 eV, EI) m/z (%): 291 (100), 276 (30), 275 (26), 260 (48), 204 (18), 108 (11), 61 (15), 41 (82). 
IR ATR  (cm-1): 3044, 3001, 2956, 2934, 2835, 1607, 1580, 1576, 1513, 1494, 1460, 1418, 1296, 
1240, 1174, 1124, 1104, 1041, 1023, 998, 935, 836, 797, 780, 752, 677.  
HRMS (EI) for C19H17NO2 (291.1259) [M]
+: 291.1257. 
 
Synthesis of 2-(4-fluorophenyl)-4-(thiophen-2-yl)pyridine (3f) according to TP1: 
 
According to TP1, the substituted pyridine 3f was prepared from 0.5 mmol of 1f with 1.0 mmol of 2e 
at 25 °C for 15 min. Flash column chromatography (i-hexane/ethyl acetate 4:1 + 0.5% NEt3) furnished 
3f as yellow oil (89 mg, 70%). 
 
1H NMR (300 MHz, CDCl3) /ppm: 6.95 - 7.24 (m, 3 H), 7.32 - 7.49 (m, 2 H), 7.56 (d, J=3.59 Hz, 1 H), 
7.85 (s, 1 H), 8.03 (dd, J=8.71, 5.39 Hz, 2 H), 8.65 (d, J=5.25 Hz, 1 H). 
13C NMR (75 MHz, CDCl3) /ppm: 115.5, 115.8, 116.6, 118.4, 126.9 (d, J=230.31 Hz), 127.2, 128.8 (d, 
J=8.26 Hz), 135.4 (d, J=3.13 Hz), 141.4, 142.3, 150.2, 157.3, 162.0, 165.3. 
MS (70 eV, EI) m/z (%):255 (100), 254 (49), 86 (11), 84 (17), 70 (10), 61 (15), 45 (14), 43 (92). 
IR ATR  (cm-1): 3106, 3073, 2924, 2852, 1600, 1591, 1541, 1510, 1471, 1431, 1416, 1388, 1343, 
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1296, 1222, 1156, 1096, 1050, 1013, 989, 879, 836, 819, 761, 747, 696. 
HRMS (EI) for C15H10FNS (255.0518) [M]
+: 255.0511. 
 
Synthesis of 4-(4-chloro-2-fluorophenyl)-2-(naphthalen-1-yl)pyrimidine (3g) according to TP1: 
 
According to TP1, the substituted pyrimidine 3g was prepared from 0.5 mmol of 1g with 1.0 mmol of 
2f at 25 °C for 15 min. Flash column chromatography (i-hexane/ethyl acetate 19:1 + 0.5% NEt3) 
furnished 3g as white solid (95 mg, 57%). 
 
m.p.: 119 - 121 °C. 
1H NMR (300 MHz, CDCl3) /ppm: 7.19 - 7.36 (m, 2 H), 7.48 - 7.67 (m, 3 H), 7.81 (dd, J=5.39, 1.80 Hz, 
1 H), 7.90 - 8.05 (m, 2 H), 8.17 (dd, J=7.19, 0.83 Hz, 1 H), 8.34 (t, J=8.57 Hz, 1 H), 8.67 - 8.80 (m, 1 H), 
8.99 (d, J=5.25 Hz, 1 H). 
 13C NMR (75 MHz, CDCl3) /ppm: 117.2 (d, J=26.42 Hz) 117.4, 118.2 (d, J=12.81 Hz), 123.5 (d, 
J=10.25 Hz), 125.2, 125.4 (d, J=3.42 Hz), 125.8, 125.9, 126.9, 128.5, 129.6, 130.7, 131.1, 131.8 (d, 
J=3.42 Hz), 134.2, 135.8, 137.7 (d, J=10.82 Hz), 157.9, 159.1 (d, J=2.85 Hz), 161.4 (d, J=256.22 Hz), 
167.1. 
MS (70 eV, EI) m/z (%):336 (21), 335 (39), 334 (55), 333 (100), 205 (7), 153 (10), 149 (5), 126 (5). 
IR ATR  (cm-1): 3078, 3040, 2922, 2263, 1927, 1713, 1605, 1562, 1544, 1511, 1482, 1465, 1423, 
1398, 1315, 1285, 1255, 1236, 1164, 1133, 1056, 856, 825, 809, 795, 786, 770, 760. 
HRMS (EI) for C20H11ClFN2 (333.0595) [M-H]
+: 333.0588. 
 
Synthesis of 6-chloro-2-(4-fluorophenyl)quinoline (3h) according to TP1: 
 
According to TP1, the substituted quinoline 3h was prepared from 0.5 mmol of 1h with 1.0 mmol of 
2e at 25 °C for 15 min. Flash column chromatography (i-hexane/ethyl acetate 20:1) furnished 3h as 
white solid (80 mg, 63 %). 
 
m.p.: 148.4 - 149.5 °C 
1H NMR (300 MHz, CDCl3) δ/ppm: 7.11 - 7.27 (m, 2 H), 7.64 (dd, J=8.98, 2.35 Hz, 1 H), 7.73 - 7.89 (m, 
2 H), 7.98 - 8.23 (m, 4 H). 
13C NMR (75.5 MHz, CDCl3) δ/ppm: 115.8 (d, J=21.60 Hz), 119.3, 126.1, 127.6, 129.3 (d, J=8.41 Hz), 
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130.7, 131.2, 132.0, 135.3 (d, J=3.08 Hz), 135.9, 146.6, 156.4, 162.4 (d, J=249.64 Hz). 
MS (70 eV, EI) m/z (%): 257 (100), 222 (30), 111 (45), 75 (7). 
IR ATR ν (cm-1): 3054, 1595, 1551, 1513, 1487, 1414, 1372, 1335, 1318, 1296, 1276, 1242, 1215, 
1189, 1164, 1127, 1106, 1089, 1073, 1050, 1010, 972, 946, 881, 843, 828, 811, 789. 
HRMS (EI) for C15H9ClFN (257.0408) [M]
+: 257.0404. 
 
Synthesis of 6-(4-fluorophenyl)-2-phenylquinoline (3i) according to TP1: 
 
According to TP1, the substituted quinoline 3i was prepared from 0.5 mmol of 1i with 1.0 mmol of 2e 
at 50 °C for 15 min. Flash column chromatography (i-hexane/ethyl acetate 25:1) furnished 3i as 
white solid (83 mg, 55 %). 
 
m.p.: 206.2 - 209.0 °C. 
1H NMR (300 MHz, CDCl3): δ/ppm: 7.18 (t, J=8.57 Hz, 2 H), 7.43 - 7.59 (m, 3 H), 7.68 (dd, J=8.43, 
5.39 Hz, 2 H), 7.83 - 7.99 (m, 3 H), 8.21 (dd, J=16.59, 7.74 Hz, 4 H). 
13C NMR (75.5 MHz, CDCl3): δ/ppm: 162.7 (d, J=247.71 Hz), 157.3, 147.3, 139.5, 138.0, 136.9, 136.5 
(d, J=3.02 Hz), 130.2, 129.4, 129.2, 129.0, 128.9 (d, J=8.32 Hz), 127.5, 127.3, 125.0, 119.4, 115.8 (d, 
J=21.92 Hz). 
MS (70 eV, EI) m/z (%): 299 (100), 298 (29), 204 (4), 150 (7), 139 (5). 
IR ATR ν (cm-1): 3048, 2953, 2924, 2853, 1600, 1515, 1488, 1414, 1396, 1333, 1312, 1232, 1140, 
1104, 1076, 1053, 1026, 956, 890, 761. 
HRMS (EI) for C21H14FN (299.1110) [M]
+: 299.1107. 
 
Synthesis of 2-phenyl-pyridine (3b) according to TP2: 
 
According to TP2, the substituted pyridine 3b was prepared from 0.5 mmol of 1b with 1.0 mmol of 
2a at 25 °C for 15 min. Flash column chromatography (i-hexane/ethyl acetate 6:1 + 0.5% NEt3) 
furnished 3b as colorless oil (70 mg, 90 %). 
 
1H NMR (300 MHz, CDCl3) δ/ppm: 7.23 (m, 1 H), 7.45 (m, 3 H), 7.75 (m, 2 H), 8.01 (m, 2H), 8.70 (d, 
J=4.7 Hz, 1 H). 
13C NMR (75 MHz, CDCl3) δ/ppm: 120.6, 122.1, 126.9, 128.7, 129.0, 136.8, 139.2, 149.5, 157.4. 
MS (70 eV, EI) m/z (%): 155 (100), 154 (60), 128 (10), 127 (10), 77 (9), 59 (10), 43 (7). 
IR ATR ν (cm-1): 3062, 3036, 3008, 2927, 1586, 1580, 1564, 1468, 1449, 1424, 1293, 1152, 1074, 
1020, 988, 800, 737, 692. 
HRMS (EI) for C11H9N (155.1735) [M]
+: 155.1731. 
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Synthesis of N,N-dimethyl-6-phenylpyridin-3-amine (3j) according to TP2: 
 
According to TP2, the substituted pyridine 3j was prepared from 0.5 mmol of 1j with 1.0 mmol of 2a 
at 25 °C for 15 min. Flash column chromatography (i-hexane/ethyl acetate 95:5 + 0.5% NEt3) 
furnished 3j as yellow solid (77 mg, 78 %). 
 
m.p.: 117.8 - 120.1 °C. 
1H NMR (300 MHz, CDCl3) δ/ppm: 8.24 (d, J=3.09 Hz, 1H), 7.94 – 7.91 (m, 2H), 7.60 (dd, J=8.79, 
0.71 Hz, 1H), 7.46 – 7.40 (m, 2H), 7.34 – 7.29 (m, 1H), 7.05 (dd, J=8.78, 3.10 Hz, 1H), 3.01 (s, 6H). 
13C NMR (75.5 MHz, CDCl3) δ/ppm: 145.3, 144.9, 139.4, 134.4, 128.4, 127.2, 125.6, 120.1, 119.2, 
77.2, 77.2, 76.8, 76.5, 39.9. 
MS (70 eV, EI) m/z (%): 199 (13), 198 (100), 197 (66), 182 (12), 115 (12). 
IR ATR ν (cm-1): 3061, 2921, 2853, 1894, 1587, 1488, 1442, 1364, 1219, 1066, 826, 774, 730, 691. 
HRMS (EI) for C12H8F3N (198.1157) [M]
+: 198.1151. 
 
Synthesis of 2-phenyl-5-(trifluoromethyl)pyridine (3k) according to TP2: 
 
According to TP2, the substituted pyridine 3k was prepared from 0.5 mmol of 1k with 1.0 mmol of 2a 
at 25 °C for 15 min. Flash column chromatography (i-hexane/ethyl acetate 95:5 + 0.5% NEt3) 
furnished 3k as white solid (88 mg, 79 %). 
 
m.p.: 90.1 - 91.5 °C. 
1H NMR (300 MHz, CDCl3) δ/ppm: 7.26 (s, 1 H), 7.44 - 7.55 (m, 2 H), 7.85 (d, J=8.29 Hz, 1 H), 7.91 - 
8.15 (m, 3 H), 8.95 (s, 1 H).  
13C NMR (75.5 MHz, CDCl3) δ/ppm: 119.9, 123.7 (q, J=271.80 Hz), 124.0, 124.6, 125.0, 127.2, 128.9, 
130.0, 137.94, 133.9 (q, J=7.28 Hz), 146.6 (q, J=8.13 Hz), 160.7. 
MS (70 eV, EI) m/z (%): 224 (27), 223 (100), 222 (50), 204 (15). 
IR ATR ν (cm-1): 2945, 2925, 2854, 1601, 1566, 1482, 1449, 1388, 1326, 1294, 1273, 1167, 1116, 
1085, 1073, 1011, 940, 862, 838, 789, 739, 692, 652, 614.  
HRMS (EI) for C12H8F3N (223.0609) [M]
+: 223.0603.  
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3. CHROMIUM(II)-CATALYZED CROSS-COUPLING REACTIONS BETWEEN CSP2 
CENTERS 
3.1 STARTING MATERIALS SYNTHESIS 
 
Grignard reagents 6a-h, 6k, 6m-q were prepared via LiCl-assisted Mg-insertion into the 
corresponding aromatic halides according to a literature procedure.[122] 
Grignard reagents 6i-j, 6l and 6r were prepared via halogen-magnesium exchange reaction.[124] 
 
Starting materials 5a, 5d-h, 5j, 8a, (Z)-12, 14a-I are commercially available. 
The syntheses of compounds 5b, 5c and 5i are described in the literature.[114a] 
The syntheses of compounds 8b and 8c are described in the literature.[148] 
The synthesis of compound 10 is described in the literature.[149] 
The synthesis of compound (Z)-12 is described in the literature.[130a] 
 
3.2 GENERAL PROCEDURES 
3.2.1 Typical procedure for the Cr-catalyzed cross-coupling reactions in THF (TP3) 
 
A solution of the appropriate Grignard reagent (concentration in THF varying depending on the 
nature of the Grignard reagent, 1.2 mmol, 1.2 equiv) was added dropwise to a suspension of 
anhydrous CrCl2 (3.7 mg, 0.03 mmol, 0.03 equiv, 97% purity) and the aryl halide (1 mmol, 1.0 equiv) 
in THF (5 mL) at 25 C. The suspension was stirred at 25 C for the indicated time before being 
quenched with brine and extracted with EtOAc. The organic layer was dried with MgSO4, filtered, and 
concentrated in vacuo to yield the crude compound, which was purified by column chromatography 
to yield the final compound as an analytically pure substance. 
 
3.2.2 Typical procedure for the Cr-catalyzed cross-coupling reactions with imine 10 (TP4) 
 
A solution of the appropriate Grignard reagent (concentration in THF varying depending on the 
nature of the Grignard reagent, 1.2 mmol, 1.2 equiv) was added dropwise to a suspension of 
anhydrous CrCl2 (3.7 mg, 0.03 mmol, 0.03 equiv; 97% purity) and the aryl halide (1 mmol, 1.0 equiv) 
in THF (5 mL) at 25 C. The suspension was stirred at 25 C for the indicated time before being 
quenched with an aq. solution of HCl (2M) and extracted with EtOAc. The organic layer was dried 
with MgSO4, filtered, and concentrated in vacuo to yield the crude compound, which was purified by 
column chromatography to yield the final compound as an analytically pure substance. 
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3.2.3 Typical procedure for the Cr-catalyzed cross-coupling reactions with alkenyl iodide 
(E or Z)-8 (TP5) 
 
A solution of the appropriate Grignard reagent (concentration in THF varying depending on the 
nature of the Grignard reagent, 1.5 mmol, 1.5 equiv) was added dropwise to a suspension of 
anhydrous CrCl2 (3.7 mg, 0.03 mmol, 0.03 equiv; 97% purity) and the E or Z aryl halide (1 mmol, 1.0 
equiv) in THF (5 mL) at 25 C. The suspension was stirred at 25 C for the indicated time before being 
quenched with brine and extracted with EtOAc. The organic layer was dried with MgSO4, filtered, and 
concentrated in vacuo to yield the crude compound, which was purified by column chromatography 
to yield the final compound as an analytically pure substance. 
 
3.2.4 Typical procedure for the Cr-catalyzed cross-coupling reactions in CPME (TP6) 
 
A solution of the appropriate Grignard reagent (concentration in THF varying depending on the 
nature of the Grignard reagent, 1.2 mmol, 1.2 equiv) was added dropwise to a suspension of 
anhydrous CrCl2 (3.7 mg, 0.03 mmol, 0.03 equiv; 97% purity) and the aryl halide (1 mmol, 1.0 equiv) 
in CPME (5 mL) at 25 C. The suspension was stirred at 25 C for the indicated time before being 
quenched with brine and extracted with EtOAc. The organic layer was dried with MgSO4, filtered, and 
concentrated in vacuo to yield the crude compound, which was purified by column chromatography 
to yield the final compound as an analytically pure substance. 
 
3.2.5 Typical procedure for the evaluation of recovery and chromium levels prior to 
chromatography, using various scavengers (TP7)  
 
A solution of 2a in THF (1.2 mmol, 1.2 equiv, 1.7 M) was added dropwise to a suspension of 
anhydrous CrCl2 (3.7 mg, 0.03 mmol, 0.03 equiv; 97% purity) and 1a (1 mmol, 1.0 equiv) in THF (5 
mL) at 25 °C. The suspension was stirred at 25 °C for 15 min before being quenched by addition of a 
saturated aqueous solution of NH4Cl and the mixture was extracted using EtOAc. The organic phase 
was poured into the solid support and it was agitated on a mechanic shaker for 24 h. The mixture 
was filtered and the solvent was evaporated to give the crude product, which was sent for analysis to 
"Intertek Pharmaceutical Services" (Whitehouse, New Jersey, USA). 
 
3.3 PRODUCT SYNTHESIS ACCORDING TO THE GENERAL PROCEDURES 
 
Synthesis of 2-phenylpyridine (7a) according to TP3: 
 
According to TP3, the substituted pyridine 7a was prepared from 1.0 mmol of 6a with 1.2 mmol of 5a 
(1.61 M) at 25 °C for 15 min. Flash column chromatography (i-hexane/ethyl acetate 6:1 + 0.5% NEt3) 
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furnished 7a as colorless oil (140 mg, 90%). 
 
Other analytical data can be found in part C/2.3 of this dissertation. 
 
Synthesis of 3-(but-3-en-1-yl)-2-phenylpyridine (7b) according to TP3: 
 
According to TP3, the substituted pyridine 7b was prepared from 1.0 mmol of 5b with 1.2 mmol of 
6a (1.61 M) at 25 °C for 15 min. Flash column chromatography (i-hexane/ethyl acetate 6:1 + 0.5% 
NEt3) furnished 7b as colorless oil (199 mg, 95%). 
 
1H NMR (300 MHz, CDCl3) /ppm: 2.18 - 2.32 (m, 2 H), 2.68 - 2.84 (m, 2 H), 4.86 - 5.00 (m, 2 H), 5.63 - 
5.80 (m, 1 H), 7.21 (dd, J=7.8, 4.8 Hz, 1 H), 7.32 - 7.54 (m, 5 H), 7.57 - 7.64 (m, 1 H), 8.53 (dd, J=4.9, 
1.31 Hz, 1 H). 
13C NMR (75 MHz, CDCl3) /ppm: 31.8, 34.6, 115.4, 122.1, 127.9, 128.2, 128.8, 134.6, 137.3, 140.6, 
147.0, 159.0. 
MS (70 eV, EI) m/z (%): 209 (42), 208 (51), 180 (15), 168 (25), 167 (100). 
IR ATR  (cm-1): 3060, 3027, 2977, 2925, 2860, 1640, 1579, 1564, 1495, 1453, 1433, 1421, 1019, 995, 
912, 791, 749, 732, 699. 
HRMS (EI) for C15H15N (209.1204) [M]
+: 209.1191. 
 
Synthesis of 4-(3-(4-chlorophenyl)pyridin-2-yl)-N,N-dimethylaniline (7c) according to TP3: 
 
According to TP3, the substituted pyridine 7c was prepared from 1.0 mmol of 5c with 1.2 mmol of 6b 
(1.12 M) at 25 °C for 90 min. Flash column chromatography (dichloromethane/ethyl acetate 9:1 + 
0.5% NEt3) furnished 7c as light yellow oil (247 mg, 80%). 
 
1H NMR (300 MHz, CDCl3) /ppm: 2.95 (s, 6 H), 6.59 (d, J=8.9 Hz, 2 H), 7.08 - 7.35 (m, 7 H), 7.61 (dd, 
J=7.8, 1.66 Hz, 1 H), 8.65 (dd, J=4.7, 1.66 Hz, 1 H). 
13C NMR (75 MHz, CDCl3) /ppm: 40.3, 111.6, 120.9, 127.5, 128.6, 130.8, 130.9, 132.9, 133.9, 138.3, 
139.3, 148.5, 150.1, 157.2. 
MS (70 eV, EI) m/z (%): 308 (100), 307 (45), 291 (19), 153 (9), 136 (12). 
IR ATR  (cm-1): 3037, 2885, 2855, 2801, 1606, 1576, 1524, 1489, 1425, 1394, 1353, 1193, 1168, 
1090, 999, 945, 834, 821, 799, 778, 758, 728, 718, 704. 
HRMS (EI) for C19H17ClN2 (308.1080) [M]
+: 308.1060. 
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Synthesis of 3-chloro-2-(4-(trifluoromethyl)phenyl)pyridine (7d) according to TP3: 
 
According to TP3, the substituted pyridine 7d was prepared from 1.0 mmol of 5d with 1.2 mmol of 6c 
(0.93 M) at 25 °C for 15 min. Flash column chromatography (i-hexane/ethyl acetate 8:1 + 0.5% NEt3) 
furnished 7d as white solid (195 mg, 76%). 
 
m.p.: 53.0 - 54.0 °C. 
1H NMR (300 MHz, CDCl3) /ppm: 7.27 (dd, J=8.0, 4.7 Hz, 1 H), 7.69 - 7.78 (m, 2 H), 7.79 - 7.92 (m, 
3 H), 8.62 (dd, J=4.7, 1.66 Hz, 1 H). 
13C NMR (75 MHz, CDCl3) /ppm: 123.7, 124.0 (q, J=272.1 Hz), 125.0 (q, J=3.9 Hz), 129.8, 130.3, 130.8 
(q, J=32.5 Hz), 138.3, 141.6, 147.8, 155.1. 
MS (70 eV, EI) m/z (%): 257 (46), 237 (28), 222 (98), 81 (13), 71 (16), 43 (100). 
IR ATR  (cm-1): 3052, 1616, 1564, 1436, 1428, 1402, 1324, 1164, 1132, 1108, 1090, 1066, 1040, 
1026, 1012, 848, 792, 768, 758, 736, 690. 
HRMS (EI) for C12H7ClF3N (257.0219) [M]
+: 257.0219. 
 
Synthesis of 4-(5-fluoropyridin-2-yl)phenyl pivalate (7e) according to TP3: 
 
According to TP3, the substituted pyridine 7e was prepared from 1.0 mmol of 5e with 1.2 mmol of 
6d (0.78 M) at 25 °C for 15 min. Flash column chromatography (i-hexane/ethyl acetate 6:1 + 0.5% 
NEt3) furnished 7e as white solid (180 mg, 66%). 
 
m.p.: 76.6 - 76.8 °C. 
1H NMR (300 MHz, CDCl3) /ppm: 1.38 (s, 9 H), 7.16 (m, 2 H), 7.46 (td, J=8.4, 3.3 Hz, 1 H), 7.69 (dd, 
J=8.9, 4.42 Hz, 1 H), 7.95 (m, 2 H), 8.53 (d, J=2.8 Hz, 1 H). 
13C NMR (75 MHz, CDCl3) /ppm: 27.1, 39.1, 121.1, 121.2, 121.8, 123.5, 123.7, 127.8, 135.8, 137.5, 
137.8, 151.8, 152.9, 152.9, 157.1, 160.5, 176.9. 
MS (70 eV, EI) m/z (%): 273 (9), 190 (11), 189 (100), 160 (4), 159 (3). 
IR ATR  (cm-1): 2982, 2966, 2932, 2908, 2890, 1750, 1742, 1600, 1470, 1416, 1396, 1382, 1368, 
1276, 1264, 1224, 1198, 1166, 1112, 1026, 1010, 974, 960, 942, 924, 898, 834, 826, 810, 796, 750.  
HRMS (EI) for C16H16FNO2 (273.1165) [M]
+: 273.1154. 
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Synthesis of 2-(benzo[d][1,3]dioxol-5-yl)-6,7-dimethoxy-4-methylquinoline (7f) according to TP3: 
 
According to TP3, the substituted quinoline 7f was prepared from 1.0 mmol of 5f with 1.2 mmol of 
6e (1.11 M) at 25 °C for 1 h. Flash column chromatography (i-hexane/ethyl acetate 3:1 + 0.5% NEt3) 
furnished 7f as yellow solid (239 mg, 74%). 
 
m.p.: 195 - 221 °C. 
1H NMR (300 MHz, CDCl3) /ppm: 2.67 (s, 3 H), 4.04 (d, J=5.5 Hz, 6 H), 6.02 (s, 2 H), 6.92 (d, J=8.3 Hz, 
1 H), 7.13 (s, 1 H), 7.50 (d, J=5.8 Hz, 2 H), 7.59 (dd, J=8.2, 1.8 Hz, 1 H), 7.65 (d, J=1.9 Hz, 1 H). 
13C NMR (75 MHz, CDCl3) /ppm: 19.2, 56.0, 56.1, 101.2, 101.5, 107.7, 108.4, 108.6, 117.9, 121.3, 
122.2, 134.3, 143.0, 144.8, 148.2, 148.4, 149.3, 152.2, 154.5. 
MS (70 eV, EI) m/z (%): 323 (100), 308 (18), 280 (15), 278 (6), 161 (9). 
IR ATR  (cm-1): 2922, 2898, 2834, 1618, 1604, 1592, 1494, 1486, 1476, 1466, 1450, 1432, 1416, 
1382, 1352, 1336, 1240, 1222, 1206, 1166, 1138, 1114, 1066, 1048, 1028, 998, 926, 876, 862, 852, 
834, 808. 
HRMS (EI) for C19H17NO4 (323.1158) [M]
+: 323.1149. 
 
Synthesis of N,N-dimethyl-4-(2-phenylquinolin-4-yl)aniline (7g) according to TP3: 
 
According to TP3, the substituted quinoline 7g was prepared from 1.0 mmol of 5g with 1.2 mmol of 
6b (1.12 M) at 25 °C for 15 min. Flash column chromatography (i-hexane/ethyl acetate 8:1 + 0.5% 
NEt3) furnished 7g as red solid (253 mg, 78%). 
 
m.p.: 152.0 - 154.0 °C. 
1H NMR (300 MHz, CDCl3) /ppm: 3.06 (s, 6 H), 6.89 (dd, J=8.71, 1.80 Hz, 2 H), 7.43 - 7.59 (m, 6 H), 
7.70 - 7.77 (m, 1 H), 7.83 (d, J=1.66 Hz, 1 H), 8.09 (d, J=8.29 Hz, 1 H), 8.19 - 8.30 (m, 3 H). 
13C NMR (75 MHz, CDCl3) /ppm: 40.4, 112.2, 113.1, 119.1, 125.9, 126.1, 127.0, 127.6, 128.8, 129.2, 
129.3, 130.0, 130.6, 139.9, 148.9, 149.5, 150.6, 156.9. 
MS (70 eV, EI) m/z (%): 324 (100), 323 (42), 307 (16), 280 (13), 240 (63), 225 (23), 161 (15), 119 (14). 
IR ATR  (cm-1): 2922, 2866, 2806, 1610, 1592, 1542, 1524, 1504, 1492, 1460, 1442, 1424, 1414, 
1402, 1356, 1226, 1196, 1162, 1138, 1120, 1064, 944, 818, 808, 788, 772, 762, 694, 680. 
HRMS (EI) for C23H20N2 (324.1626) [M]
+: 324.1621. 
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Synthesis of 4,6-dimethyl-2-(4-(trifluoromethoxy)phenyl)pyrimidine (7h) according to TP3: 
 
According to TP3, the substituted pyrimidine 7h was prepared from 1.0 mmol of 5h with 1.2 mmol of 
6f (0.80 M) at 25 °C for 2 h. Flash column chromatography (i-hexane/ethyl acetate 6:1 + 0.5% NEt3) 
furnished 7h as white solid (190 mg, 71%). 
 
m.p.: 66.0 - 67.4 °C. 
1H NMR (300 MHz, CDCl3) /ppm: 2.53 (s, 6 H), 6.93 (s, 1 H), 7.29 (d, J=8.3 Hz, 2 H), 8.48 (d, J=8.6 Hz, 
2 H). 
13C NMR (75 MHz, CDCl3) /ppm: 24.1, 118.2, 120.5, 120.5 (q, J=257.6 Hz), 129.9, 136.6, 150.9, 
162.8, 166.9. 
MS (70 eV, EI) m/z (%): 269 (13), 268 (100), 253 (12), 189 (15), 187 (20). 
IR ATR  (cm-1): 1602, 1582, 1544, 1504, 1434, 1368, 1288, 1256, 1196, 1148, 1102, 1030, 1012, 958, 
920, 874, 866, 852, 810, 786, 734, 680. 
HRMS (EI) for C13H11F3N2O (268.0823) [M]
+: 268.0803. 
 
Synthesis of 2-(3-((tert-butyldimethylsilyl)oxy)phenyl)-4-(4-(trifluoromethyl)-phenyl)-pyrimidine 
(7i) according to TP3: 
 
According to TP3, the substituted pyrimidine 7i was prepared from 1.0 mmol of 5i with 1.2 mmol of 
6g (1.00 M) at 25 °C for 15 min. Flash column chromatography (i-hexane/ethyl acetate 8:1 + 0.5% 
NEt3) furnished 7i as light yellow oil (344 mg, 80%). 
 
1H NMR (300 MHz, CDCl3) /ppm: 0.29 (s, 6 H), 1.05 (s, 9 H), 7.02 (dd, J=7.6, 2.1 Hz, 1 H), 7.40 (t, 
J=7.9 Hz, 1 H), 7.63 (d, J=5.3 Hz, 1 H), 7.81 (m, 2 H), 8.08 (dd, J=2.2, 1.7 Hz, 1 H), 8.17 - 8.22 (m, 1 H), 
8.33 (m, 2 H), 8.90 (d, J=5.25 Hz, 1 H). 
13C NMR (75 MHz, CDCl3) /ppm: -4.3, 18.3, 25.7, 107.6, 108.4, 112.6, 114.8, 119.9, 121.4, 122.9, 
123.9 (q, J=272.6 Hz), 125.9 (q, J=3.9 Hz), 127.6, 129.6, 129.9, 132.4, 140.3, 156.1, 156.7, 158.0, 
162.5, 164.5. 
MS (70 eV, EI) m/z (%): 430 (7), 374 (26), 373 (100), 224 (4), 167 (23). 
IR ATR  (cm-1): 2958, 2932, 2860, 1712, 1566, 1550, 1452, 1426, 1410, 1382, 1362, 1326, 1284, 
1272, 1256, 1220, 1168, 1146, 1128, 1094, 1070, 950, 838, 810, 784. 
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HRMS (EI) for C23H25F3N2OSi (430.1688) [M]
+: 430.1682. 
Synthesis of 2-(4-methoxyphenyl)pyrazine (7j) according to TP3: 
 
According to TP3, the substituted pyrazine 7j was prepared from 1.0 mmol of 5j with 1.2 mmol of 6h 
(1.34 M) at 25 °C for 30 min. Flash column chromatography (i-hexane/ethyl acetate 6:1 + 0.5% NEt3) 
furnished 7j as white solid (134 mg, 72%). 
 
m.p.: 93.8 - 95.2 °C. 
1H NMR (300 MHz, CDCl3) /ppm: 3.87 (s, 3 H), 6.98 - 7.07 (m, 2 H), 7.95 - 8.01 (m, 2 H), 8.43 (d, 
J=2.5 Hz, 1 H), 8.58 (dd, J=2.5, 1.4 Hz, 1 H), 8.97 (d, J=1.4 Hz, 1 H). 
13C NMR (75 MHz, CDCl3) /ppm: 55.4, 114.5, 128.3, 128.8, 141.5, 141.9, 144.0, 152.5, 161.2. 
MS (70 eV, EI) m/z (%): 186 (19), 149 (7), 133 (7), 109 (6), 83 (8), 71 (8), 69 (24). 
IR ATR  (cm-1): 2956, 2914, 2836, 1604, 1586, 1516, 1474, 1458, 1424, 1400, 1302, 1246, 1178, 
1148, 1108, 1078, 1034, 1014, 834, 818, 750. 
HRMS (EI) for C11H10N2O (186.0793) [M]
+: 186.0785. 
 
Synthesis of ethyl 2'-benzoyl-[1,1'-biphenyl]-3-carboxylate (9a) according to TP3: 
 
According to TP3, the substituted benzophenone 9a was prepared from 1.0 mmol of 8a with 1.2 
mmol of 6i (0.81 M) at 25 °C for 15 min. Flash column chromatography (i-hexane/diethyl ether 9:1) 
furnished 9a as white solid (261 mg, 79%). 
 
m.p.: 65.1 - 66.7 °C. 
1H NMR (300 MHz, CDCl3) /ppm: 1.33 (t, J=7.1 Hz, 3 H), 4.32 (q, J=7.2 Hz, 2 H), 7.23 - 7.32 (m, 3 H), 
7.38 – 7.69 (m, 8 H), 7.85 (dt, J=7.8, 1.5 Hz, 1 H), 7.98 (t, J=1.7 Hz, 1 H). 
13C NMR (75 MHz, CDCl3) /ppm: 14.2, 60.9, 127.4, 128.1, 128.2, 128.4, 128.9, 129.8, 129.9, 130.1, 
130.5, 130.5, 132.9, 133.3, 137.3, 138.9, 140.2, 140.3, 166.1, 198.3. 
MS (70 eV, EI) m/z (%): 330 (100), 285 (37), 257 (53), 253 (30), 207 (97), 152 (30), 105 (83), 77 (45). 
IR ATR  (cm-1): 3054, 2971, 2912, 1714, 1662, 1595, 1580, 1567, 1447, 1440, 1428, 1306, 1283, 
1264, 1238, 1180, 1167, 1153, 1120, 1112, 1106, 1075, 1054, 1033, 1023, 1000, 937, 923, 894, 882, 
861, 805, 768, 747, 712, 704, 695, 669. 
HRMS (EI) for C22H18O3 (330.1256) [M]
+: 330.1247. 
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Synthesis of 2'-benzoyl-[1,1'-biphenyl]-3-carbonitrile (9b) according to TP3: 
 
According to TP3, the substituted benzophenone 9b was prepared from 1.0 mmol of 8a with 0.7 
mmol of 6j (0.51 M) at 25 °C for 2 h. Flash column chromatography (i-hexane/ethyl acetate 95:5) 
furnished 9b as colorless oil (261 mg, 71%). 
 
1H NMR (300 MHz, CDCl3) /ppm: 7.22– 7.39 (m, 3H), 7.41– 7.50 (m, 4H), 7.51– 7.68 (m, 6H). 
13C NMR (75 MHz, CDCl3) /ppm: 112.5, 118.5, 128.0, 128.4, 129.0, 129.2, 130.1, 130.8, 130.9, 132.2, 
133.3, 133.4, 137.2, 138.8, 138.9, 141.5, 197.8. 
MS (70 eV, EI) m/z (%): 283 (98), 282 (28), 206 (79), 151 (25), 105 (100), 77 (53). 
IR ATR  (cm-1): 3061, 3028, 2230, 1661, 1595, 1579, 1470, 1448, 1412, 1314, 1284, 1276, 1264, 
1177, 1152, 1110, 1074, 1026, 1000, 928, 905, 846, 802, 757, 727, 707, 690. 
HRMS (EI) for C20H13NO (283.0997) [M]
+: 283.0988. 
 
Synthesis of phenyl(4'-(trifluoromethyl)-[1,1'-biphenyl]-2-yl)methanone (9c) according to TP3: 
 
According to TP3, the substituted benzophenone 9c was prepared from 1.0 mmol of 8a with 1.2 
mmol of 6c (0.93 M) at 25 °C for 15 min. Flash column chromatography (i-hexane/ethyl acetate 96:4) 
furnished 9c as colorless oil (305 mg, 93%). 
 
1H NMR (300 MHz, CDCl3) /ppm: 7.26 - 7.42 (m, 4 H), 7.43 - 7.65 (m, 7 H), 7.66 - 7.71 (m, 2 H). 
13C NMR (75 MHz, CDCl3) /ppm: 124.1 (q, J=272.1 Hz), 125.2 (q, J=3.9 Hz), 127.7, 128.3, 128.9, 
129.3, 129.4 (q, J=32.5 Hz), 129.9, 130.1, 130.6, 133.2, 137.3, 138.9, 139.9, 143.9, 198.1. 
MS (70 eV, EI) m/z (%): 326 (100), 325 (27), 249 (91), 201 (34), 152 (24), 105 (74), 77 (42). 
IR ATR  (cm-1): 3063, 1663, 1618, 1597, 1581, 1450, 1405, 1322, 1281, 1260, 1162, 1120, 1114, 
1068, 1020, 1006, 926, 843, 806, 764, 737, 709, 698. 
HRMS (EI) for C20H13F3O (326.0918) [M]
+: 326.0904. 
 
Synthesis of (4'-(dimethylamino)-[1,1'-biphenyl]-2-yl)(phenyl)methanone (9d) according to TP3: 
 
According to TP3, the substituted benzophenone 9d was prepared from 1.0 mmol of 8a with 1.2 
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mmol of 6b (1.12 M) at 25 °C for 15 min. Flash column chromatography (i-hexane/ethyl acetate 97:3 
+ 4% Et3N) furnished 9d as orange solid (282 mg, 94%). 
 
m.p.: 112.4 - 113.8 °C. 
1H NMR (300 MHz, CDCl3) /ppm: 2.87 (s, 6 H), 6.53 - 6.62 (m, 2 H), 7.14 - 7.21 (m, 2 H), 7.24 - 7.33 
(m, 2 H), 7.35 - 7.44 (m, 2 H), 7.45 - 7.58 (m, 3 H), 7.68 - 7.75 (m, 2 H). 
13C NMR (75 MHz, CDCl3) /ppm: 40.4, 112.3, 126.0, 128.1, 128.1, 128.6, 129.8, 129.8, 129.9, 130.2, 
132.7, 137.5, 138.6, 141.2, 149.7, 199.3. 
MS (70 eV, EI) m/z (%): 302 (21), 301 (100), 300 (36), 77 (12). 
IR ATR  (cm-1): 2924, 2854, 2802, 1663, 1611, 1594, 1580, 1570, 1525, 1479, 1447, 1349, 1315, 
1293, 1281, 1247, 1222, 1204, 1168, 1161, 1150, 1130, 1104, 1062, 1028, 945, 938, 932, 921, 879, 
823, 804, 775, 766, 726, 720, 703, 690, 676. 
HRMS (EI) for C21H19NO (301.1467) [M]
+: 301.1452. 
 
Synthesis of (2-(benzo[b]thiophen-3-yl)phenyl)(phenyl)methanone (9e) according to TP3: 
 
According to TP3, the substituted benzophenone 9e was prepared from 1.0 mmol of 8a with 1.2 
mmol of 6k (0.96 M) at 50 °C for 2 h. Flash column chromatography (i-hexane/ethyl acetate 96:4) 
furnished 9e as red solid (305 mg, 89%). 
 
m.p.: 121.2 - 123.1 °C. 
1H NMR (300 MHz, CDCl3) /ppm: 7.05 - 7.13 (m, 2 H), 7.18 (s, 1 H), 7.20 - 7.38 (m, 3 H), 7.49 - 7.75 
(m, 8 H). 
13C NMR (75 MHz, CDCl3) /ppm: 122.5, 122.7, 124.3, 124.3, 126.0, 127.7, 127.8, 129.1, 129.1, 130.3, 
130.4, 132.4, 134.5, 135.6, 137.2, 138.3, 139.9, 140.1, 198.5. 
MS (70 eV, EI) m/z (%): 314 (100), 313 (21), 285 (19), 234 (76), 165 (30), 105 (21), 77 (27). 
IR ATR  (cm-1): 1663, 1593, 1577, 1448, 1424, 1316, 1285, 1270, 1255, 1210, 1183, 1163, 1147, 
1062, 944, 926, 836, 808, 764, 758, 733, 717, 704. 
HRMS (EI) for C21H14OS (314.0765) [M]
+: 314.0755.  
 
Synthesis of [1,1'-biphenyl]-2-yl(6-chloropyridin-3-yl)methanone (9f) according to TP3: 
 
According to TP3, the substituted benzophenone 9f was prepared from 1.0 mmol of 8b with 1.2 
mmol of 6a (1.61 M) at 25 °C for 15 min. Flash column chromatography (i-hexane/diethyl ether 2:1) 
Ph
O
S
Ph
O
N Cl
C. EXPERIMENTAL SECTION 
103 
furnished 9f as white crystals (211 mg, 72%). 
 
m.p.: 108.6 - 111.2 °C. 
1H NMR (300 MHz, CDCl3) /ppm: 7.12 - 7.24 (m, 6 H), 7.48 - 7.68 (m, 4 H), 7.81 (dd, J=8.3, 2.5 Hz, 
1 H), 8.42 (dd, J=2.5, 0.6 Hz, 1 H). 
13C NMR (75 MHz, CDCl3) /ppm: 123.8, 127.7, 127.8, 128.6, 129.0, 129.1, 130.1, 131.4, 131.8, 137.6, 
138.9, 139.6, 141.2, 151.2, 154.8, 196.3. 
MS (70 eV, EI) m/z (%): 293 (97), 292 (100), 266 (11), 264 (26), 182 (10), 153 (30), 152 (50), 151 (13), 
140 (18). 
IR ATR  (cm-1): 1671, 1594, 1576, 1564, 1478, 1460, 1448, 1433, 1376, 1363, 1289, 1276, 1266, 
1251, 1139, 1115, 1100, 1076, 1052, 1041, 1020, 1008, 970, 961, 926, 918, 884, 844, 786, 774, 752, 
744, 715, 699. 
HRMS (EI) for C18H12ClNO (293.0613) [M]
+: 293.0569. 
 
Synthesis of thiophen-2-yl(2-(thiophen-3-yl)phenyl)methanone (9g) according to TP3: 
 
According to TP3, the substituted benzophenone 9g was prepared from 0.68 mmol of 8c with 
0.82 mmol of 6l (0.79 M) at 25 °C for 15 min. Flash column chromatography (i-hexane/diethyl ether 
9:1) furnished 9g as light brown solid (165 mg, 90%). 
 
m.p.: 68.8 - 70.2 °C. 
1H NMR (300 MHz, CDCl3) /ppm: 6.94 (dd, J=4.8, 3.7 Hz, 1 H), 7.09 (dd, J=4.8, 1.5 Hz, 1 H), 7.17 - 
7.28 (m, 3 H), 7.38 - 7.45 (m, 1 H), 7.47 - 7.65 (m, 4 H). 
13C NMR (75 MHz, CDCl3) /ppm: 123.4, 125.9, 127.0, 127.9, 128.1, 128.2, 129.7, 130.3, 134.7, 134.8, 
135.2, 138.7, 140.5, 144.5, 190.8. 
MS (70 eV, EI) m/z (%): 270 (100), 269 (33), 241 (32), 237 (85), 115 (31), 111 (38). 
IR ATR  (cm-1): 3094, 2923, 2853, 1628, 1595, 1567, 1511, 1481, 1443, 1407, 1366, 1354, 1295, 
1268, 1258, 1231, 1195, 1164, 1149, 1106, 1085, 1052, 1042, 1026, 889, 859, 842, 804, 795, 779, 
756, 748, 728, 723, 706, 697, 669. 
HRMS (EI) for C15H10OS2 (270.0173) [M]
+: 270.0169. 
 
Synthesis of [1,1'-biphenyl]-2-carbaldehyde (11a) according to TP4: 
 
According to TP4, the substituted benzaldehyde 11a was prepared from 1 mmol of 10 with 1.2 mmol 
of 6a (1.61 M) at 25 °C for 15 min. Flash column chromatography (i-hexane/diethyl ether 9:1) 
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furnished 11a as yellow oil (152 mg, 84%). 
 
1H NMR (300 MHz, CDCl3) /ppm: 7.37 - 7.41 (m, 2 H), 7.43 - 7.52 (m, 5 H), 7.64 (td, J=7.5, 1.5 Hz, 1 
H), 8.04 (dd, J=7.7, 1.4 Hz, 1 H), 10.00 (d, J=0.8 Hz, 1 H).  
13C NMR (75 MHz, CDCl3) /ppm: 127.6, 127.8, 128.1, 128.4, 130.1, 130.8, 133.5, 133.7, 137.7, 146.0, 
192.4. 
MS (70 eV, EI) m/z (%): 182 (72), 181 (100), 154 (19), 153 (41), 152 (49), 76 (13). 
IR ATR  (cm-1): 3060, 3028, 2845, 2752, 1688, 1655, 1596, 1498, 1473, 1453, 1437, 1392, 1301, 
1252, 1194, 1160, 1101, 1075, 1048, 1033, 1008, 919, 827, 778, 756, 745, 700. 
HRMS (EI) for C13H10O (182.0732) [M]
+: 182.0701. 
 
Synthesis of 4'-methoxy-[1,1'-biphenyl]-2-carbaldehyde (11b) according to TP4: 
 
According to TP4, the substituted benzaldehyde 11b was prepared from 1 mmol of 10 with 1.2 mmol 
of 6h (1.34 M) at 25 °C for 15 min. Flash column chromatography (i-hexane/diethyl ether 95:5) 
furnished 11b as yellow oil (152 mg, 69%). 
 
1H NMR (300 MHz, CDCl3) /ppm: 3.87 (d, J=0.8 Hz, 3 H), 6.97 - 7.04 (m, 2 H), 7.25 - 7.34 (m, 2 H), 
7.40 - 7.49 (m, 2 H), 7.57 - 7.65 (m, 1 H), 8.00 (dt, J=7.8, 0.7 Hz, 1 H), 10.00 (t, J=0.7 Hz, 1 H). 
13C NMR (75 MHz, CDCl3) /ppm: 55.4, 113.9, 127.3, 127.6, 130.0, 130.8, 131.3, 133.5, 133.8, 145.6, 
159.7, 192.6. 
MS (70 eV, EI) m/z (%): 212 (100), 211 (30), 197 (20), 181 (27), 169 (59), 168 (19), 152 (21), 140 (20), 
139 (51), 115 (57). 
IR ATR  (cm-1): 3031, 2957, 2935, 2837, 2750, 1688, 1657, 1609, 1596, 1578, 1514, 1474, 1449, 
1442, 1391, 1297, 1271, 1243, 1192, 1177, 1160, 1112, 1100, 1047, 1033, 1016, 1000, 833, 803, 763, 
742, 713. 
HRMS (EI) for C14H12O2: (212.0837) [M]
+: 212.0838. 
 
Synthesis of 2-(thiophen-3-yl)benzaldehyde (11c) according to TP4: 
 
According to TP4, the substituted benzaldehyde 11c was prepared from 1 mmol of 10 with 1.2 mmol 
of 6l (0.79 M) at 25 °C for 16 h. Flash column chromatography (i-hexane/diethyl ether 95:5) 
furnished 11c as yellow oil (140 mg, 75%). 
 
1H NMR (300 MHz, CDCl3) /ppm: 7.17 - 7.21 (m, 1 H), 7.29 (dd, J=2.9, 1.2 Hz, 1 H), 7.42 - 7.51 (m, 
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3 H), 7.58 - 7.65 (m, 1 H), 7.97 - 8.03 (m, 1 H), 10.10 (d, J=0.6 Hz, 1 H). 
13C NMR (75 MHz, CDCl3) /ppm: 125.0, 126.3, 127.6, 127.8, 129.3, 130.6, 133.6, 134.0, 138.3, 140.4, 
192.3. 
MS (70 eV, EI) m/z (%): 188 (100), 160 (100), 159 (24), 158 (21), 116 (20), 115 (85), 43 (31). 
IR ATR  (cm-1): 3099, 2847, 2750, 1683, 1596, 1570, 1474, 1447, 1406, 1389, 1362, 1270, 1243, 
1194, 1160, 1100, 1082, 1047, 1028, 859, 830, 813, 792, 756, 731, 684, 653. 
HRMS (EI) for C11H8OS: (188.0296) [M]
+: 188.0300.  
 
Synthesis of (E)-N,N-dimethyl-4-(oct-1-en-1-yl)aniline (13a) according to TP5: 
 
According to TP5, the substituted styrene 13a was prepared from 1 mmol of (E)-12 with 1.5 mmol of 
6b (1.12 M) at 25 °C for 15 min. Flash column chromatography (i-hexane/ethyl acetate 9:1) furnished 
13a as light yellow oil (162 mg, 70%). 
 
1H NMR (300 MHz, CDCl3) /ppm: 0.84 - 0.96 (m, 3 H), 1.23 - 1.52 (m, 8 H), 2.10 - 2.26 (m, 2 H), 2.95 
(s, 6 H), 5.97 - 6.10 (m, 1 H), 6.30 (d, J=16.0 Hz, 1 H), 6.66 - 6.74 (m, 2 H), 7.21 - 7.29 (m, 2 H). 
13C NMR (75 MHz, CDCl3) /ppm: 14.1, 22.7, 28.9, 29.7, 31.8, 33.1, 40.7, 112.8, 126.7, 127.2, 129.4, 
149.6. 
MS (70 eV, EI) m/z (%): 232 (15), 231 (100), 161 (26), 160 (40), 145 (14), 134 (30). 
IR ATR  (cm-1): 2954, 2923, 2871, 2852, 2801, 1610, 1519, 1480, 1466, 1454, 1444, 1348, 1221, 
1187, 1164, 1129, 1061, 961, 947, 831, 801, 725. 
HRMS (EI) for C16H25N (231.1987) [M]
+: 231.1964. 
 
Synthesis of (E)-1-methoxy-4-(oct-1-en-1-yl)benzene (13b) according to TP5: 
 
According to TP5, the substituted styrene 13b was prepared from 1 mmol of (E)-12 with 1.5 mmol of 
6h (1.34 M) at 25 °C for 15 min. Flash column chromatography (i-hexane/ethyl acetate 20:1) 
furnished 13b as colorless oil (164 mg, 75%). 
 
1H NMR (300 MHz, CDCl3) /ppm: 0.87 - 0.99 (m, 3 H), 1.28 - 1.52 (m, 8 H), 2.14 - 2.27 (m, 2 H), 3.81 
(s, 3 H), 6.04 - 6.17 (m, 1 H), 6.29 - 6.39 (m, 1 H), 6.85 (m, 2 H), 7.29 (m, 2 H). 
13C NMR (75 MHz, CDCl3) /ppm: 14.1, 22.7, 28.9, 29.5, 31.8, 33.0, 55.3, 113.9, 126.9, 129.0, 129.1, 
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130.8, 158.6. 
MS (70 eV, EI) m/z (%): 218 (27), 148 (14), 147 (100), 134 (19), 121 (24), 115 (10), 91 (16).  
IR ATR  (cm-1): 2955, 2924, 2871, 2854, 2836, 1608, 1510, 1465, 1441, 1287, 1244, 1174, 1105, 
1037, 963, 840, 803, 758, 724. 
HRMS (EI) for C15H22O (218.1671) [M]
+: 218.1666. 
 
Synthesis of (E)-tert-butyldimethyl(3-(oct-1-en-1-yl)phenoxy)silane (13c) according to TP5: 
 
According to TP5, the substituted styrene 13c was prepared from 1 mmol of (E)-12 with 1.5 mmol of 
6g (1.00 M) at 25 °C for 15 min. Flash column chromatography (i-hexane) furnished 13c as colorless 
oil (255 mg, 80%). 
 
1H NMR (300 MHz, CDCl3) /ppm: 0.22 (s, 6 H), 0.87 - 0.97 (m, 3 H), 1.02 (s, 9 H), 1.22 - 1.58 (m, 8 H), 
2.22 (q, J=7.3 Hz, 2 H), 6.15 - 6.26 (m, 1 H), 6.30 - 6.38 (m, 1 H), 6.70 (dd, J=8.0, 2.2 Hz, 1 H), 6.94 - 
7.00 (m, 1 H), 7.12 - 7.28 (m, 2 H). 
13C NMR (75 MHz, CDCl3) /ppm: -4.4, 14.1, 18.2, 22.6, 25.7, 28.9, 29.3, 31.8, 33.0, 117.5, 118.5, 
119.1, 120.1, 129.5, 131.3, 139.5, 155.8. 
MS (70 eV, EI) m/z (%): 318 (13), 262 (20), 261 (100), 163 (9), 151 (6). 
IR ATR  (cm-1): 2956, 2928, 2857, 1597, 1578, 1490, 1472, 1464, 1439, 1277, 1252, 1170, 1156, 
1001, 965, 939, 916, 876, 837, 778, 713, 688, 665.  
HRMS (EI) for C20H34OSi (318.2379) [M]
+: 318.2376. 
 
Synthesis of (E)-1-(dimethoxymethyl)-4-(oct-1-en-1-yl)benzene (13d) according to TP5: 
 
According to TP5, the substituted styrene 13d was prepared from 1 mmol of (E)-12 with 1.5 mmol of 
6m (0.93 M) at 25 °C for 15 min. Flash column chromatography (i-hexane/ethyl acetate 20:1) 
furnished 13d as colorless oil (181 mg, 69%). 
 
1H NMR (300 MHz, DMSO) /ppm: 0.81 - 0.87 (m, 3 H), 1.23 - 1.32 (m, 6 H), 1.36 - 1.45 (m, 2 H), 2.15 
(q, J=6.6 Hz, 2 H), 3.32 (s, 6 H), 5.33 (s, 1 H), 6.24 - 6.39 (m, 2 H), 7.28 (m, 2 H), 7.36 (m, 2 H). 
13C NMR (75 MHz, DMSO) /ppm: 14.4, 22.5, 28.8, 29.2, 31.6, 32.9, 52.8, 102.9, 125.9, 127.2, 129.6, 
131.7, 137.1, 137.9. 
MS (70 eV, EI) m/z (%): 216 (24), 133 (11), 132 (100), 131 (30), 117 (66), 91 (24). 
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IR ATR  (cm-1): 2954, 2927, 2856, 1689, 1609, 1577, 1466, 1422, 1379, 1286, 1268, 1208, 1170, 
1107, 1016, 893, 856, 828, 804, 790, 762, 733, 724, 702. 
HRMS (EI) for C17H26O2 (262.1933) [M]
+: 262.1916. 
 
Synthesis of (Z) -1-methoxy-4-(oct-1-en-1-yl)benzene (13e) according to TP5: 
 
According to TP5, the substituted styrene 13e was prepared from 0.5 mmol of (Z)-12 with 0.75 mmol 
of 6h (0.79 M) at 25 °C for 14 h. Flash column chromatography (i-hexane) furnished 13e as colorless 
oil (76 mg, 70%). 
 
1H NMR (300 MHz, CDCl3) /ppm: 0.84 - 0.93 (m, 3 H), 1.26 - 1.56 (m, 8 H), 2.24 - 2.41 (m, 2 H), 3.82 
(s, 3 H), 5.58 (dt, J=11.6, 7.2 Hz, 1 H), 6.28 - 6.40 (m, 1 H), 6.82 - 6.92 (m, 2 H,), 7.18 - 7.28 (m, 2 H). 
13C NMR (75 MHz, CDCl3) /ppm: 14.1, 22.6, 28.7, 29.1, 30.0, 31.7, 55.2, 113.5, 128.0, 129.9, 130.5, 
131.7, 158.1. 
MS (70 eV, EI) m/z (%): 218 (27), 148 (12), 147 (100), 134 (17), 121 (15), 115 (11), 91 (17), 43 (21). 
IR ATR  (cm-1): 2955, 2924, 2871, 2854, 2836, 1608, 1510, 1464, 1301, 1247, 1174, 1113, 1037, 964, 
837, 818, 752, 725. 
HRMS (EI) for C15H22O (218.1671) [M]
+: 218.1662. 
 
Synthesis of 4-chloro-2-phenylpyridine (15a) according to TP3: 
 
According to TP3, the substituted pyridine 15a was prepared from 1 mmol of 14a with 1.2 mmol of 
6a (1.7 M) at 25 °C for 15 min. Flash column chromatography (i-hexane/ethyl acetate 6:1 + 0.5% 
NEt3) furnished 15a as light yellow oil (152 mg, 80%).  
 
1H NMR (300 MHz, CDCl3) /ppm: 7.21 - 7.29 (m, 1 H), 7.41 - 7.57 (m, 3 H), 7.74 (dd, J=1.94, 0.55 Hz, 
1 H), 7.90 - 8.08 (m, 2 H), 8.59 (dd, J=5.25, 0.55 Hz, 1 H). 
13C NMR (75 MHz, CDCl3) /ppm: 120.8, 122.3, 127.0, 128.9, 129.6, 138.1, 144.74, 150.5, 159.0 
MS (70 eV, EI) m/z (%): 189 (51) [M]+, 188 (14), 154 (27), 127 (12), 70 (11), 43 (100). 
IR ATR  (cm-1): 3044, 2358, 1571, 1549, 1497, 1462, 1442, 1382, 1112, 1096, 1072, 1053, 872, 823, 
802, 771, 728, 703, 690, 668, 659. 
HRMS (EI) for C11H8ClN (189.0345) [M]
+: 189.0337. 
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Synthesis of 3-chloro-2-phenylpyridine (15b) according to TP3: 
 
According to TP3, the substituted pyridine 15b was prepared from 1 mmol of 14b with 1.2 mmol of 
2a (1.7 M) at 25 °C for 15 min. Flash column chromatography (i-hexane/ethyl acetate 6:1 + 0.5% 
NEt3) furnished 15b as light yellow oil (144 mg, 76%).  
 
1H NMR (300 MHz, CDCl3) /ppm: 7.22 (dd, J=8.02, 4.70 Hz, 1 H), 7.43 - 7.53 (m, 3 H), 7.72 - 7.84 (m, 
3 H), 8.61 (dd, J=4.70, 1.38 Hz, 1 H). 
13C NMR (75 MHz, CDCl3) /ppm: 123.0, 128.0, 128.8, 129.3, 130.2, 138.1, 138.2, 147.6, 156.6. 
MS (70 eV, EI) m/z (%): 189 (22), 154 (50), 61 (18), 43 (100). 
IR ATR  (cm-1): 3057, 3042, 2362, 1570, 1553, 1496, 1450, 1431, 1415, 1222, 1181, 1131, 1089, 
1075, 1031, 1016, 1002, 974, 918, 794, 786, 761, 737, 694, 681, 668, 659, 654. 
HRMS (EI) for C11H8ClN (189.0345) [M]
+: 189.0344. 
 
Synthesis of 5-chloro-2-phenylpyridine (15c) according to TP3: 
 
According to TP3, the substituted pyridine 15c was prepared from 1 mmol of 14c with 1.2 mmol of 
2a (1.7 M) at 25 °C for 15 min. Flash column chromatography (i-hexane/ethyl acetate 6:1 + 0.5% 
NEt3) furnished 15c as white crystals (165 mg, 87%). 
 
m.p.: 65.8 - 67.8 °C. 
1H NMR (300 MHz, CDCl3) /ppm: 7.42 - 7.52 (m, 3 H), 7.66 - 7.69 (m, 1 H), 7.71 - 7.74 (m, 1 H), 7.95 - 
8.01 (m, 2 H), 8.65 (dd, J=2.34, 0.78 Hz, 1 H). 
13C NMR (75 MHz, CDCl3) /ppm: 121.1, 126.8, 128.9, 129.3, 130.6, 136.5, 138.2, 148.5, 155.5. 
MS (70 eV, EI) m/z (%): 191 (33), 189 (100), 154 (41), 127 (13). 
IR ATR  (cm-1): 3062, 3037, 2360, 1574, 1554, 1460, 1456, 1442, 1436, 1419, 1365, 1290, 1136, 
1112, 1074, 1022, 1007, 991, 979, 929, 920, 853, 834, 774, 755, 730, 707, 690, 676, 672, 668, 663, 
658, 655, 653. 
HRMS (EI) for C11H8ClN (189.0345) [M]
+: 189.0340. 
 
Synthesis of 4-chloro-5-methyl-2-phenylpyridine (15d) according to TP3: 
 
According to TP3, the substituted pyridine 15d was prepared from 1 mmol of 14d with 1.2 mmol of 
2a (3.0 M) at 25 °C for 15 min. Flash column chromatography (0-40% MTBE/heptane) furnished 15d 
as colorless oil (173 mg, 85%). 
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1H NMR (300 MHz, CDCl3) /ppm: 2.39 (s, 3H), 7.37 - 7.53 (m, 3H), 7.71 (s, 1H), 7.90 - 8.01 (m, 2H), 
8.50 (s, 1H). 
13C NMR (75 MHz, CDCl3) /ppm: 16.5, 120.7, 126.7, 128.8, 129.2, 130.2, 138.2, 144.7, 151.1, 156.6. 
MS (70 eV, EI) m/z (%): 217 (8), 206 (33), 204 (100), 202 (2). 
HRMS (EI) for C12H10ClN (203.0502) [M]
+: 203.0505. 
 
Synthesis of 4-chloro-3-methyl-2-phenylpyridine (15e) according to TP3: 
 
According to TP3, the substituted pyridine 15e was prepared from 1 mmol of 14e with 1.2 mmol of 
2a (3.0 M) at 25 °C for 15 min. Flash column chromatography (0-40% MTBE/heptane) furnished 15e 
as colorless oil (179 mg, 88%). 
 
1H NMR (300 MHz, CDCl3) /ppm: 2.38 (s, 3H), 7.30 (d, J=5.3 Hz, 1H), 7.33 - 7.52 (m, 5H), 8.41 (d, 
J=5.3 Hz, 1H). 
13C NMR (75 MHz, CDCl3) /ppm: 17.2, 123.0, 128.2, 128.3, 129.0, 129.8, 140.1, 145.4, 147.0, 160.6. 
MS (70 eV, EI) m/z (%): 225 (4), 206 (35), 204 (100). 
HRMS (EI) for C12H10ClN (203.0502) [M]
+: 203.0512. 
 
Synthesis of 4-chloro-3-(1,3-dioxolan-2-yl)-2-phenylpyridine (15f) according to TP3: 
 
According to TP3, the substituted pyridine 15f was prepared from 1 mmol of 14f with 1.2 mmol of 2a 
(1.7 M) at 25 °C for 30 min. Flash column chromatography (i-hexane/ethyl acetate 4:1 + 0.5% NEt3) 
furnished 15f as white solid (175 mg, 67%). 
 
m.p.: 59.3 - 61.0 °C. 
1H NMR (300 MHz, CDCl3) /ppm: 3.85 - 4.02 (m, 2 H), 4.02 - 4.20 (m, 2 H), 5.97 (s, 1 H), 7.30 - 7.67 
(m, 6 H), 8.54 (d, J=5.25 Hz, 1 H). 
13C NMR (75 MHz, CDCl3) /ppm: 65.8, 101.4, 125.0, 127.5, 128.0, 128.5, 129.4, 139.1, 145.2, 149.9, 
162.1. 
MS (70 eV, EI) m/z (%): 218 (30), 216 (89), 191 (33), 189 (100), 183 (26), 154 (47). 
IR ATR  (cm-1): 2971, 2894, 2362, 1559, 1552, 1452, 1446, 1379, 1222, 1171, 1103, 1057, 1018, 973, 
962, 938, 922, 862, 844, 838, 810, 792, 771, 763, 724, 707, 702, 685, 673, 668, 661, 656, 653. 
HRMS (EI) for C14H12ClNO2 (261.0557) [M]
+: 261.0554. 
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Synthesis of 4-chloro-2-phenyl-3-(((tetrahydro-2H-pyran-2-yl)oxy)methyl)pyridine (15g) according 
to TP3: 
 
According to TP3, the substituted pyridine 15g was prepared from 1 mmol of 14g with 1.2 mmol of 
2a (1.7 M) at 25 °C for 30 min. Flash column chromatography (i-hexane/ethyl acetate 4:1 + 0.5% 
NEt3) furnished 15g as colorless oil (231 mg, 76%). 
 
1H NMR (300 MHz, CDCl3) /ppm: 1.52 - 1.92 (m, 6 H), 3.46 - 3.55 (m, 1 H), 3.79 - 3.90 (m, 1 H), 4.39 
(d, J=10.50 Hz, 1 H), 4.77 (t, J=3.04 Hz, 1 H), 4.83 (d, J=10.50 Hz, 1 H), 7.36 (d, J=5.25 Hz, 1 H), 7.41 - 
7.51 (m, 3 H), 7.62 - 7.71 (m, 2 H), 8.52 (d, J=5.25 Hz, 1 H). 
13C NMR (75 MHz, CDCl3) /ppm: 18.9, 25.4, 30.4, 61.7, 64.6, 99.0, 123.6, 128.1, 128.7, 129.2, 129.3, 
139.4, 146.8, 149.3, 162.1. 
MS (70 eV, EI) m/z (%): 219 (16), 204 (30), 202 (100), 167 (14), 85 (33). 
IR ATR  (cm-1): 2940, 2894, 2362, 2338, 1560, 1548, 1496, 1452, 1438, 1410, 1378, 1348, 1200, 
1182, 1174, 1131, 1118, 1103, 1076, 1068, 1055, 1037, 1022, 1001, 989, 962, 938, 922, 905, 890, 
869, 843, 837, 818, 816, 810, 793, 779, 757, 732, 730, 724, 700, 686, 668, 653. 
HRMS (EI) for C17H18ClNO2 (303.1026) [M]
+: 303.0949. 
 
Synthesis of 5-chloro-2-(3-methoxyphenyl)pyridine (15h) according to TP3: 
 
According to TP3, the substituted pyridine 15h was prepared from 1 mmol of 14c with 1.2 mmol of 
6n (1.24 M) at 25 °C for 30 min. Flash column chromatography (i-hexane/Et2O 9:1 + 0.5% NEt3) 
furnished 15h as white solid (156 mg, 71%). 
 
m.p.: 60.2 - 62.8 °C. 
1H NMR (300 MHz, CDCl3) /ppm: 3.90 (s, 3 H), 6.99 (dd, J=8.16, 2.63 Hz, 1 H), 7.39 (t, J=8.02 Hz, 1 H), 
7.49 - 7.59 (m, 2 H), 7.64 - 7.75 (m, 2 H), 8.64 (d, J=2.49 Hz, 1 H). 
13C NMR (75 MHz, CDCl3) /ppm: 55.4, 112.0, 115.3, 119.1, 121.2, 129.8, 130.7, 136.4, 139.6, 148.4, 
155.3, 160.1. 
MS (70 eV, EI) m/z (%): 219 (66), 190 (50), 176 (11), 154 (50), 141 (36), 113 (17). 
IR ATR  (cm-1): 3002, 2956, 2834, 2360, 2331, 1608, 1586, 1575, 1554, 1471, 1459, 1430, 1370, 
1365, 1302, 1292, 1227, 1219, 1208, 1182, 1176, 1168, 1111, 1053, 1035, 1010, 894, 889, 885, 876, 
858, 855, 848, 840, 836, 824, 791, 755, 749, 689, 668. 
HRMS (EI) for C12H10ClNO (219.0451) [M]
+: 219.0435. 
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Synthesis of 2-(benzo[d][1,3]dioxol-5-yl)-6-chloroquinoline (15i) according to TP3: 
 
According to TP3, the substituted pyridine 15i was prepared from 1 mmol of 14a with 1.2 mmol of 6c 
(1.08 M) at 25 °C for 15 min. Flash column chromatography (i-hexane/ethyl acetate 8:1 + 0.5% NEt3) 
furnished 15i as white solid (179 mg, 77%). 
 
m.p.: 108.5 - 111.0 °C. 
1H NMR (300 MHz, CDCl3) /ppm: 6.03 (s, 2 H), 6.90 (d, J=8.02 Hz, 1 H), 7.19 (dd, J=5.25, 1.94 Hz, 1 
H), 7.45 - 7.53 (m, 2 H), 7.63 (d, J=1.94 Hz, 1 H), 8.53 (d, J=5.25 Hz, 1 H). 
13C NMR (75 MHz, CDCl3) /ppm: 101.4, 107.3, 108.5, 120.2, 121.2, 121.8, 132.5, 144.6, 148.4, 149.0, 
150.3, 158.4. 
MS (70 eV, EI) m/z (%): 233 (100), 140 (19), 113 (13). 
IR ATR  (cm-1): 2894, 2359, 1573, 1550, 1500, 1493, 1462, 1442, 1378, 1351, 1278, 1257, 1216, 
1114, 1108, 1037, 934, 888, 869, 865, 861, 834, 815, 811, 780, 734, 719, 717, 701, 686, 684, 668. 
HRMS (EI) for C12H8ClNO2 (233.0244) [M]
+: 233.0244. 
 
Synthesis of 5-(3-chloro-5-(trifluoromethyl)pyridin-2-yl)-1-methyl-1H-indole (15j) according to TP3: 
 
According to TP3, the substituted pyridine 15j was prepared from 1 mmol of 14h with 1.2 mmol of 
6o (1.02 M) at 50 °C for 1 h. Flash column chromatography (i-hexane/ethyl acetate 6:1 + 0.5% NEt3) 
furnished 15j as beige solid (174 mg, 56%). 
 
m.p.: 83.9 - 85.9 °C. 
1H NMR (300 MHz, CDCl3) /ppm: 3.85 (s, 3 H), 6.60 (d, J=3.04 Hz, 1 H), 7.13 (d, J=3.04 Hz, 1 H), 7.44 
(d, J=8.57 Hz, 1 H), 7.68 (dd, J=8.85, 1.66 Hz, 1 H), 8.08 (dd, J=18.94, 2.07 Hz, 2 H), 8.87 (d, J=1.94 Hz, 
1 H). 
13C NMR (75 MHz, CDCl3) /ppm: 33.0, 102.1, 108.9, 122.8, 123.0, 123.0, 125.1 (q, J=33.59 Hz), 
128.1, 128.2, 129.9, 130.1, 135.2 (q, J=3.42 Hz, 1 C), 137.2, 144.0 (q, J=3.99 Hz), 161.2. 
MS (70 eV, EI) m/z (%): 310 (100), 275 (16), 111 (13), 97 (16), 85 (15). 
IR ATR  (cm-1): 2923, 2853, 2357, 1596, 1485, 1455, 1443, 1437, 1325, 1310, 1293, 1288, 1280, 
1271, 1243, 1232, 1220, 1202, 1188, 1181, 1153, 1133, 1118, 1109, 1093, 1066, 1027, 1004, 1003, 
949, 941, 937, 931, 916, 899, 887, 884, 871, 848, 839, 825, 814, 809, 793, 783, 771, 766, 758, 752, 
735, 730, 724, 718, 708, 693, 681, 676, 668, 660, 652. 
HRMS (EI) for C15H10ClF3N2 (310.0485) [M]
+: 310.0472. 
N
Cl
O
O
N
ClF3C
N Me
C. EXPERIMENTAL SECTION 
112 
Synthesis of 2-(3-((tert-butyldimethylsilyl)oxy)phenyl)-3-chloropyridine (15k) according to TP3: 
 
According to TP3, the substituted pyridine 15k was prepared from 1 mmol of 14b with 1.2 mmol of 
6g (1.11 M) at 25 °C for 15 min. Flash column chromatography (i-hexane/Et2O 9:1) furnished 15k as 
colorless oil (262 mg, 82%). 
 
1H NMR (300 MHz, CDCl3) /ppm: 0.24 (s, 6 H), 1.01 (s, 9 H), 6.93 (dt, J=7.26, 2.18 Hz, 1 H), 7.17 - 
7.25 (m, 2 H), 7.28 - 7.38 (m, 2 H), 7.79 (dd, J=8.02, 1.66 Hz, 1 H), 8.59 (dd, J=4.56, 1.52 Hz, 1 H). 
13C NMR (75 MHz, CDCl3) /ppm: -4.38, 18.2, 25.7, 120.5, 121.1, 122.3, 123.0, 129.1, 130.1, 138.0, 
139.5, 147.5, 155.2, 156.4. 
MS (70 eV, EI) m/z (%): 319 (13), 264 (38), 262 (100), 226 (9). 
IR ATR  (cm-1): 2955, 2928, 2857, 2360, 2338, 1602, 1581, 1570, 1486, 1471, 1462, 1439, 1419, 
1415, 1406, 1306, 1272, 1259, 1251, 1243, 1227, 1199, 1130, 1029, 1001, 937, 884, 830, 816, 791, 
778, 760, 723, 696, 685, 677, 668, 662. 
HRMS (EI) for C17H22ClNOSi (319.1159) [M]
+: 319.1154. 
 
Synthesis of 2-(4-(1,3-dioxolan-2-yl)phenyl)-3-chloro-5-(trifluoromethyl)pyridine (15l) according to 
TP3: 
 
According to TP3, the substituted pyridine 15l was prepared from 1 mmol of 14h with 1.2 mmol of 
6p (1.08 M) at 25 °C for 15 min. Flash column chromatography (i-hexane/ethyl acetate 8:1 + 0.5% 
NEt3) furnished 15l as white solid (233 mg, 71%). 
 
m.p.: 72.4 - 74.0 °C. 
1H NMR (300 MHz, CDCl3) /ppm: 4.02 - 4.22 (m, 4 H), 5.92 (s, 1 H), 7.63 (m, 2 H), 7.80 (m, 2 H), 8.05 
(d, J=1.36 Hz, 1 H), 8.85 (dd, J=2.05, 0.88 Hz, 1 H). 
13C NMR (75 MHz, CDCl3) /ppm: 65.3, 103.2, 122.7 (q, J=272.93 Hz), 126.1 (q, J=33.59 Hz), 126.3, 
129.5, 130.3, 135.3 (q, J=3.65 Hz), 137.7, 139.5, 144.2 (q, J=4.03 Hz), 159.5 (q, J=1.54 Hz). 
MS (70 eV, EI) m/z (%): 329 (19), 328 (69), 286 (16), 271 (14), 257 (100), 222 (81), 73 (62). 
IR ATR  (cm-1): 2899, 2361, 2339, 1599, 1380, 1324, 1309, 1216, 1153, 1119, 1093, 1081, 1069, 
1028, 1014, 988, 981, 970, 957, 941, 911, 858, 843, 835, 824, 768, 735, 731, 695, 685. 
HRMS (EI) for C15H11ClF3NO2 (329.0430) [M]
+: 328.0355. 
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Synthesis of 2-(4-(1,3-dioxolan-2-yl)phenyl)-4-chloro-3-(((tetrahydro-2H-pyran-2-yl)oxy)-methyl)-
pyridine (15m) according to TP3: 
 
According to TP3, the substituted pyridine 15m was prepared from 1 mmol of 14g with 1.2 mmol of 
6p (1.08 M) at 25 °C for 30 min. Flash column chromatography (i-hexane/ethyl acetate 3:1 + 0.5% 
NEt3) furnished 15m as colorless oil (248 mg, 66%). 
 
1H NMR (300 MHz, CDCl3) /ppm: 1.51 - 1.90 (m, 6 H), 3.45 - 3.60 (m, 1 H), 3.78 - 3.95 (m, 1 H), 3.99 - 
4.22 (m, 4 H), 4.37 (d, J=10.78 Hz, 1 H), 4.73 - 4.91 (m, 2 H), 5.90 (s, 1 H), 7.36 (d, J=5.25 Hz, 1 H), 7.57 
(m, 2 H), 7.71 (m, 2 H), 8.52 (d, J=5.25 Hz, 1 H). 
13C NMR (75 MHz, CDCl3) /ppm: 19.0, 25.4, 30.4, 61.8, 64.5, 65.3, 99.0, 103.4, 123.6, 126.2, 129.3, 
129.4, 138.5, 140.2, 146.9, 149.3, 161.7. 
MS (70 eV, EI) m/z (%): 291 (25), 274 (40), 230 (13), 202 (36), 166 (16), 73 (100). 
IR ATR  (cm-1): 2941, 2884, 2366, 2334, 1561, 1548, 1446, 1412, 1385, 1363, 1349, 1200, 1182, 
1130, 1117, 1078, 1064, 1053, 1036, 1023, 989, 966, 941, 905, 890, 880, 869, 824, 816, 788, 775, 
754, 729, 712, 710, 707, 693, 689, 687, 685, 681, 675, 668, 659, 658, 654. 
HRMS (EI) for C20H22ClNO4 (375.1237) [M]
+: 374.1157. 
 
Synthesis of 4-chloro-2-(4-(trifluoromethyl)phenyl)pyridine (15n) according to TP3: 
 
According to TP3, the substituted pyridine 15n was prepared from 1 mmol of 14a with 1.2 mmol of 
6c (0.98 M) at 25 °C for 30 min. Flash column chromatography (i-hexane/diethyl ether 9:1) furnished 
15n as white crystals (237 mg, 92%). 
 
m.p.: 44.9 - 46.6 °C. 
1H NMR (300 MHz, CDCl3) /ppm: 7.31 (dd, J=5.25, 1.11 Hz, 1 H), 7.69 - 7.80 (m, 3 H), 8.05 - 8.16 (m, 
2 H), 8.62 (d, J=5.25 Hz, 1 H). 
13C NMR (75 MHz, CDCl3) /ppm: 121.2, 123.1, 124.0 (q, J=272.35 Hz), 125.8 (q, J=3.65 Hz), 127.3, 
131.4 (q, J=32.54 Hz), 141.4 (q, J=1.40 Hz), 145.0, 150.7, 157.3. 
MS (70 eV, EI) m/z (%): 257 (100), 222 (50), 202 (12), 188 (15), 43 (47). 
IR ATR  (cm-1): 2366, 2334, 1617, 1572, 1549, 1380, 1323, 1315, 1265, 1168, 1105, 1095, 1069, 
1047, 1013, 988, 977, 956, 849, 840, 829, 818, 785, 765, 750, 739, 728, 706, 690, 668, 662. 
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HRMS (EI) for C12H7ClF3N: (257.0219) [M]
+: 257.0211. 
 
Synthesis of 3-chloro-2-(4-chloro-3-(trifluoromethyl)phenyl)-5-(trifluoromethyl)pyridine (15o) 
according to TP3: 
 
According to TP3, the substituted pyridine 15o was prepared from 1 mmol of 14h with 1.2 mmol of 
6q (0.95 M) at 25 °C for 30 min. Flash column chromatography (i-hexane/ethyl acetate 15:1) 
furnished 15o as colorless oil (239 mg, 66%). 
 
1H NMR (300 MHz, CDCl3) /ppm: 7.65 (d, J=8.02 Hz, 1 H), 7.95 (dd, J=8.57, 2.21 Hz, 1 H), 8.09 (d, 
J=1.94 Hz, 1 H), 8.17 (d, J=1.94 Hz, 1 H), 8.88 (s, 1 H). 
13C NMR (75 MHz, CDCl3) /ppm: 122.5 (q, J=273.20 Hz), 122.6 (q, J=273.48 Hz), 126.9 (q, J=33.94 
Hz), 128.6 (q, J=31.70 Hz), 128.9 (q, J=5.33 Hz), 130.2, 131.3, 133.6, 133.9 (q, J=1.68 Hz), 135.6, 135.7 
(q, J=3.65 Hz), 144.5 (q, J=3.93 Hz), 157.1 (q, J=1.68 Hz). 
MS (70 eV, EI) m/z (%): 359 (81), 339 (14), 324 (100), 304 (17), 290 (12). 
IR ATR  (cm-1): 2362, 2342, 1602, 1487, 1456, 1413, 1380, 1329, 1315, 1295, 1278, 1260, 1238, 
1214, 1127, 1113, 1099, 1079, 1038, 1031, 910, 873, 836, 813, 766, 737, 718, 665. 
HRMS (EI) for C13H5Cl2F6N (358.9703) [M]
+: 358.9690. 
 
Synthesis of ethyl 3-(3-chloro-5-(trifluoromethyl)pyridin-2-yl)benzoate (15p) according to TP3: 
 
According to TP3, the substituted pyridine 15p was prepared from 1 mmol of 14h with 1.2 mmol of 
6i (0.61 M) at 25 °C for 15 min. Flash column chromatography (i-hexane/ethyl acetate 9:1 + 0.5% 
NEt3) furnished 15p as light yellow oil (231 mg, 70%). 
 
1H NMR (300 MHz, CDCl3) /ppm: 1.41 (t, J=7.19 Hz, 3 H), 4.42 (q, J=7.19 Hz, 2 H), 7.59 (t, J=7.88 Hz, 
1 H), 7.96 (dt, J=7.74, 1.52 Hz, 1 H), 8.07 (d, J=2.21 Hz, 1 H), 8.18 (dt, J=7.95, 1.42 Hz, 1 H), 8.46 (t, 
J=1.80 Hz, 1 H), 8.87 (d, J=1.11 Hz, 1 H). 
13C NMR (75 MHz, CDCl3) /ppm: 14.3, 61.2, 122.6 (q, J=272.92 Hz), 126.4 (q, J=33.66 Hz), 128.3, 
130.3, 130.6, 130.7, 130.7, 133.6, 135.4 (q, J=3.65 Hz), 137.2, 144.3 (q, J=3.39 Hz), 158.9 (q, J=1.40 
Hz), 166.1 
MS (70 eV, EI) m/z (%): 329 (33), 301 (22), 284 (100), 257 (55), 221 (15). 
IR ATR  (cm-1): 2982, 2367, 2335, 1718, 1717, 1600, 1368, 1322, 1312, 1285, 1249, 1223, 1214, 
1160, 1131, 1093, 1082, 1075, 1036, 1020, 1001, 912, 847, 820, 741, 710, 693, 668, 662. 
HRMS (EI) for C15H11ClF3NO2 (329.0430) [M]
+: 329.0419. 
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Synthesis of 4-chloro-3-(1,3-dioxolan-2-yl)-2-(4-fluorophenyl)pyridine (15q) according to TP3: 
 
According to TP3, the substituted pyridine 15q was prepared from 1 mmol of 14f with 1.2 mmol of 6r 
(1.0 M) at 25 °C for 30 min. Flash column chromatography (i-hexane/ethyl acetate 4:1 + 0.5% NEt3) 
furnished 15q as white crystals (221 mg, 79%). 
 
m.p.: 76.2 - 79.0 °C. 
1H NMR (300 MHz, CDCl3) /ppm: 3.88 - 4.13 (m, 4 H), 5.95 (s, 1 H), 7.06 - 7.20 (m, 2 H), 7.36 (d, 
J=5.25 Hz, 1 H), 7.45 - 7.60 (m, 2 H), 8.52 (d, J=5.25 Hz, 1 H). 
13C NMR (75 MHz, CDCl3) /ppm: 65.8, 101.3, 114.8, 115.1, 125.0, 127.5, 131.3, 131.4, 135.2, 135.2, 
145.3, 149.8, 161.0, 161.4, 164.6. 
MS (70 eV, EI) m/z (%): 236 (29), 234 (84), 220 (11), 207 (100), 183 (42), 171 (22), 144 (17). 
IR ATR  (cm-1): 2983, 2899, 2360, 2344, 1603, 1564, 1556, 1511, 1457, 1381, 1234, 1224, 1213, 
1179, 1159, 1154, 1102, 1096, 1057, 1019, 1013, 984, 971, 958, 940, 883, 846, 832, 821, 776, 726, 
720, 691, 668. 
HRMS (EI) for C14H11ClFNO2 (279.0462) [M]
+: 278.0372. 
 
Synthesis of 3-chloro-1-phenylisoquinoline (15r) according to TP6: 
 
According to TP6, the substituted isoquinoline 15r was prepared from 1 mmol of 14j with 1.2 mmol 
of 6a (1.7 M) at 25 °C for 1 h. Flash column chromatography (i-hexane/ethyl acetate 3:1 + 0.5% NEt3) 
furnished 15r as light yellow solid (170 mg, 71%). 
 
m.p.: 75.9 - 77.9 °C. 
1H NMR (300 MHz, CDCl3) /ppm: 7.47 - 7.60 (m, 4 H), 7.67 - 7.75 (m, 4 H), 7.79 - 7.84 (m, 1 H), 8.10 
(d, J=8.57 Hz, 1 H). 
13C NMR (75 MHz, CDCl3) /ppm: 118.9, 125.5, 126.3, 127.3, 127.8, 128.4, 129.1, 130.0, 130.9, 138.2, 
139.0, 144.8, 161.5. 
MS (70 eV, EI) m/z (%): 239 (100), 202 (71), 176 (18), 151 (15), 101 (17). 
IR ATR  (cm-1): 3054, 3028, 2363, 2331, 1616, 1572, 1570, 1560, 1558, 1542, 1489, 1443, 1430, 
1396, 1385, 1376, 1359, 1319, 1307, 1269, 1215, 1147, 1077, 1069, 1028, 999, 978, 974, 964, 922, 
874, 854, 850, 799, 766, 757, 749, 724, 698, 677, 668, 658, 653. 
HRMS (EI) for C15H10ClN (239.0502) [M]
+: 239.0477. 
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Synthesis of 4-chloro-2-phenylquinoline (15s) according to TP6: 
 
According to TP6, the substituted quinoline 15s was prepared from 1 mmol of 14k with 1.2 mmol of 
6a (3.00 M) at 25 °C for 1 h. Flash column chromatography (0-80% ethyl acetate /heptane) furnished 
15s as white solid (167 mg, 70%). 
 
1H NMR (300 MHz, CDCl3) /ppm: 7.43 - 7.68 (m, 4H), 7.77 (ddd, J=8.4, 6.9, 1.5 Hz, 1H), 7.96 (s, 1H), 
8.07 - 8.28 (m, 4H). 
13C NMR (75 MHz, CDCl3) /ppm: 119.1, 124.0, 125.3, 127.2, 127.5, 128.9, 129.8, 130.2, 130.6, 138.6, 
143.1, 149.2, 157.3. 
MS (70 eV, EI) m/z (%): 243 (5), 242 (32), 241 (18), 240 (100). 
IR ATR  (cm-1): 3060, 3020, 2363, 2331, 1625, 1570, 1500, 1443, 1319, 1250, 1052, 1021, 982, 964, 
920, 870, 854, 799, 677. 
HRMS (EI) for C15H10ClN (239.0502) [M]
+: 239.0508. 
 
Synthesis of 7-chloro-2-(3-methoxyphenyl)quinoline (15t) according to TP3: 
 
According to TP3, the substituted quinoline 15t was prepared from 1 mmol of 14l with 1.2 mmol of 
6n (1.24 M) at 25 °C for 2 h. Flash column chromatography (i-hexane/ethyl acetate 9:1 + 0.5% NEt3) 
furnished 15t as white solid (194 mg, 72%). 
 
m.p.: 66.2 - 67.5 °C. 
1H NMR (300 MHz, CDCl3) /ppm: 3.94 (s, 3 H), 7.04 (ddd, J=6.91, 1.66, 1.38 Hz, 1 H), 7.41 - 7.51 (m, 
2 H), 7.68 - 7.80 (m, 3 H), 7.86 (d, J=8.29 Hz, 1 H), 8.12 - 8.22 (m, 2 H). 
13C NMR (75 MHz, CDCl3) /ppm: 55.4, 112.7, 115.7, 119.2, 120.0, 125.6, 127.3, 128.6, 128.7, 129.8, 
135.4, 136.5, 140.6, 148.6, 158.0, 160.2. 
MS (70 eV, EI) m/z (%): 269 (71), 268 (100), 239 (45), 204 (12), 190 (16). 
IR ATR  (cm-1): 2940, 2920, 2830, 2359, 1611, 1597, 1587, 1557, 1545, 1483, 1469, 1456, 1436, 
1329, 1308, 1292, 1278, 1241, 1218, 1188, 1183, 1157, 1152, 1133, 1087, 1069, 1046, 1037, 997, 
927, 880, 871, 849, 837, 806, 778, 766, 692, 674, 668, 659. 
HRMS (EI) for C16H12ClNO (269.0607) [M]
+: 268.0524. 
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Synthesis of 2-(benzo[d][1,3]dioxol-5-yl)-6-chloroquinoline (15u) according to TP6: 
 
According to TP6, the substituted quinoline 15u was prepared from 1 mmol of 14m with 1.2 mmol of 
6e (1.08 M) at 25 °C for 1 h. Flash column chromatography (i-hexane/ethyl acetate 8:1 + 0.5% NEt3) 
furnished 15u as white solid (232 mg, 82%). 
 
m.p.: 159.2 - 160.9 °C. 
1H NMR (300 MHz, CDCl3) /ppm: 6.05 (s, 2 H), 6.95 (d, J=8.02 Hz, 1 H), 7.64 (ddd, J=8.71, 2.35, 
2.21 Hz, 2 H), 7.70 - 7.83 (m, 3 H), 8.06 (dd, J=8.71, 2.63 Hz, 2 H). 
13C NMR (75 MHz, CDCl3) /ppm: 101.4, 107.8, 108.5, 119.3, 121.7, 126.1, 127.5, 130.5, 131.1, 131.6, 
133.6, 135.7, 146.5, 148.4, 149.0, 156.8. 
MS (70 eV, EI) m/z (%): 283 (100), 225 (14), 190 (25), 44 (20). 
IR ATR  (cm-1): 2903, 2366, 2336, 1593, 1548, 1507, 1499, 1481, 1455, 1438, 1351, 1329, 1293, 
1287, 1256, 1241, 1214, 1190, 1145, 1120, 1111, 1072, 1036, 948, 936, 924, 913, 894, 881, 861, 830, 
824, 815, 809, 788, 775, 724, 706, 653. 
HRMS (EI) for C16H10ClNO2 (283.0400) [M]
+: 283.0389. 
 
Synthesis of 4-(6-chloroquinolin-2-yl)-N,N-dimethylaniline (15v) according to TP3: 
 
According to TP3, the substituted quinoline 15v was prepared from 1 mmol of 14m with 1.2 mmol of 
6b (1.17 M) at 25 °C for 3 h. Flash column chromatography (i-hexane/ethyl acetate 8:1 + 0.5% NEt3) 
furnished 15v as beige solid (199 mg, 71%). 
 
m.p.: 188.0 - 188.8 °C. 
1H NMR (300 MHz, CDCl3) /ppm: 3.06 (s, 6 H), 6.84 (d, J=9.12 Hz, 2 H), 7.61 (dd, J=8.98, 2.35 Hz, 1 
H), 7.75 (d, J=2.49 Hz, 1 H), 7.84 (d, J=8.85 Hz, 1 H), 7.97 - 8.15 (m, 4 H). 
13C NMR (75 MHz, CDCl3) /ppm: 40.3, 112.2, 119.0, 126.0, 126.9, 127.2, 128.4, 130.2, 130.8, 130.8, 
135.3, 146.8, 151.5, 157.5. 
MS (70 eV, EI) m/z (%): 282 (100), 281 (47), 266 (9), 238 (11). 
IR ATR  (cm-1): 2915, 2830, 2366, 1613, 1597, 1539, 1484, 1470, 1457, 1437, 1330, 1310, 1288, 
1279, 1240, 1231, 1220, 1202, 1188, 1168, 1157, 1152, 1133, 1067, 1062, 1046, 1037, 949, 941, 930, 
882, 871, 849, 838, 825, 809, 794, 778, 767, 760, 757, 693, 681, 675, 668. 
HRMS (EI) for C17H15ClN2 (282.0924) [M]
+: 282.0921. 
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Synthesis of 6-chloro-2-(4-chloro-3-(trifluoromethyl)phenyl)quinoline (15w) according to TP6: 
 
According to TP6, the substituted quinoline 15w was prepared from 1 mmol of 14m with 1.2 mmol 
of 6q (0.95 M) at 25 °C for 1 h. Flash column chromatography (i-hexane/ethyl acetate 12:1 + 0.5% 
NEt3) furnished 15w as white solid (299 mg, 87%). 
 
m.p.: 118.8 - 121.7 °C. 
1H NMR (300 MHz, CDCl3) /ppm: 7.62 - 7.73 (m, 2 H), 7.82 (d, J=2.21 Hz, 1 H), 7.87 (d, J=8.57 Hz, 1 
H), 8.10 (d, J=8.85 Hz, 1 H), 8.17 (d, J=8.29 Hz, 1 H), 8.26 (dd, J=8.29, 2.21 Hz, 1 H), 8.54 (d, J=2.21 Hz, 
1 H). 
13C NMR (75 MHz, CDCl3) /ppm: 118.9, 122.8 (q, J=273.30 Hz), 126.2, 126.5 (q, J=5.41 Hz), 127.9, 
128.7, 128.9 (q, J=31.60 Hz), 131.0, 131.3, 131.9, 132.7, 133.5 (q, J=1.71 Hz), 136.3, 137.9, 146.5, 
154.5. 
MS (70 eV, EI) m/z (%): 341 (100), 308 (10), 306 (28), 286 (14), 272 (12). 
IR ATR  (cm-1): 2926, 2860, 2360, 2331, 1595, 1476, 1411, 1328, 1321, 1315, 1276, 1259, 1251, 
1236, 1164, 1155, 1133, 1123, 1113, 1075, 1056, 1034, 948, 904, 899, 874, 848, 827, 811, 781, 775, 
729, 675, 668, 664, 658. 
HRMS (EI) for C16H8Cl2F3N: (340.9986) [M]
+: 340.9969. 
 
3.4 TREATMENT OF PYRIDINE 14A WITH SCAVENGERS TO EVALUATE RECOVERY AND 
CHROMIUM LEVELS PRIOR TO CHROMATOGRAPHY 
 
A constant volume of the organic layer (50 μL) from the crude reaction mixture or the solution 
containing the scavenger-treated organic layer was diluted into 10 mL (1:1 acetonitrile: water) and 
HPLC area under the curve (AUC) was recorded. Recovery was based on the ratio of the AUC for the 
treated material to the untreated material.  
 
Scavenger 
HPLC 
AUC 
AUC Treated/ 
AUC Crude 
% Recovery 
3a 
Cr Content 
(ppm) 
Activated charcoal 600 0,67 67 5,6 
Untreated charcoal 783 0,88 88 3,8 
Darco KB-G 789 0,89 89 2,8 
Darco G-60 540 0,61 61 6,3 
Smopex 101 304 0,34 34 18,5 
Smopex 234 596 0,67 67 12,2 
Si-Thiourea 890 1,00 100 36,6 
N
Cl
Cl
CF3
C. EXPERIMENTAL SECTION 
119 
Ecosorb C-941 793 0,89 89 3 
Ecosorb C-944 517 0,58 58 15,5 
Ecosorb C-947 598 0,67 67 2,6 
Darco KB-WJ 528 0,59 59 0,8 
Darco 100 mesh 464 0,52 52 8,7 
Florisil -200 mesh 621 0,70 70 19,8 
Decolorizing charcoal 526 0,59 59 5,7 
Neutral alumina 819 0,92 92 12,8 
Basic alumina 799 0,90 90 13,5 
Silica gel 60 842 0,95 95 7,6 
Ecosorb C-906 573 0,64 64 3,3 
Crude Reaction 890 1,00 
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4. CHROMIUM(II)-CATALYZED AMINATION OF N-HETEROCYCLIC CHLORIDES 
WITH MAGNESIUM AMIDES  
4.1 STARTING MATERIALS SYNTHESIS 
 
Starting materials 16a-i are commercially available. 
Amines 18a-k are commercially available and were previously distilled and stored under argon 
before use.  
 
4.2 GENERAL PROCEDURES 
4.2.1 Typical procedure for the formation of magnesium amides (TP8) 
 
A dry and argon flushed Schlenk-tube was charged with the appropriate amine (2 equiv) and  
i-PrMgClLiCl (2 equiv, 1.2 M solution in THF) was added dropwise at 0 °C. This reaction mixture was 
warmed to room temperature (23 °C) and stirred for approximately 1 h at this temperature in order 
to get full conversion to the magnesium amide.  
 
4.2.2 Typical procedure for the Cr-catalyzed amination with CrCl2 (TP9) 
 
The solution of the magnesium amide previously prepared according to TP8 was transferred via 
syringe to a second dry and argon-flushed Schlenk-tube, containing the N-heterocyclic halide in THF 
(1 equiv, 2 M in THF) and water-free CrCl2 (0.1 equiv) at 23 °C. The resulting reaction mixture was 
stirred at 50 °C until the N-heterocyclic halide was consumed. The solvent was evaporated in vacuo 
and the crude product was purified on silica gel to afford the desired product.  
 
4.2.3 Typical procedure for the Cr-catalyzed amination with Cr(acac)3 (TP10) 
 
The solution of the magnesium amide previously prepared according to TP8 was transferred via 
syringe to a second dry and argon-flushed Schlenk-tube, containing the N-heterocyclic halide in THF 
(1 equiv, 2 M in THF) and Cr(acac)3 (0.1 equiv) at 23 °C. The resulting reaction mixture was stirred at 
50 °C until the N-heterocyclic halide was consumed. The solvent was evaporated in vacuo and the 
crude product was purified on silica gel to afford the desired product. 
 
4.3 PREPARATION OF THE SYNTHESIZED AMINATED N-HETEROCYCLES 
 
Synthesis of 2-(pyrrolidin-1-yl)pyridine (19a) according to TP9: 
 
N N
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According to TP9, the substituted pyridine 19a was prepared from 1 mmol of 16a (113 mg) with 
2 mmol of 17a (1 M from 142 mg of pyrrolidine) at 50 °C for 3 h. Flash column chromatography 
(i-hexane/diethyl ether 8:2 + 2% NEt3) furnished 19a as colorless oil (140 mg, 95%). 
 
1H NMR (300 MHz, CDCl3) /ppm: 1.97 - 2.04 (m, 4 H), 3.40 - 3.50 (m, 4 H), 6.30 - 6.38 (m, 1 H), 6.46 - 
6.54 (m, 1 H), 7.37 - 7.46 (m, 1 H), 8.11 - 8.20 (m, 1 H). 
13C NMR (75 MHz, CDCl3) /ppm: 25.5 (2 C), 46.6 (2 C), 106.4, 111.1, 136.8, 148.1, 157.2. 
MS (70 eV, EI) m/z (%): 148 (30), 120 (33), 119 (100), 93 (12), 79 (20), 78 (24), 70 (18). 
IR ATR  (cm-1): 2968, 2851, 2361, 1707, 1598, 1555, 1499, 1484, 1444, 1385, 1347, 1300, 1242, 
1155, 993, 769, 733, 668, 467. 
HRMS (EI) for C9H12N2 (148.1000) [M]
+: 148.1003. 
 
Synthesis of 4-(pyridin-2-yl)morpholine (19b) according to TP9: 
 
According to TP9, the substituted pyridine 19b was prepared from 1 mmol of 16a (113 mg) with 
2 mmol of 17b (1 M from 174 mg of morpholine) at 50 °C for 12 h. Flash column chromatography 
(i-hexane/diethyl ether 8:2 + 2% NEt3) furnished 19b as brown oil (123 mg, 75%). 
 
1H NMR (300 MHz, CDCl3) /ppm: 3.50 (t, J=5,0 Hz, 4 H), 3.83 (t, J=5,0 Hz, 4 H), 6.60 - 6.70 (m, 2 H), 
7.50 (ddd, J=8.7, 7.1, 1.9 Hz, 1 H), 8.18 - 8.24 (m, 1 H). 
13C NMR (75 MHz, CDCl3) /ppm: 45.6 (2 C), 66.7 (2C), 106.9, 113.8, 137.5, 147.9, 159.5. 
MS (70 eV, EI) m/z (%): 164 (86), 163 (53), 134 (14), 133 (89), 119 (29), 107 (50), 106(14), 79 (100), 
78 (27). 
IR ATR  (cm-1): 2922, 2854, 1591, 1479, 1435, 1311, 1241, 1116, 1069, 1029, 980, 942, 773, 733. 
HRMS (EI) for C9H12N2O (164.0950) [M]
+: 164.0937. 
 
Synthesis of N,N-dibutylpyridin-2-amine (19c) according to TP9: 
 
According to TP9, the substituted pyridine 19c was prepared from 1 mmol of 16a (113 mg) with 
2 mmol of 17c (1 M from 259 mg of dibutylamine) at 50 °C for 5 h. Flash column chromatography 
(i-hexane/diethyl ether 9:1 + 0,5% NEt3) furnished 19c as colorless oil (155 mg, 75%). 
 
1H NMR (300 MHz, CDCl3) /ppm: 0.97 (t, J=7.2 Hz, 6 H), 1.27 - 1.44 (m, 4 H), 1.52 - 1.66 (m, 4 H), 
3.44 (dd, J=7.5 Hz, 4 H), 6.38 - 6.49 (m, 2 H), 7.38 (ddd, J=8.7, 7.0, 1.9 Hz, 1 H), 8.10 - 8.18 (m, 1 H). 
13C NMR (75 MHz, CDCl3) /ppm: 13.9 (2 C), 20.3 (2 C), 29.8 (2 C), 48.3 (2 C), 105.4, 110.5, 136.7, 
148.0, 157.9. 
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MS (70 eV, EI) m/z (%): 206 (31), 183 (28), 163 (100), 149 (28), 127 (25), 121 (71), 112 (34), 111 (32), 
107 (42), 97 (25), 85 (23), 83 (39), 78 (25), 71 (40), 70 (25). 57 (51), 41 (41). 
IR ATR  (cm-1): 2956, 2930, 2872, 2861, 1594, 1558, 1492, 1466, 1439, 1429, 1372, 1324, 1292, 
1225, 1189, 1159, 1094, 976, 927, 765, 730. 
HRMS (EI) for C13H22N2 (206.1783) [M]
+: 206.1764. 
 
Synthesis of 5-methyl-2-(pyrrolidin-1-yl)pyridine (19d) according to TP9: 
 
According to TP9, the substituted pyridine 19d was prepared from 1 mmol of 16b (128 mg) with 
2 mmol of 17a (1 M from 142 mg of pyrrolidine) at 50 °C for 24 h. Flash column chromatography 
(i-hexane/diethyl ether 8:2 + 2% NEt3) furnished 19d as yellow oil (156 mg, 96%). 
 
1H NMR (300 MHz, CDCl3) /ppm: 1.93 - 2.02 (m, 4 H), 2.16 (s, 3 H), 3.35 - 3.46 (m, 4 H), 6.27 (d, 
J=8.3 Hz, 1 H), 7.19 - 7.29 (m, 1 H), 7.96 (s, 1 H). 
13C NMR (75 MHz, CDCl3) /ppm: 17.3, 25.5 (2 C), 46.7 (2 C), 106.1, 119.5, 137.9, 147.7, 155.9. 
MS (70 eV, EI) m/z (%): 162 (44), 161 (14), 134 (32), 133 (100), 120 (12), 107 (15), 93 (17), 92 (15), 65 
(13). 
IR ATR  (cm-1): 2965, 2854, 1612, 1557, 1503, 1483, 1461, 1406, 1379, 1369, 1347, 1339, 1300, 
1239, 1181, 1162, 1016, 984, 802. 
HRMS (EI) for C10H14N2 (162.1157) [M]
+: 162.1150. 
 
Synthesis of 2-chloro-6-(pyrrolidin-1-yl)pyridine (19e) according to TP9: 
 
According to TP9, the substituted pyridine 19e was prepared from 1 mmol of 16c (148 mg) with 
2 mmol of 17a (1 M from 142 mg of pyrrolidine) at 50 °C for 7 h. Flash column chromatography  
(i-hexane/diethyl ether 9:1 + 0,5% NEt3) furnished 19e as yellow solid (148 mg, 81%). 
 
m.p.: 70.4 - 72.0 °C. 
1H NMR (300 MHz, CDCl3) /ppm: 1.88 - 2.12 (m, 4 H), 3.43 (t, J=6.6 Hz, 4 H), 6.20 (d, J=8.3 Hz, 1 H), 
6.49 (d, J=7.5 Hz, 1 H), 7.21 - 7.43 (m, 1 H). 
13C NMR (75 MHz, CDCl3) /ppm: 25.4 (2 C), 46.7 (2 C), 104.2, 109.9, 138.9, 149.6, 157.1. 
MS (70 eV, EI) m/z: 184 (7), 182 (29), 97 (42), 83 (35), 71 (35), 69 (41), 57 (29), 56 (29), 47 (31). 
IR ATR  (cm-1): 2969, 2858, 1591, 1486, 1454, 1410, 1384, 1164, 1124, 1001, 969, 769, 720, 705. 
HRMS (EI) for C9H11ClN2 (182.0611) [M]
+: 182.0590. 
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Synthesis of N,N-dibenzyl-4-chloropyridin-2-amine (19f) according to TP9: 
 
According to TP9, the substituted pyridine 19f was prepared from 1 mmol of 16d (148 mg) with 
2 mmol of 17d (0.94 M from 395 mg of dibenzylamine) at 50 °C for 3 h. Flash column 
chromatography (i-hexane/diethyl ether 9:1 + 0,5% NEt3) furnished 19f as colorless oil (154 mg, 
50%). 
 
1H NMR (300 MHz, CDCl3) /ppm: 4.78 (s, 4 H), 6.46 - 6.51 (m, 1 H), 6.61 (dd, J=5.5, 1.4 Hz, 1 H), 7.20 
- 7.36 (m, 10 H), 8.10 (d, J=5.5 Hz, 1 H). 
13C NMR (75 MHz, CDCl3) /ppm: 50.9 (2 C), 105.5, 112.8, 127.0 (2 C), 127.1 (2 C), 128.7 (2 C), 137.7, 
144.9, 148.8 (2 C), 159.6. 
MS (70 eV, EI) m/z: 308 (5), 219 (34), 217 (100), 91 (42), 65 (18). 
IR ATR  (cm-1): 3062, 3028, 2907, 1588, 1575, 1541, 1488, 1451, 1425, 1355, 1230, 1106, 974, 953, 
823, 790, 728, 694. 
HRMS (EI) for C19H17ClN2 (308.1080) [M]
+: 308.1077. 
 
Synthesis of 1-(4-chloropyridin-2-yl)indoline (19g) according to TP9: 
 
According to TP9, the substituted pyridine 19g was prepared from 1 mmol of 16d (148 mg) with 
2 mmol of 17e (1 M from 238 mg of indoline) at 50 °C for 3 h. Flash column chromatography  
(i-hexane/diethyl ether 9:1 + 0,5% NEt3) furnished 19g as white solid (125 mg, 54%). 
 
m.p.: 119.8 - 121.7 °C. 
1H NMR (300 MHz, CDCl3) /ppm: 3.23 (t, J=8.6 Hz, 2 H), 4.01 (t, J=8.6 Hz, 2 H), 6.71 - 6.81 (m, 2 H), 
6.86 - 6.97 (m, 1 H), 7.15 - 7.26 (m, 2 H), 8.24 (d, J=6.1 Hz, 2 H). 
13C NMR (75 MHz, CDCl3) /ppm: 27.6 (2 C), 49.3 (2 C), 108.2, 114.1, 114.6, 121.1, 124.6, 127.3, 
131.4, 144.4, 144.5, 148.8, 156.2. 
MS (70 eV, EI) m/z: 232 (26), 231 (20), 230 (67), 229 (50), 118 (100), 117 (29), 91 (18). 
IR ATR  (cm-1): 2960, 2925, 2882, 2857, 1572, 1548, 1487, 1478, 1456, 1433, 1107, 1020, 983, 814, 
786, 748, 722, 706. 
HRMS (EI) for C13H11ClN2 (230.0611) [M]
+: 230.0610. 
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Synthesis of N,N-dibutyl-3-chloropyridin-2-amine (19h) according to TP9: 
 
According to TP9, the substituted pyridine 19h was prepared from 1 mmol of 16e (148 mg) with 
2 mmol of 17c (1 M from 259 mg of dibutylamine) at 50 °C for 5 h. Flash column chromatography 
(i-hexane/diethyl ether 9:1 + 0,5% NEt3) furnished 19h as yellow oil (171 mg, 71%). 
 
1H NMR (300 MHz, CDCl3) /ppm: 0.90 (t, J=7.3 Hz, 6 H), 1.23 - 1.38 (m, 4 H), 1.48 - 1.61 (m, 4 H), 
3.33 (dd, J=7.7, 7.2 Hz, 4 H), 6.70 (dd, J=7.7, 4.7 Hz, 1 H), 7.52 (dd, J=7.7, 1.1 Hz, 1 H), 8.13 (dd, J=4.7, 
1.1 Hz, 1 H). 
13C NMR (75 MHz, CDCl3) /ppm: 14.0 (2 C), 20.3 (2 C), 30.2 (2 C), 50.6 (2 C), 116.1, 121.7, 138.8, 
145.3, 158.1. 
MS (70 eV, EI) m/z (%): 240 (18), 199 (40), 197 (100), 183 (19), 157 (23), 155 (84), 143 (20), 141 (69). 
IR ATR  (cm-1): 2957, 2930, 2872, 2862, 1577, 1476, 1466, 1460, 1455, 1428, 1374, 1287, 1219, 
1118, 1099, 1074, 1031, 927, 778, 743. 
HRMS (EI) for C13H21ClN2 (240.1393) [M]
+: 240.1399. 
 
Synthesis of N,N-diallyl-3-chloropyridin-2-amine (19i) according to TP9: 
 
According to TP9, the substituted pyridine 19i was prepared from 1 mmol of 16e (148 mg) with 2 
mmol of 17f (1 M from 194 mg of diallylamine) at 50 °C for 5 h. Flash column chromatography 
(i-hexane/diethyl ether 9:1 + 0,5% NEt3) furnished 19i as yellow oil (171 mg, 82%). 
 
1H NMR (300 MHz, CDCl3) /ppm: 4.00 (d, J=5.8 Hz, 4 H), 5.13 - 5.27 (m, 4 H), 5.94 (dddd, J=16.9, 
10.6, 6.0, 5.8 Hz, 2 H), 6.75 (dd, J=7.7, 4.7 Hz, 1 H), 7.55 (dd, J=7.8, 1.4 Hz, 1 H), 8.14 (dd, J=4.6, 1.4 
Hz, 1 H). 
13C NMR (75 MHz, CDCl3) /ppm: 52.2 (2 C), 116.7 (2 C), 117.2 (2 C), 121.3, 135.0, 139.0, 145.4, 
157.6. 
MS (70 eV, EI) m/z: 208 (5), 168 (12), 167 (100), 165 (11), 154 (13), 153 (12), 112 (16). 
IR ATR  (cm-1): 3077, 2982, 2920, 2853, 1577, 1463, 1434, 1411, 1343, 1248, 1231, 1118, 1105, 
1076, 1031, 991, 918, 780, 753. 
HRMS (EI) for C11H13ClN2 (208.0767) [M]
+: 208.0759. 
 
Synthesis of N-benzyl-3-chloro-N-methylpyridin-2-amine (19j) according to TP9: 
N NBu2
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According to TP9, the substituted pyridine 19j was prepared from 1 mmol of 16e (148 mg) with 2 
mmol of 17g (1 M from 242 mg of N-methyl-1-phenylmethanamine) at 50 °C for 3 h. Flash column 
chromatography (i-hexane/diethyl ether 9:1 + 0,5% NEt3) furnished 19j as colorless oil (193 mg, 
83%). 
 
1H NMR (300 MHz, CDCl3) /ppm: 2.91 (s, 3 H), 4.57 (s, 2 H), 6.79 (dd, J=7.7, 4.7 Hz, 1 H), 7.22 - 7.45 
(m, 1 H), 7.59 (dd, J=7.7, 1.7 Hz, 1 H), 8.18 (dd, J=4.7, 1.4 Hz, 1 H). 
13C NMR (75 MHz, CDCl3) /ppm: 38.3, 57.1, 116.9, 121.5, 127.0, 127.9 (2 C), 128.3 (2 C), 138.6, 
138.9, 145.5, 158.7. 
MS (70 eV, EI) m/z: 234 (16), 232 (53), 219 (33), 217 (100), 203 (37), 143 (26), 120 (65), 91 (89), 65 
(26), 42 (53). 
IR ATR  (cm-1): 3061, 3047, 3028, 2957, 2848, 2798, 1576, 1494, 1475, 1450, 1435, 1406, 1360, 
1228, 1114, 1067, 1029, 946, 782, 731, 696. 
HRMS (EI) for C13H13ClN2 (232.0767) [M]
+: 232.0758. 
 
Synthesis of 4-(3-chloropyridin-2-yl)morpholine (19k) according to TP9: 
 
According to TP9, the substituted pyridine 19k was prepared from 1 mmol of 16e (148 mg) with 
2 mmol of 17b (1 M from 174 mg of morpholine) at 50 °C for 4 h. Flash column chromatography 
(i-hexane/diethyl ether 4:1 + 0,5% NEt3) furnished 19k as white solid (171 mg, 86%). 
 
m.p.: 99.0 - 100.8 °C. 
1H NMR (300 MHz, CDCl3) /ppm: 3.35 (dd, J=4.7 Hz, 4 H), 3.86 (dd, J=4.4 Hz, 4 H), 6.86 (dd, J=7.7, 
4.7 Hz, 1 H), 7.59 (dd, J=7.7, 1.7 Hz, 1 H), 8.19 (dd, J=4.7, 1.4 Hz, 1 H). 
13C NMR (75 MHz, CDCl3) /ppm: 49.5 (2 C), 66.9 (2 C), 118.1, 122.6, 138.9, 145.8, 158.1. 
MS (70 eV, EI) m/z: 200 (24), 199 (38), 198 (100), 197 (60), 169 (27), 168 (22), 167 (58), 154 (25), 153 
(44), 152 (24), 153 (44), 142 (24), 141 (87), 140 (55), 115 (43), 43 (44). 
IR ATR  (cm-1): 2960, 2854, 1577, 1440, 1430, 1422, 1370, 1247, 1226, 1109, 1071, 1031, 942, 924, 
846, 798, 779, 760, 695. 
HRMS (EI) for C9H11ClN2O (198.0560) [M]
+: 198.0548. 
 
 
Synthesis of 1-(3-chloropyridin-2-yl)-4-methylpiperazine (19l) according to TP9: 
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According to TP9, the substituted pyridine 19l was prepared from 1 mmol of 16e (148 mg) with 2 
mmol of 17h (1 M from 200 mg of 1-methylpiperazine) at 50 °C for 5 h. Flash column 
chromatography (EtOAc/methanol 9:1) furnished 19l as yellow oil (150 mg, 71%). 
 
1H NMR (300 MHz, CDCl3) /ppm: 2.34 (s, 3 H), 2.53 - 2.60 (m, 4 H), 3.34 - 3.42 (m, 4 H), 6.80 (dd, 
J=7.7, 4.7 Hz, 1 H), 7.55 (dd, J=7.7, 1.7 Hz, 1 H), 8.16 (dd, J=4.7, 1.4 Hz, 1 H). 
13C NMR (75 MHz, CDCl3) /ppm: 46.1, 48.9 (2 C), 55.0 (2 C), 117.7, 122.5, 138.7, 145.7, 158.3. 
MS (70 eV, EI) m/z: 213 (6), 211 (16). 154 (22), 153 (14), 140 (100), 83 (15), 71 (11). 
IR ATR  (cm-1): 2935, 2842, 2793, 1575, 1460, 1432, 1370, 1288, 1242, 1143, 1119, 1030, 1008, 944, 
784, 759. 
HRMS (EI) for C10H14ClN3 (211.0876) [M]
+: 211.0878. 
 
Synthesis of N,N-dicyclohexylquinolin-2-amine (19m) according to TP9: 
 
According to TP9, the substituted quinoline 19m was prepared from 1 mmol of 16f (164 mg) with 
2 mmol of 17i (1 M from 363 mg of dicyclohexylamine) at 50 °C for 23 h. Flash column 
chromatography (i-hexane/ethyl acetate 15:1) furnished 19m as light green oil (220 mg, 85%). 
 
1H NMR (300 MHz, CDCl3) /ppm: 1.06 - 1.23 (m, 4 H), 1.26 - 1.41 (m, 5 H), 1.53 - 1.69 (m, 7 H), 1.78 
(d, J=12.9 Hz, 5 H), 1.89 - 2.06 (m, 4 H), 3.71 - 3.83 (m, 2 H), 6.86 (d, J=9.3 Hz, 1 H), 7.05 (t, J=7.3 Hz, 
1 H), 7.39 (t, J=7.6 Hz, 1 H), 7.45 (d, J=8.1 Hz, 1 H), 7.56 (d, J=8.3 Hz, 1 H), 7.67 (d, J=9.0 Hz, 1 H). 
13C NMR (75 MHz, CDCl3) /ppm: 4.9 (2 C), 5.7 (4 C), 10.3 (4 C), 35.2 (2 C), 91.1, 100.2, 101.4, 105.4, 
106.0, 107.9, 114.8, 127.10 135.7. 
MS (70 eV, EI) m/z (%): 308 (18), 251 (20), 225 (100), 183 (18), 169 (43), 129 (14), 128 (19), 55 (11). 
IR ATR  (cm-1): 3051, 2924, 2850, 1618, 1602, 1556, 1503, 1476, 1430, 1380, 1363, 1322, 1293, 
1238, 1174, 1124, 1052, 1017, 893, 811, 750. 
HRMS (EI) for C21H28N2 (308,2252) [M]
+: 308.2247. 
 
Synthesis of 4-(quinolin-2-yl)morpholine (19n) according to TP9: 
 
According to TP9, the substituted quinoline 19n was prepared from 1 mmol of 16f (164 mg) with 
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2 mmol of 17b (1 M from 174 mg of morpholine) at 50 °C for 8 h. Flash column chromatography 
(i-hexane/diethyl ether 1:1) furnished 19n as white crystals (182 mg, 85%). 
 
m.p.: 95.9 – 97.3 °C. 
1H NMR (300 MHz, CDCl3) /ppm: 3.65 - 3.73 (m, 4 H), 3.80 - 3.87 (m, 4 H), 6.91 (d, J=9.1 Hz, 1 H), 
7.21 - 7.29 (m, 1 H), 7.51 - 7.64 (m, 2 H), 7.75 (d, J=8.6 Hz, 1 H), 7.89 (d, J=9.1 Hz, 1 H). 
13C NMR (75 MHz, CDCl3) /ppm: 45.4 (2 C), 66.7 (2 C), 109.1, 122.5, 123.2, 126.6, 127.1, 129.5, 
137.4, 147.6, 157.4. 
MS (70 eV, EI) m/z: 214 (49), 213 (25), 183 (63), 169 (28), 157 (54), 156 (18), 129 (100), 128 (48), 101 
(22), 92 (16). 
IR ATR  (cm-1): 3044, 2971, 2858, 2829, 1614, 1602, 1506, 1477, 1430, 1393, 1332, 1318, 1264, 
1234, 1218, 1112, 1054, 975, 966, 924, 865, 806, 780, 755, 685. 
HRMS (EI) for C13H14N2O (214.1106) [M]
+: 214.1099. 
 
N-(3-bromobenzyl)-N-methylquinolin-2-amine (19o) according to TP9: 
 
According to TP9, the substituted quinoline 19o was prepared from 1 mmol of 16f (164 mg) with 
2 mmol of 17j (1 M from 400 mg of 1-(3-bromophenyl)-N-methylmethanamine) at 50 °C for 6 h. 
Flash column chromatography (i-hexane/ethyl acetate 1:1) furnished 19o as yellow oil (314 mg, 
95%). 
 
1H NMR (300 MHz, CDCl3) /ppm: 3.21 (s, 3 H), 4.95 (s, 2 H), 6.88 (d, J=9.1 Hz, 1 H), 7.16 - 7.25 (m, 
3 H), 7.39 (d, J=8.0 Hz, 1 H), 7.46 (br. s, 1 H), 7.53 - 7.58 (m, 1 H), 7.62 (d, J=8.0 Hz, 1 H), 7.72 (d, J=8.5 
Hz, 1 H), 7.89 (d, J=9.3 Hz, 1 H). 
13C NMR (75 MHz, CDCl3) /ppm: 36.2, 52.6, 108.8, 121.9, 122.7, 122.8, 125.9, 126.5, 127.2, 129.5, 
130.1 (2 C), 130.3, 137.6, 141.3, 148.0, 157.0. 
MS (70 eV, EI) m/z (%): 328 (52), 327 (21), 326 (44), 314 (20), 313 (100), 311 (99), 157 (55), 129 (45), 
128 (60). 
IR ATR  (cm-1): 3054, 2948, 2922, 2854, 1616, 1604, 1558, 1508, 1492, 1426, 1388, 1339, 1111, 
1069, 808, 777, 754. 
HRMS (EI) for C17H15BrN2 (326.0419) [M]
+: 326.0416. 
 
Synthesis of 2-(pyrrolidin-1-yl)quinoline (19p) according to TP9: 
 
According to TP9, the substituted quinoline 19p was prepared from 1 mmol of 16f (164 mg) with 
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2 mmol of 17a (1 M from 142 mg of pyrrolidine) at 50 °C for 10 h. Flash column chromatography 
(i-hexane/diethyl ether 1:1 + 1% NEt3) furnished 19p as yellow crystals (178 mg, 90%). 
 
m.p.: 88.7 – 90.9 °C. 
1H NMR (300 MHz, CDCl3) /ppm: 1.97 - 2.11 (m, 4 H), 3.53 - 3.71 (m, 4 H), 6.72 (d, J=9.1 Hz, 1 H), 
7.12 - 7.22 (m, 1 H), 7.48 - 7.61 (m, 2 H), 7.73 (d, J=8.6 Hz, 1 H), 7.84 (d, J=8.8 Hz, 1 H). 
13C NMR (75 MHz, CDCl3) /ppm: 25.5 (2 C), 46.7 (2 C), 110.2, 121.2, 122.5, 126.1, 127.3, 129.3, 
136.9, 148.6, 155.7. 
MS (70 eV, EI) m/z (%): 198 (48), 170 (27), 169 (100), 143 (11), 129 (17), 128 (18). 
IR ATR  (cm-1): 3053, 2966, 2923, 2862, 1605, 1506, 1478, 1468, 1456, 1428, 1401, 1343, 1309, 
1165, 1143, 807, 779, 750. 
HRMS (EI) for C13H14N2 (198.1157) [M]
+: 198.1152. 
 
Synthesis of N-benzyl-4-chloro-N-methylquinolin-2-amine (19q) according to TP9: 
 
According to TP9, the substituted isoquinoline 19q was prepared from 1 mmol of 16g (198 mg) with 
2 mmol of 17g (1 M from 242 mg of N-methyl-1-phenylmethanamine) at 50 °C for 5 h. Flash column 
chromatography (i-hexane/diethyl ether 8:2 + 0,5% NEt3) furnished 19q as yellow solid (153 mg, 
54%). 
 
m.p.: 73.8 – 75.1 °C. 
1H NMR (300 MHz, CDCl3) /ppm: 3.20 (s, 3 H), 4.94 (s, 2 H), 7.02 (s, 1 H), 7.24 - 7.39 (m, 6 H), 7.56 - 
7.63 (m, 1 H), 7.75 (d, J=8.3 Hz, 1 H), 8.02 (d, J=7.5 Hz, 6 H). 
13C NMR (75 MHz, CDCl3) /ppm: 36.0, 53.1, 108.7, 120.8, 122.4, 123.8, 126.8, 127.1, 127.2 (2 C), 
128.6 (2 C), 130.4, 138.1, 143.1, 148.8, 156.8. 
MS (70 eV, EI) m/z: 284 (17), 283 (14), 282 (49), 269 (32), 268 (22), 267 (100), 193 (19), 191 (54), 162 
(34), 128 (18), 162 (34), 128 (18), 120 (26), 91 (24). 
IR ATR  (cm-1): 3057, 3022, 2905, 2864, 2791, 1595, 1583, 1544, 1505, 1495, 1418, 1409, 1390, 
1384, 1354, 1189, 954, 824, 755, 725, 694, 682. 
HRMS (EI) for C17H15ClN2 (282.0924) [M]
+: 282.0916. 
 
Synthesis of 1-(pyrrolidin-1-yl)isoquinoline (19r) according to TP9: 
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According to TP9, the substituted isoquinoline 19r was prepared from 1 mmol of 16h (164 mg) with 
2 mmol of 17a (1 M from 142 mg of pyrrolidine) at 50 °C for 2 h. Flash column chromatography 
(i-hexane/ethyl acetate 1:1 + 0,5% NEt3) furnished 19r as yellow oil (184 mg, 93%). 
 
1H NMR (300 MHz, CDCl3) /ppm: 1.96 - 2.03 (m, 4 H), 3.80 - 3.86 (m, 4 H), 6.97 (d, J=5.8 Hz, 1 H), 
7.38 (ddd, J=8.5, 6.8, 1.5 Hz, 1 H), 7.49 - 7.57 (m, 1 H), 7.66 (dd, J=8.0, 1.4 Hz, 1 H), 8.02 (d, J=5.5 Hz, 
1 H), 8.20 (d, J=8.6 Hz, 1 H). 
13C NMR (75 MHz, CDCl3) /ppm: 25.9 (2 C), 51.4 (2 C), 111.5, 120.0, 124.2, 126.1, 126.5, 129.0, 
138.7, 140.8, 157.9. 
MS (70 eV, EI) m/z (%): 198 (24), 170 (25), 169 (100). 
IR ATR  (cm-1): 3047, 2965, 2865, 1547, 1504, 1451, 1413, 1360, 1338, 1288, 1140, 798, 742, 677. 
HRMS (EI) for C13H14N2 (198.1157) [M]
+: 198.1159. 
 
Synthesis of 4-(isoquinolin-1-yl)morpholine (19s) according to TP9: 
 
According to TP9, the substituted isoquinoline 19s was prepared from 1 mmol of 16h (164 mg) with 
2 mmol of 17b (1 M from 174 mg of morpholine) at 50 °C for 2 h. Flash column chromatography 
(i-hexane/ethyl acetate 1:1 + 0,5% NEt3) furnished 19s as beige solid (191 mg, 89%). 
 
m.p.: 74.0 - 75.8 °C. 
1H NMR (300 MHz, CDCl3) /ppm: 3.43 (dd, J=5.0, 4.4 Hz, 4 H), 3.99 (dd, J=4.4, 4.4 Hz, 4 H), 7.27 - 
7.30 (m, 1 H), 7.49 - 7.57 (m, 1 H), 7.59 - 7.68 (m, 1 H), 7.77 (d, J=8.6 Hz, 1 H), 8.11 (d, J=8.3 Hz, 1 H), 
8.17 (d, J=5.8 Hz, 1 H). 
13C NMR (75 MHz, CDCl3) /ppm: 51.9 (2 C), 67.1 (2 C), 116.2, 121.6, 125.4, 126.2, 127.2, 129.8, 
138.2, 140.5, 161.1. 
MS (70 eV, EI) m/z (%): 214 (11), 213 (14), 169 (14), 157 (18), 156 (12), 129 (36), 128 (12), 70 (11), 61 
(14), 45 (12), 44 (19), 43 (100). 
IR ATR  (cm-1): 2983, 2974, 2965, 2833, 1556, 1398, 1361, 1263, 1115, 1107, 1070, 1031, 1014, 930, 
857, 820, 756, 722, 682. 
HRMS (EI) for C13H14N2O (214.1106) [M]
+: 214.1126. 
 
 
N
N
N
N
O
C. EXPERIMENTAL SECTION 
130 
Synthesis of 1,4-dimethyl-1,2,3,4-tetrahydropyrazino[2,3-b]quinoxaline (19t) according to TP9: 
 
According to TP9, the substituted quinoxaline 19t was prepared from 1 mmol of 16i (200 mg) with 
2 mmol of 17k (1 M from 176 mg of N1,N2-dimethylethane-1,2-diamine) at 50 °C for 3 h. Flash 
column chromatography (i-hexane/diethyl ether 2:1) furnished 19t as beige solid (184 mg, 86%). 
 
m.p.: 187.0 – 189.1 °C. 
1H NMR (300 MHz, CDCl3) /ppm: 3.12 (s, 6 H), 3.41 (s, 4 H), 7.09 - 7.20 (m, 2 H), 7.46 (dd, J=5.9, 
3.4 Hz, 2 H). 
13C NMR (75 MHz, CDCl3) /ppm: 36.3 (2 C), 46.9 (2 C), 124.2 (2 C), 125.1 (2 C), 137.3 (2 C), 144.0 (2 
C). 
MS (70 eV, EI) m/z: 215 (11), 214 (100), 213 (20), 199 (15), 186 (10), 185 (19), 128 (9), 102 (10), 42 
(6). 
IR ATR  (cm-1): 2921, 2885, 2856, 1568, 1528, 1465, 1458, 1418, 1393, 1356, 1342, 1287, 1261, 
1201, 1116, 1082, 1025, 1014, 947, 846, 765, 749, 674. 
HRMS (EI) for C12H14N4 (214.1218) [M]
+: 214.1216. 
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5. SYNTHESIS OF PYRIDO[3,2-F][1,7]NAPHTHYRIDINE AND RELATED 
HETEROCYCLES 
 
5.1 STARTING MATERIAL SYNTHESIS 
 
Starting materials 28a-b, as well as trichloroisocyanuric acid, potassium phthalimide and chloranil 
are commercially available reagents and were used without further purification.  
 
Synthesis of 3-iodo-2-methylpyridine (27a): 
 
A dry, argon flushed Schlenk-flask equipped with a magnetic stirring bar and a septum was charged 
with LiCl (128 mg, 1.5 equiv) and heated with a heat gun under high vacuum (5 min). After cooling to 
room temperature, magnesium turnings (122 mg, 2.5 equiv) were added, followed by THF (2 mL). 
The magnesium was activated using 1,2-dibromoethane (5 mol%) and TMSCl (5 mol%). Then, ZnCl2-
solution (2.2 mL, 1.1 equiv, 1 M in THF) was added followed by 3-bromo-2-methylpyridine (344 mg, 1 
equiv). The reaction mixture was stirred at 25 °C until GC-analysis of hydrolyzed reaction aliquot 
showed full consumption of the starting material (12 h). To the reaction mixture was added dropwise 
an iodine solution in THF (1.01 g, 2.0 equiv, 1 M in THF) at 0 °C and stirred for 1 h at 25 °C. The 
suspension was then quenched with a saturated aqueous solution of Na2S2O3 and extracted with 
EtOAc (3x). The organic layer was dried with MgSO4, filtered, and concentrated in vacuo to obtain 
the crude compound. Flash column chromatography (DCM) furnished 27a as yellow solid (267 mg, 
61%). 
 
m.p.: 169.1 - 170.3 °C. 
1H NMR (400 MHz, CDCl3) /ppm: 2.74 (s, 3 H), 6.82 (dd, J=7.78, 4.75 Hz, 1 H), 8.05 (d, J=7.88 Hz, 
1 H), 8.44 (d, J=4.78 Hz, 1 H). 
13C NMR (101 MHz, CDCl3) /ppm: 28.9, 96.3, 122.1, 146.2, 148.2, 160.0. 
MS (70 eV, EI) m/z (%): 219 (5), 218 (100), 92 (49), 65 (29). 
IR ATR  (cm-1): 2948, 2922, 2852, 1588, 1450, 1412, 1206, 1076, 1038, 1012, 792, 702. 
HRMS (EI) for C6H6IN (218.9545) [M]
+: 218.9534. 
 
Synthesis of 6-chloro-3-iodo-2-methylpyridine (27b): 
 
A dry, argon flushed Schlenk-flask equipped with a magnetic stirring bar and a septum was charged 
with n-BuMgCl (7.15 mL, 0.5 equiv, 0.5 M in THF) in 10 mL THF and n-BuLi (8.2 mL, 1.0 equiv, 2.44 M) 
was added at 0 °C. The reaction mixture was stirred for 10 min at 0 °C and added dropwise to a 
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solution of 6-chloro-3-bromo-2-methylpyridine (4.13 g, 1.0 equiv) in 8 mL THF at 0 °C. After 15 min, 
GC-analysis of hydrolyzed reaction aliquot showed full consumption of the starting material. An 
iodine solution in THF (10.1 g, 2 equiv) was added to the reaction mixture at 0 °C and stirred 30 min. 
The suspension was then quenched with a saturated aqueous solution of Na2S2O3 and extracted with 
EtOAc. The organic layer was dried with MgSO4, filtered, and concentrated in vacuo to obtain the 
crude compound. Flash column chromatography (DCM) furnished 27b as yellow oil (4.49 g, 89%). 
 
1H NMR (400 MHz, CDCl3) /ppm: 2.70 (s, 3 H), 6.89 (d, J=8.21 Hz, 1 H), 7.95 (d, J=8.19 Hz, 1 H). 
13C NMR (101 MHz, CDCl3) /ppm: 28.8, 93.8, 123.1, 148.7, 150.5, 161.3. 
MS (70 eV, EI) m/z (%): 254 (28), 253 (100), 126 (48), 91 (24), 90 (29), 85 (28), 71 (37), 57 (73), 55 
(29), 43 (45), 41(22). 
IR ATR  (cm-1): 3096, 3048, 2998, 2952, 2920, 1556, 1538, 1432, 1412, 1380, 1206, 1146, 1012, 974, 
876, 814, 724, 684. 
HRMS (EI) for C6H5ClIN (252.9155) [M]
+: 252.9154. 
 
5.2 GENERAL PROCEDURES 
 
5.2.1 Typical procedure for the preparation of pyridyl-zinc reagents (TP11) 
 
A dry, argon flushed Schlenk-flask equipped with a magnetic stirring bar and a septum was charged 
with the neat pyridyl bromide (1 equiv) in THF (0.5 mL/mmol). i-PrMgCl·LiCl (1.1 equiv, 1.25 M in 
THF) was added dropwise to the starting material solution in THF at 0 °C and the reaction mixture 
was stirred at 0 °C until GC-analysis of iodinated reaction aliquot showed full consumption of the 
starting material. ZnCl2 in THF (1.2 equiv, 1 M) was then added dropwise to the Grignard reagent at 
0 °C and the solution was stirred 30 min for transmetallation. The synthesized organozinc reagents 
were then directly used in Negishi cross-couplings (see TP12 and TP13). 
 
5.2.2 Typical procedure for the Pd(PPh3)4-catalyzed  Negishi cross-coupling (TP12) 
 
A dry, argon flushed Schlenk-flask equipped with a magnetic stirring bar and a septum was charged 
with the pyridyl iodide (0.9 equiv) and Pd(PPh3)4 (2 mol%). THF was added (1 mL/mmol) and the 
suspension was stirred 15 min at 25 °C. The desired freshly prepared zinc reagent in THF was added 
dropwise to the reaction mixture at 25 °C and the mixture was then stirred for the given time at 
50 °C. The reaction mixture was quenched with sat. NaCl solution and extracted with EtOAc (3x). The 
combined organic phases were dried over MgSO4 and concentrated in vacuo. The crude residue 
obtained was purified by flash column chromatography to give the analytically pure product. 
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5.2.3 Typical procedure for the Pd(OAc)2/SPhos-catalyzed Negishi cross-coupling (TP13) 
 
A dry, argon flushed Schlenk-flask equipped with a magnetic stirring bar and a septum was charged 
with the pyridyl iodide (0.9 equiv), Pd(OAc)2 (2 mol%) and SPhos (4 mol%). THF was added 
(1 mL/mmol) and the suspension was stirred 15 min at 25 °C. The desired freshly prepared zinc 
reagent in THF was added dropwise to the reaction mixture at 25 °C and the mixture was then stirred 
for the given time at 50 °C. The reaction mixture was quenched with sat. NaCl solution and extracted 
with EtOAc (3x). The combined organic phases were dried over MgSO4 and concentrated in vacuo. 
The crude residue obtained was purified by flash column chromatography to give the analytically 
pure product. 
 
5.2.4 Typical procedure for the chlorination using trichloroisocyanuric acid (TP14) 
 
A round-bottom flask was charged with the picolyl-derivative (1 equiv) and benzamide (0.03 equiv) in 
chloroform (3 mL/mmol) at 25 °C. Trichloroisocyanuric acid (0.54 equiv) was added portionwise to 
this solution at 25 °C. The reaction mixture was then stirred and heated to reflux until GC-MS 
analysis of a reaction aliquot showed full consumption of the starting material. After cooling down, 
water was added to the reaction mixture, the solution was neutralized with sat. NaHCO3 and 
extracted with DCM (3x). The combined organic phases were dried over MgSO4 and concentrated in 
vacuo. The crude residue obtained was purified by flash column chromatography to give the 
analytically pure product. 
 
5.2.5 Typical procedure for the chlorination via deprotonation by LDA and TMSCl trapping 
(TP15) 
 
A dry, argon flushed Schlenk-flask equipped with a magnetic stirring bar and a septum was charged 
with a solution of lithium diisopropylamide (1.2 equiv, 0.5 M in THF) and was cooled to -78 °C. A 
solution of the desired picolyl-derivative (1 equiv) in THF (8 mL/mmol) was added dropwise to the 
cooled solution. This solution was stirred for 2 h at -78°C and TMSCl (1.3 equiv) was added to the 
rapidly stirred lithium reagent and let warm up to 25 °C overnight (12 h). Sat. aq. NaHCO3 was added 
to the reaction mixture and the aqueous phase was extracted with EtOAc (3x). The combined organic 
layers were dried over MgSO4 and concentrated in vacuo. The resulting oil containing the product 
and ca. 10% of the bis(trimethylsilylmethyl) compound was dried on the high vacuum line and used 
in the next step without further purification. 
Hexachloroethane (2 equiv) and finely ground and dried CsF (2 equiv) were placed in a round-bottom 
flask equipped with a stirring bar, a septum and purged with argon. A solution of the freshly 
synthesized (trimethylsilyl)methyl-derivative (1 equiv) in dry MeCN (2 mL/mmol) was added to the 
flask and the mixture was stirred and heated to reflux for 3 h. Sat. NaCl was poured to the reaction 
mixture and extracted with EtOAc (3x). The combined organic phases were dried over MgSO4 and 
concentrated in vacuo. The crude residue obtained was purified by flash column chromatography to 
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give the analytically pure product. 
 
5.2.6 Typical procedure for the Gabriel substitution of chloromethyl-derivatives (TP16) 
 
A round-bottom-flask was equipped with the chloromethyl-derivative (1 equiv) in DMF (2 mL/mmol) 
and potassium phthalimide (1.2 equiv) was added at 25 °C. The reaction mixture was stirred and 
warmed up to 100 °C until TLC-monitoring showed full consumption of the starting material. Water 
was added to the solution and the aqueous phase was extracted with EtOAc (3x). The combined 
organic phases were dried over MgSO4 and concentrated in vacuo. The crude residue obtained was 
purified by flash column chromatography to give the analytically pure product. 
 
5.2.7 Typical procedure for the Manske-Ing phthalimide deprotection (TP17) 
 
A round-bottom-flask was equipped with the phthalimide-derivative (1 equiv) in abs. EtOH 
(15 mL/mmol). To the suspension was added hydrazine hydrate (3 equiv) at 25 °C and the reaction 
mixture was heated to reflux for 2 h. After cooling down to 25 °C, 2N HCl was added carefully 
(2 mL/mmol) and the suspension was brought to reflux for 5 min, until the precipitate dissolves. The 
solution was cooled down to 25 °C and sat. NaHCO3 was added dropwise until neutralization. EtOH 
was evaporated in vacuo and the aqueous phase was extracted with DCM (3x). The combined 
organic phases were dried over MgSO4 and concentrated in vacuo. The crude residue obtained was 
used without further purification. 
 
5.2.8 Typical procedure for the aromatization with chloranil (TP18) 
 
The crude dihydroazaphenanthrene (1 equiv) obtained by TP17 was charged in a round-bottom flask 
and solubilized in DMF (3 mL/mmol) at 25 °C. Chloranil (1.2 equiv) was added portionwise and the 
reaction mixture was stirred 2 h at 25 °C until TLC-monitoring showed full consumption of the 
starting material. Water was added to the suspension and the aqueous phase was extracted with 
DCM (3x). The combined organic phases were dried over MgSO4 and concentrated in vacuo. The 
crude residue obtained was purified by flash column chromatography to give the analytically pure 
product. 
 
5.2.9 Typical procedure for the preparation of organolithium reagents (TP19) 
 
Solutions of lithium reagents were freshly prepared and titrated against i-PrOH with 
1,10-phenantroline as indicator: phenyllithium 34a and (4-methoxyphenyl)lithium 34b were 
prepared by addition of Li metal (2.0 equiv) to the iodides (1.0 equiv) in diethyl ether (0.5 M) at 0 °C 
and obtained as reddish ca. 0.5 M solutions after 30 min. (4-(trifluoromethyl)phenyl)lithium 34c and  
(3-fluorophenyl)lithium 34d were obtained as colored solutions (ca. 0.6-0.9 M) according to a 
literature procedure by adding t-BuLi solution (2.0 equiv) to the corresponding iodide (1.0 equiv) in 
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diethyl ether (1.0 M) at -78 °C and stirring for 30 min.[150] Heteroaryl α-lithiated reagents 34e-h were 
prepared by adding n-BuLi solution (1.05 equiv) to the heteroaryl compound (1.0 equiv) in THF 
(1.0 M) at -78 °C and stirring for 30 min, followed by 1 h at -10 °C and 5 min at 25 °C. Titration 
indicated a 0.5-0.9 M concentration of these reagents. (1-ethoxyvinyl)lithium 34i was prepared 
according to a literature procedure[151] and obtained as ca. 0.6 M solution in THF/hexanes. 
 
5.2.10 Typical procedure for the addition of organolithiums and rearomatization (TP20) 
 
Pyrido[3,2-f][1,7]naphthyridine (23a, 18 mg, 0.1 mmol, 1.0 equiv) was dissolved in 1 mL dry THF 
under an argon atmosphere. Brief heating was applied to ensure that all material was dissolved. The 
solution was then cooled to -60 °C in a dry ice/acetone bath. The organolithium solution was cooled 
to -60 °C prior to addition or -40 °C, if precipitation was observed at lower temperature. The 
precooled solution of organolithium compound (34, 0.15 mmol, 1.5 equiv) was then added dropwise 
via syringe to 23a and the mixture was stirred for 30 min at -60 °C. The dry ice cooling was 
subsequently changed to an ice bath (0 °C) and stirring was continued for 5 min. In order to quench 
the reaction, 3 mL of sat. aq. NH4Cl solution was added. The organic phase was separated, and the 
aqueous phase was extracted with EtOAc (3x). The combined organic layers were dried over MgSO4 
and solvents were removed in vacuo. The solid residues were dissolved in 2 mL DMF and chloranil 
(30 mg, 0.12 mmol, 1.2 equiv) was added at once. The mixture was stirred overnight at room 
temperature in an open flask. Water (10 mL) and ca. 200 mg LiCl were then added. The mixture was 
extracted with EtOAc (5x). After removal of the solvent in vacuo, the analytically pure product of 
type 33 was obtained after flash column chromatography (silica gel, EtOAc + 5% NEt3). 
 
5.3 COMPOUNDS SYNTHESIZED ACCORDING TO THE GENERAL PROCEDURES 
 
Synthesis of 2-chloro-2'-methyl-3,3'-bipyridine (25a) according to (TP12): 
 
According to TP12, the substituted bipyridine 25a was synthesized from the Negishi cross-coupling of 
26a (1 mmol, preparation according to TP11) with 27a (0.9 equiv) in the presence of 2 mol% 
Pd(PPh3)4 at 50 °C for 1 h. Flash column chromatography (i-hexane/ethyl acetate 8:2 + 2% NEt3) 
furnished 25a as yellow oil (171 mg, 93%). 
 
1H NMR (400 MHz, CDCl3) /ppm: 2.33 (s, 3 H), 7.19 (dd, J=7.64, 4.90 Hz, 1 H), 7.31 (dd, J=7.50, 
4.81 Hz, 1 H), 7.43 (dd, J=7.70, 1.79 Hz, 1 H), 7.56 (dd, J=7.49, 1.97 Hz, 1 H), 8.41 (dd, J=4.80, 1.98 Hz, 
1 H), 8.53 (dd, J=4.89, 1.75 Hz, 1 H). 
13C NMR (101 MHz, CDCl3) /ppm: 23.0, 121.0, 122.6, 132.5, 135.0, 137.2, 139.6, 149.3 (2C), 150.4, 
156.3. 
MS (70 eV, EI) m/z (%): 206 (29), 204 (100), 169 (79), 168 (57), 167 (12). 
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IR ATR  (cm-1): 3046, 2956, 2924, 2856, 1732, 1568, 1556, 1432, 1392, 1190, 1162, 1126, 1096, 
1070, 1062, 1000, 802, 758, 752, 736, 722, 676. 
HRMS (EI) for C11H9ClN2 (204.0454) [M]
+: 204.0446. 
Synthesis of 2,5-dichloro-2'-methyl-3,3'-bipyridine (25b) according to (TP13): 
 
According to TP13, the substituted bipyridine 25b was synthesized from the Negishi cross-coupling of 
26b (1 mmol, preparation according to TP11) with 27a (0.9 equiv) in the presence of 2 mol% 
Pd(OAc)2 and 4 mol% SPhos at 50 °C for 5 h. Flash column chromatography (i-hexane/ethyl acetate 
9:1 + 2% NEt3) furnished 25b as yellow oil (86 mg, 40%). 
 
1H NMR (400 MHz, CDCl3) /ppm: 2.40 (s, 3 H), 7.24 (dd, J=7.70, 4.85 Hz, 1 H), 7.46 (dd, J=7.71, 
1.78 Hz, 1 H), 7.60 (d, J=2.58 Hz, 1 H), 8.42 (d, J=2.58 Hz, 1 H), 8.60 (dd, J=4.90, 1.76 Hz, 1 H). 
13C NMR (101 MHz, CDCl3) /ppm: 23.1, 121.1, 131.0, 131.4, 136.0, 137.2, 139.1, 148.0, 148.5, 149.8, 
156.2. 
MS (70 eV, EI) m/z (%): 240 (73), 238 (100), 203 (66), 168 (78), 57 (46). 
IR ATR  (cm-1): 3050, 2924, 2854, 1566, 1440, 1430, 1402, 1388, 1278, 1214, 1124, 1088, 1016, 912, 
822, 810, 744, 694, 678. 
HRMS (EI) for C11H8Cl2N2 (238.0065) [M]
+: 238.0065. 
 
Synthesis of 2',6-dichloro-2-methyl-3,3'-bipyridine (25c) according to (TP12): 
 
According to TP12, the substituted bipyridine 25c was synthesized from the Negishi cross-coupling of 
26a (1 mmol, preparation according to TP1) with 27b (0.9 equiv) in the presence of 2 mol% Pd(PPh3)4 
at 50 °C for 2 h. Flash column chromatography (i-hexane/ethyl acetate 8:2 + 2% NEt3) furnished 25c 
as yellow solid (147 mg, 68%). 
 
m.p.: 73.8 - 75.4 °C. 
1H NMR (400 MHz, CDCl3) /ppm: 2.36 (s, 3 H), 7.26 – 7.29 (m, 1 H), 7.37 (dd, J=7.52, 4.80 Hz, 1 H), 
7.44 (d, J=8.03 Hz, 1 H), 7.58 (dd, J=7.51, 1.97 Hz, 1 H), 8.49 (dd, J=4.83, 1.95 Hz, 1 H). 
13C NMR (101 MHz, CDCl3) /ppm: 22.8, 121.6, 122.7, 131.3, 133.9, 139.7, 140.0, 149.8, 150.5, 150.7, 
157.5. 
MS (70 eV, EI) m/z (%): 240 (45), 238 (67), 167 (50), 71 (44), 57 (70), 43 (100). 
IR ATR  (cm-1): 3066, 2924, 1556, 1398, 1384, 1150, 1126, 1090, 850, 810, 760, 752, 692. 
HRMS (EI) for C11H8Cl2N2 (238.0065) [M]
+: 238.0049. 
 
Synthesis of 2-chloro-2'-(chloromethyl)-3,3'-bipyridine (29a) according to (TP14): 
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According to TP14, the substituted chloromethyl-bipyridine 29a was synthesized from 25a (1 mmol) 
with trichloroisocyanuric acid (0.53 equiv) in the presence of benzamide (0.03 equiv) at reflux for 4 h. 
Flash column chromatography (i-hexane/ethyl acetate 8:2 + 2% NEt3) furnished 29a as yellow oil 
(194 mg, 81%). 
 
1H NMR (800 MHz, CDCl3) /ppm: 4.39 (d, J=11.34 Hz, 1 H), 4.59 (d, J=11.30 Hz, 1 H), 7.37 – 7.40 (m, 
2 H), 7.58 (dd, J=7.74, 1.74 Hz, 1 H), 7.74 (dd, J=7.47, 1.94 Hz, 1 H), 8.50 (dd, J=4.85, 1.95 Hz, 1 H), 
8.70 (dd, J=4.81, 1.73 Hz, 1 H). 
13C NMR (201 MHz, CDCl3) /ppm:  45.1, 122.6, 123.4, 133.0, 133.2, 138.5, 140.2, 150.0, 150.2, 
150.2, 154.2. 
MS (70 eV, EI) m/z (%): 240 (56), 238 (82), 203 (50), 168 (59), 167 (100), 140 (20), 43 (53). 
IR ATR  (cm-1): 3052, 2253, 1558, 1437, 1427, 1393, 1265, 1130, 1116, 1092, 999, 903, 802, 723. 
3050, 2924, 2854, 1566, 1440, 1430, 1402, 1388, 1214, 1124, 1088, 1016, 912, 822, 810, 790, 744, 
694, 678. 
HRMS (EI) for C11H8Cl2N2 (238.0065) [M]
+: 238.0058. 
 
Synthesis of 2,5-dichloro-2'-(chloromethyl)-3,3'-bipyridine (29b) according to (TP14): 
 
According to TP14, the substituted chloromethyl-bipyridine 29b was synthesized from 25b (1 mmol) 
with trichloroisocyanuric acid (0.53 equiv) in the presence of benzamide (0.03 equiv) at reflux for 
12 h. Flash column chromatography (i-hexane/ethyl acetate 9:1 + 2% NEt3) furnished 29b as yellow 
oil (213 mg, 78%). 
 
1H NMR (400 MHz, CDCl3) /ppm: 4.36 (d, J=11.31 Hz, 1 H), 4.55 (d, J=11.29 Hz, 1 H), 7.35 (dd, 
J=7.75, 4.79 Hz, 1 H), 7.54 (dd, J=7.73, 1.72 Hz, 1 H), 7.71 (d, J=2.62 Hz, 1 H), 8.40 (d, J=2.64 Hz, 1 H), 
8.66 (dd, J=4.78, 1.73 Hz, 1 H). 
13C NMR (101 MHz, CDCl3) /ppm: 44.9, 123.4, 130.9, 131.7, 134.0, 138.3, 139.5, 148.0, 148.4, 150.4, 
153.9. 
MS (70 eV, EI) m/z (%): 276 (23), 274 (62), 272 (63), 237 (38), 203 (45), 202 (83), 201 (83), 97 (31), 71 
(42), 57 (55), 43 (45), 43 (100). 
IR ATR  (cm-1): 3050, 2924, 2854, 1566, 1440, 1430, 1402, 1388, 1214, 1124, 1088, 1016, 912, 822, 
810, 790, 744, 694, 678. 
HRMS (EI) for C11H7Cl3N2 (271.9675) [M]
+: 271.9671.  
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Synthesis of 2',6-dichloro-2-(chloromethyl)-3,3'-bipyridine (29c) according to (TP15): 
 
According to TP15, the substituted (trimethylsilyl)methyl-derivative 30 was synthesized from 25c 
(1 mmol) after deprotonation with LDA (1.2 equiv), followed by trapping with TMSCl (1.3 equiv). The 
desired chloromethyl-bipyridine 29c was then obtained from the reaction of 30 with CsF (2 equiv) 
and C2Cl6 (2 equiv) at reflux for 3 h. Flash column chromatography (DCM) furnished 29c as beige 
powder (168 mg, 62% over these two steps). 
 
m.p.: 79.6 - 81.2 °C. 
1H NMR (400 MHz, CDCl3) /ppm: 4.29 (d, J=11.22 Hz, 1 H), 4.48 (d, J=11.20 Hz, 1 H), 7.36 – 7.40 (m, 
2 H), 7.54 (d, J=8.10 Hz, 1 H), 7.72 (dd, J=7.52, 1.92 Hz, 1 H), 8.47 (dd, J=4.79, 1.94 Hz, 1 H). 
13C NMR (101 MHz, CDCl3) /ppm: 44.2, 122.6, 124.3, 131.8, 131.9, 140.1, 141.2, 150.0, 150.2, 151.3, 
154.7. 
MS (70 eV, EI) m/z (%): 276 (29), 274 (52), 272 (60), 237 (36), 202 (47), 201 (100), 85 (21), 71 (35), 66 
(43), 57 (50), 44 (84). 
IR ATR  (cm-1): 3050, 2924, 1570, 1552, 1432, 1396, 1380, 1126, 1116, 1082, 812, 750, 710, 696. 
HRMS (EI) for C11H7Cl3N2 (271.9675) [M]
+: 271.9664. 
 
Synthesis of 2-((2'-chloro-[3,3'-bipyridin]-2-yl)methyl)isoindoline-1,3-dione (31a) according to 
(TP16): 
 
According to TP16, the substituted phthalimide derivative 31a was synthesized from 29a (1 mmol) 
with potassium phthalimide (1.2 equiv) at 100 °C for 2 h. Flash column chromatography  
(i-hexane/ethyl acetate 7:3 + 2% NEt3) furnished 31a as white solid (283 mg, 81%). 
 
m.p.: 166.9 - 168.9 °C. 
1H NMR (400 MHz, CDCl3) /ppm: 4.59 (d, J=15.87 Hz, 1 H), 5.02 (d, J=15.89 Hz, 1 H), 7.27 – 7.30 (m, 
1 H), 7.41 (dd, J=7.53, 4.79 Hz, 1 H), 7.52 (dd, J=7.70, 1.70 Hz, 1 H), 7.71 (dd, J=5.49, 3.05 Hz, 2 H), 
7.82 – 7.86 (m, 3 H), 8.50 (dd, J=4.78, 1.95 Hz, 1 H), 8.55 (dd, J=4.79, 1.70 Hz, 1 H). 
13C NMR (101 MHz, CDCl3) /ppm: 40.9, 122.4, 122.8, 123.5 (2C), 131.9, 132.4 (2C), 133.7, 134.1 (2C), 
137.7, 140.1, 149.9 (2C), 150.8, 152.6, 168.3 (2C). 
MS (70 eV, EI) m/z (%): 351 (10), 349 (28), 315 (20), 314 (100), 304 (11), 167 (36), 160 (17), 104 (12), 
77 (11), 76 (12). 
IR ATR  (cm-1): 3050, 2924, 2854, 1718, 1674, 1430, 1418, 1390, 1354, 1320, 1192, 1126, 1112, 
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1086, 1068, 1060, 998, 952, 942, 810, 798, 750, 736, 724, 710, 694, 684. 
HRMS (EI) for C19H12ClN3O2 (349.0618) [M]
+: 349.0613. 
 
Synthesis of 2-((2',5'-dichloro-[3,3'-bipyridin]-2-yl)methyl)isoindoline-1,3-dione (31b) according to 
(TP16): 
 
According to TP16, the substituted phthalimide derivative 31b was synthesized from 29b (1 mmol) 
with potassium phthalimide (1.2 equiv) at 100 °C for 2 h. Flash column chromatography  
(i-hexane/ethyl acetate 7:3 + 2% NEt3) furnished 31b as white solid (265 mg, 69%). 
 
m.p.: 151.2 - 153.7 °C. 
1H NMR (400 MHz, CDCl3) /ppm: 4.54 (d, J=15.85 Hz, 1 H), 4.94 (d, J=15.84 Hz, 1 H), 7.19 – 7.24 (m, 
1 H), 7.44 (dd, J=7.71, 1.71 Hz, 1 H), 7.63 – 7.66 (m, 2 H), 7.75 – 7.79 (m, 3 H), 8.37 (d, J=2.58 Hz, 1 H), 
8.50 (dd, J=4.83, 1.72 Hz, 1 H). 
13C NMR (101 MHz, CDCl3) /ppm: 41.0, 122.5 (2C), 123.5, 130.6, 131.2, 132.3 (2C), 134.1 (2C), 134.6, 
137.6, 139.5, 148.4, 148.6, 150.2, 152.6, 168.1 (2C). 
MS (70 eV, EI) m/z (%): 385 (11), 383 (17), 385 (11), 383 (17), 350 (33), 349 (21), 348 (100), 203 (12), 
201 (39), 160 (28), 104 (18), 77 (15), 76 (18). 
IR ATR  (cm-1): 3048, 1710, 1392, 1016, 734, 724, 714. 
HRMS (EI) for C19H11Cl2N3O2 (383.0228) [M]
+: 383.0212. 
 
Synthesis of 2-((2',6-dichloro-[3,3'-bipyridin]-2-yl)methyl)isoindoline-1,3-dione (31c) according to 
(TP16): 
 
According to TP16, the substituted phthalimide derivative 31c was synthesized from 29c (1 mmol) 
with potassium phthalimide (1.2 equiv) at 100 °C for 4 h. Flash column chromatography (i-
hexane/ethyl acetate 7:3 + 2% NEt3) furnished 31c as white solid (353 mg, 92%). 
 
m.p.: 186.1 - 189.4 °C. 
1H NMR (800 MHz, CDCl3) /ppm: 4.55 (d, J=16.08 Hz, 1 H), 4.96 (dd, J=16.09, 0.72 Hz, 1 H), 7.31 (d, 
J=8.00 Hz, 1 H), 7.39 (dd, J=7.50, 4.78 Hz, 1 H), 7.48 (d, J=7.99 Hz, 1 H), 7.72 (dd, J=5.49, 3.01 Hz, 2 H), 
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7.80 – 7.84 (m, 3 H), 8.48 (dd, J=4.78, 1.96 Hz, 1 H). 
13C NMR (201 MHz, CDCl3) /ppm: 40.8, 123.0, 123.5, 123.7 (2C), 130.8, 132.4 (2C), 132.7, 134.3 (2C), 
140.2, 140.6, 150.3, 150.8, 151.7, 153.7, 168.1 (2C). 
MS (70 eV, EI) m/z (%): 385 (12), 383 (17), 385 (12), 383 (17), 350 (31), 349 (20), 348 (100), 201 (37), 
160 (26), 104 (18), 77 (12), 76 (16). 
IR ATR  (cm-1): 2959, 2922, 2850, 1768, 1713, 1555, 1419, 1389, 1109, 1082, 995, 947, 812, 728, 
714, 698. 
HRMS (EI) for C19H11Cl2N3O2 (383.0228) [M]
+: 383.0217. 
 
Synthesis of pyrido[3,2- f][1,7]naphthyridine (23a) according to (TP17/18): 
 
According to TP17, the substituted phthalimide derivative 31a (1 mmol) reacted with NH2NH2·H2O 
(3 equiv) in EtOH at reflux for 2 h, leading to the dihydroazaphenanthrene 32a. After acidic work-up 
and neutralization, the crude intermediate 32a was aromatized with chloranil (1.2 equiv) at 25 °C for 
2 h, as specified in TP18. Flash column chromatography (EtOAc + 2% NEt3) furnished 23a as beige 
powder (155 mg, 86% over these two steps). 
 
m.p.: 230.1 - 232.3 °C. 
1H NMR (800 MHz, CDCl3) /ppm: 7.70 (dd, J=8.08, 4.29 Hz, 1 H), 7.84 (dd, J=8.33, 4.25 Hz, 1 H), 8.89 
– 8.93 (m, 2 H), 9.15 (dd, J=4.25, 1.56 Hz, 1 H), 9.18 (dd, J=4.26, 1.86 Hz, 1 H), 9.79 (s, 1 H). 
13C NMR (201 MHz, CDCl3) /ppm: 118.4, 123.1, 126.0, 128.4, 130.5, 132.0, 142.2, 152.1, 152.6, 
153.9, 158.9. 
MS (70 eV, EI) m/z (%): 182 (15), 181 (100), 180 (26), 97 (15), 85 (16), 83 (15), 71 (21), 57 (34), 43 
(79). 
IR ATR  (cm-1): 3054, 3006, 2922, 2852, 1744, 1602, 1572, 1440, 1370, 1350, 1316, 1160, 896, 786, 
746, 710. 
HRMS (EI) for C11H7N3 (181.0640) [M]
+: 181.0633. 
 
Synthesis of 2-chloropyrido[3,2- f][1,7]naphthyridine (23b) according to (TP17/18): 
 
According to TP17, the substituted phthalimide derivative 31b (1 mmol) reacted with NH2NH2·H2O 
(3 equiv) in EtOH at reflux for 2 h, leading to the dihydroazaphenanthrene 32b. After acidic work-up 
and neutralization, the crude intermediate 32b was aromatized with chloranil (1.2 equiv) at 25 °C for 
2 h, as specified in TP18. Flash column chromatography (EtOAc + 2% NEt3) furnished 23b as 
beige/light pink powder (161 mg, 75% over these two steps). 
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m.p.: decomposition starts at 276.3 °C. 
1H NMR (800 MHz, DMSO-d6) /ppm: 8.05 (dd, J=8.34, 4.26 Hz, 1 H), 9.13 (d, J=2.52 Hz, 1 H), 9.21 
(dd, J=4.26, 1.51 Hz, 1 H), 9.40 – 9.43 (m, 1 H), 9.54 (d, J=2.56 Hz, 1 H), 9.66 (d, J=0.80 Hz, 1 H). 
13C NMR (201 MHz, DMSO-d6) /ppm: 119.2, 126.6, 127.5, 129.8, 132.1, 132.3, 141.3, 150.6, 151.1, 
152.7, 158.1. 
MS (70 eV, EI) m/z (%): 217 (31), 216 (13), 215 (100), 180 (34), 153 (12). 
IR ATR  (cm-1): 3064, 2946, 2924, 2854, 1600, 1568, 1464, 1450, 1366, 1330, 1234, 1120, 948, 900, 
878, 826, 796, 742, 726.  
HRMS (EI) for C11H6ClN3 (215.0250) [M]
+: 215.0243. 
 
Synthesis of 8-chloropyrido[3,2-f][1,7]naphthyridine (23c) according to (TP17/18): 
 
According to TP17, the substituted phthalimide derivative 31c (1 mmol) reacted with NH2NH2·H2O 
(3 equiv) in EtOH at reflux for 2 h, leading to the dihydroazaphenanthrene 32c. After acidic work-up 
and neutralization, the crude intermediate 32c was aromatized with chloranil (1.2 equiv) at 25 °C for 
2 h, as specified in TP18. Flash column chromatography (EtOAc + 2% NEt3) furnished 23c as beige 
solid (191 mg, 89% over these two steps). 
 
m.p.: decomposition starts at 226.8 °C. 
1H NMR (800 MHz, DMSO-d6) /ppm: 7.87 (dd, J=8.11, 4.26 Hz, 1 H), 8.13 (d, J=8.64 Hz, 1 H), 9.15 
(dd, J=4.28, 1.80 Hz, 1 H), 9.34 (dd, J=8.21, 1.82 Hz, 1 H), 9.39 – 9.43 (m, 1 H), 9.58 (d, J=0.76 Hz, 1 H). 
13C NMR (201 MHz, DMSO-d6) /ppm: 117.8, 123.6, 127.4, 127.6, 133.6, 135.8, 141.0, 151.9, 152.7, 
152.9, 156.3. 
MS (70 eV, EI) m/z (%): 217 (36), 215 (100), 180 (39), 153 (11), 84 (54), 66 (56), 46 (13). 
IR ATR  (cm-1): 3483, 2249, 2124, 1997, 1622, 1438, 1222, 1053, 1024, 1005, 820, 757. 
HRMS (EI) for C11H6ClN3 (215.0250) [M]
+: 215.0242. 
 
Synthesis of 6-phenylpyrido[3,2-f][1,7]naphthyridine (33a) according to (TP19/20): 
 
According to TP20, the substituted azaphenanthrene derivative 33a was synthesized from 23a 
(0.1 mmol) with the organolithium reagent 34a (0.52 M in diethyl ether, 1.5 equiv, TP19) at -60 °C for 
30 min in THF, followed by chloranil-mediated aromatization in DMF overnight. Flash column 
chromatography (EtOAc + 5% NEt3) furnished 33a as colorless solid (24 mg, 93%). 
 
m.p.: 217 - 218 °C. 
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1H NMR (400 MHz, CDCl3) /ppm: 7.48 - 7.59 (m, 3 H), 7.64 (dd, J=8.2, 4.4 Hz, 1 H), 7.80 (dd, J=8.4, 
4.3 Hz, 1 H), 8.30 (dd, J=7.7, 1.8 Hz, 2 H), 8.87 (dd, J=8.2, 1.8 Hz, 1 H), 8.94 (dd, J=8.4, 1.6 Hz, 1 H), 
9.13 - 9.16 (m, 2 H). 
13C NMR (100 MHz, CDCl3) /ppm: 118.1, 122.4, 125.2, 127.9 (2C), 129.2, 129.8, 130.6, 131.4, 131.8 
(2C), 138.1, 141.1, 150.9, 152.6, 153.1, 164.0. 
MS (70 eV, EI) m/z (%): 258 (25), 257 (100), 129 (10), 84 (12). 
IR ATR  (cm-1): 3060, 2927, 2360, 2231, 1712, 1556, 1514, 1452, 1434, 1356, 1260, 905, 793, 710, 
693, 686. 
HRMS (EI) for C17H11N3 (257.0953) [M]
+: 257.0950 
 
Synthesis of 6-(4-methoxyphenyl)pyrido[3,2-f][1,7]naphthyridine (33b) according to (TP19/20): 
 
According to TP20, the substituted azaphenanthrene derivative 33b was synthesized from 23a 
(0.1 mmol) with the organolithium reagent 34b (0.50 M, 1.5 equiv, TP19) at -60 °C for 30 min in THF, 
followed by chloranil-mediated aromatization in DMF overnight. Flash column chromatography 
(EtOAc + 5% NEt3) furnished 33b as colorless solid (25 mg, 87%). 
 
m.p.: 156 - 157 °C. 
1H NMR (400 MHz, CDCl3) /ppm: 3.91 (s, 3 H), 7.07 - 7.10 (m, 2 H), 7.63 (dd, J=8.1, 4.4 Hz, 1 H), 7.81 
(dd, J=8.4, 4.3 Hz, 1 H), 8.34 - 8.45 (m, 2 H), 8.86 (dd, J=8.2, 1.7 Hz, 1 H), 8.94 (dd, J=8.5, 1.5 Hz, 1 H), 
9.10 - 9.21 (m, 2 H). 
13C NMR (100 MHz, CDCl3) /ppm: 55.5, 113.5, 117.9, 122.1, 125.1, 129.3, 130.6 (2C), 130.7, 131.3, 
133.6 (2C), 141.2, 150.8, 152.5, 153.2, 161.3, 163.2. 
MS (70 eV, EI) m/z (%): 288 (18), 287 (92), 273 (17), 272 (100), 256 (13), 244 (30), 243 (17), 122 (10). 
IR ATR  (cm-1): 2956, 2927, 1605, 1574, 1552, 1449, 1436, 1354, 1299, 1213, 1175, 1030, 968, 833, 
789, 712. 
HRMS (EI) for C18H13N3O (287.1059) [M]
+: 287.1054. 
 
Synthesis of 6-(4-(trifluoromethyl)phenyl)pyrido[3,2-f][1,7]naphthyridine (33c) according to 
(TP19/20): 
 
According to TP20, the substituted azaphenanthrene derivative 33c was synthesized from 23a 
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(0.1 mmol) with the organolithium reagent 34c (0.65 M, 1.5 equiv, TP19) at -60 °C for 30 min in THF, 
followed by chloranil-mediated aromatization in DMF overnight. Flash column chromatography 
(EtOAc + 5% NEt3) furnished 33c as colorless solid (22 mg, 68%). 
 
m.p.: 224 °C 
1H NMR (800 MHz, CDCl3) /ppm: 7.72 (dd, J=8.1, 4.3 Hz, 1 H), 7.82 (d, J=8.0 Hz, 2 H), 7.87 (dd, J=8.3, 
4.2 Hz, 1 H), 8.43 (d, J=8.0 Hz, 2 H), 8.94 (dd, J=8.2, 1.8 Hz, 1 H), 9.01 (dd, J=8.4, 1.6 Hz, 1 H), 9.17 (dd, 
J=4.2, 1.6 Hz, 1 H), 9.20 (dd, J=4.3, 1.8 Hz, 1 H). 
13C NMR (200 MHz, CDCl3) /ppm: 118.4, 123.0, 123.7, 124.9, 125.6, 129.4, 130.8, 131.4, 131.5, 
132.1 (4C), 140.9, 141.4, 151.1, 152.9, 162.6. 
MS (70 eV, EI) m/z (%): 326 (17), 325 (100), 325 (57). 
IR ATR  (cm-1): 2924, 2854, 2360, 2340, 1737, 1714, 1597, 1565, 1453, 1442, 1322, 1259, 1207, 
1155, 1119, 1066, 959, 784, 775, 712. 
HRMS (EI) for C18H10N3F3 (325.0827): [M]
+: 325.0821. 
 
Synthesis of 6-(3-fluorophenyl)pyrido[3,2-f][1,7]naphthyridine (33d) according to (TP19/20): 
 
According to TP20, the substituted azaphenanthrene derivative 33d was synthesized from 23a 
(0.1 mmol) with the organolithium reagent 34d (0.91 M, 1.5 equiv, TP19) at -60 °C for 30 min in THF, 
followed by chloranil-mediated aromatization in DMF overnight. Flash column chromatography 
(EtOAc + 5% NEt3) furnished 33d as colorless solid (17 mg, 62%). 
 
m.p.: 237 - 238 °C. 
1H NMR (400 MHz, CDCl3) /ppm: 7.19 - 7.25 (m, 1 H), 7.48 - 7.56 (m, 1 H), 7.68 (dd, J=8.2, 4.4 Hz, 
1 H), 7.84 (dd, J=8.4, 4.3 Hz, 1 H), 8.07 - 8.11 (m, 1 H), 8.12 - 8.16 (m, 1 H), 8.90 (dd, J=8.2, 1.8 Hz, 1 
H), 8.97 (dd, J=8.5, 1.7 Hz, 1 H), 9.11-9.22 (m, 2 H).  
13C NMR (100 MHz, CDCl3) /ppm: 116.6, 116.8, 118.3, 118.8, 119.0, 122.8, 125.4, 127.6, 129.3, 
129.4, 130.7, 131.4, 151.0, 152.8, 161.3, 162.4, 163.7. 
MS (70 eV, EI) m/z (%): 276 (14), 275 (100), 274 (75). 
IR ATR  (cm-1): 2956, 2927, 2857, 1738, 1729, 1596, 1568, 1450, 1442, 1358, 1261, 1059, 791, 712. 
HRMS (EI) for C17H10FN3 (275.0859): [M]
+: 275.0852. 
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Synthesis of 6-(furan-2-yl)pyrido[3,2-f][1,7]naphthyridine (33e) according to (TP19/20): 
 
According to TP20, the substituted azaphenanthrene derivative 33e was synthesized from 23a 
(0.1 mmol) with the organolithium reagent 34e (0.52 M, 1.5 equiv, TP19) at -60 °C for 30 min in THF, 
followed by chloranil-mediated aromatization in DMF overnight. Flash column chromatography 
(EtOAc + 5% NEt3) furnished 33e as colorless solid (20 mg, 80%). 
 
m.p.: 228 °C. 
1H NMR (600 MHz, CDCl3) /ppm: 6.68 (dd, J=3.4, 1.7 Hz, 1 H), 7.59 (dd, J=8.1, 4.3 Hz, 1 H), 7.76 - 
7.84 (m, 2 H), 8.33 (dd, J=3.4, 0.7 Hz, 1 H), 8.79 (dd, J=8.1, 1.8 Hz, 1 H), 8.89 (dd, J=8.4, 1.6 Hz, 1 H), 
9.12 (dd, J=4.3, 1.8 Hz, 1 H), 9.15 (dd, J=4.2, 1.6 Hz, 1 H). 
13C NMR (150 MHz, CDCl3) /ppm: 112.5, 117.6, 120.5, 122.1, 125.4, 128.9, 130.6, 131.1, 139.9, 
145.7, 150.8, 150.8, 152.0, 152.7, 153.2. 
MS (70 eV, EI) m/z (%): 248 (24), 247 (100), 246 (12), 220 (10), 219 (36), 218 (21), 191 (11), 44 (24), 
43 (17). 
IR ATR  (cm-1): 2956, 2943, 2858, 1737, 1729, 1671, 1601, 1569, 1519, 1450, 1442, 1359, 1261, 
1058, 792, 712. 
HRMS (EI) for C15H9N3O (247.0746): [M]
+: 247.0745. 
 
Synthesis of 6-(thiophen-2-yl)pyrido[3,2-f][1,7]naphthyridine (33f) according to (TP19/20): 
 
According to TP20, the substituted azaphenanthrene derivative 33f was synthesized from 23a 
(0.1 mmol) with the organolithium reagent 34f (0.64 M, 1.5 equiv, TP19) at -60 °C for 30 min in THF, 
followed by chloranil-mediated aromatization in DMF overnight. Flash column chromatography 
(EtOAc + 5% NEt3) furnished 33f as white solid (12 mg, 46%). 
 
m.p.: 221 - 223 °C. 
1H NMR (600 MHz, CDCl3) /ppm: 7.26 -7.28 (m, 1 H), 7.60 (dd, J=8.1, 4.3 Hz, 1 H), 7.68 (dd, J=5.0, 
1.1 Hz, 1 H), 7.84 (dd, J=8.4, 4.2 Hz, 1 H), 8.82 (dd, J=8.1, 1.8 Hz, 1 H), 8.92 (dd, J=8.4, 1.6 Hz, 1 H), 
8.96 - 9.00 (m, 1 H), 9.13 (dd, J=4.2, 1.6 Hz, 1 H), 9.20 (dd, J=4.2, 1.6 Hz, 1 H). 
13C NMR (150 MHz, CDCl3) /ppm: 117.8, 121.9, 125.5, 127.7, 128.9, 130.7, 131.3, 133.1, 133.7, 
140.0, 140.7, 150.3, 152.8, 153.2, 156.5. 
MS (70 eV, EI) m/z (%):264 (18), 263 (100), 262 (61). 
IR ATR  (cm-1): 2924, 2853, 1569, 1551, 1506, 1447, 1360, 1223, 1042, 848, 786, 714, 673. 
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HRMS (EI) for C15H9N3S (263.0517): [M]
+: 263.0512. 
 
Synthesis of 6-(benzofuran-2-yl)pyrido[3,2-f][1,7]naphthyridine (33g) according to (TP19/20): 
 
According to TP20, the substituted azaphenanthrene derivative 33g was synthesized from 23a 
(0.1 mmol) with the organolithium reagent 34g (0.64 M, 1.5 equiv, TP19) at -60 °C for 30 min in THF, 
followed by chloranil-mediated aromatization in DMF overnight. Flash column chromatography 
(EtOAc + 5% NEt3) furnished 33g as colorless solid (10 mg, 34%). 
 
m.p.: 219 - 223 °C. 
1H NMR (600 MHz, CDCl3) /ppm: 7.30 (ddd, J=7.8, 7.2, 0.9 Hz, 1 H), 7.43 (ddd, J=8.3, 7.2, 1.3 Hz, 1 
H), 7.66 (dd, J=8.1, 4.3 Hz, 1 H), 7.74 (d, J=8.3 Hz, 1 H), 7.78 (d, J=7.7 Hz, 1 H), 7.88 (dd, J=8.4, 4.2 Hz, 
1 H), 8.78 - 8.83 (m, 1 H), 8.86 (dd, J=8.2, 1.8 Hz, 1 H), 8.96 (dd, J=8.4, 1.6 Hz, 1 H), 9.19 (dd, J=4.3, 1.8 
Hz, 1 H), 9.23 (dd, J=4.2, 1.7 Hz, 1 H). 
13C NMR (150 MHz, CDCl3) /ppm: 112.5, 116.7, 118.0, 122.6, 122.7, 123.2, 125.5, 126.8, 129.0, 
129.2, 130.8, 131.2, 140.5, 150.9, 151.9, 152.3, 152.9, 155.7. 
MS (70 eV, EI) m/z (%):298 (21), 297 (100), 296 (28), 269 (10), 268 (11). 
IR ATR  (cm-1): 2923, 2853, 1595, 1561, 1513, 1462, 1449, 1364, 1343, 1261, 1166, 983, 789, 751, 
694. 
HRMS (EI) for C19H11N3O (297.0902): [M]
+: 297.0898. 
 
Synthesis of 6-(benzo[b]thiophen-2-yl)pyrido[3,2-f][1,7]naphthyridine (33h) according to 
(TP19/20): 
 
According to TP20, the substituted azaphenanthrene derivative 33h was synthesized from 23a 
(0.1 mmol) with the organolithium reagent 34h (0.78 M, 1.5 equiv, TP19) at -60 °C for 30 min in THF, 
followed by chloranil-mediated aromatization in DMF overnight. Flash column chromatography 
(EtOAc + 5% NEt3) furnished 33h as colorless solid (16 mg, 51%). 
 
m.p.: 215 - 216 °C. 
1H NMR (600 MHz, CDCl3) /ppm: 7.35 - 7.45 (m, 2 H), 7.60 (dd, J=8.0, 4.3 Hz, 1 H), 7.82 (dd, J=8.3, 
4.2 Hz, 1 H), 7.95 (t, J=8.6 Hz, 2 H), 8.80 (dd, J=8.1, 1.7 Hz, 1 H), 8.89 (dd, J=8.3, 1.5 Hz, 1 H), 9.14 (dd, 
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J=4.1, 1.6 Hz, 1 H), 9.20 (dd, J=4.1, 1.4 Hz, 1 H), 9.32 (s, 1 H).  
13C NMR (150 MHz, CDCl3) /ppm: 118.1, 122.3, 122.4, 124.4, 125.4, 125.5, 126.0, 128.9, 130.7, 
131.3 (2C), 140.2, 140.5, 141.5, 143.6, 150.4, 152.9 (2C), 156.4. 
MS (70 eV, EI) m/z (%): 314 (26), 313 (100), 312 (53), 156 (15). 
IR ATR  (cm-1): 3056, 2925, 2856, 1711, 1594, 1552, 1564, 1552, 1519, 1456, 1445, 1357, 1342, 
1260, 1207, 1172, 1154, 954, 784, 775, 728, 712, 687. 
HRMS (EI) for C19H11N3S (313.0674): [M]
+: 313.0666. 
 
Synthesis of 1-(pyrido[3,2-f][1,7]naphthyridin-6-yl)ethanone (33i) according to (TP19/20): 
 
According to TP20, the substituted azaphenanthrene derivative 33i was synthesized from 23a 
(0.1 mmol) with the organolithium reagent 34i (0.91 M, 1.5 equiv, TP19) at -60 °C for 30 min in THF, 
followed by chloranil-mediated aromatization in DMF overnight. After aqueous workup and 
extraction with EtOAc, all solvents were removed in vacuo. The crude was then re-dissolved in 2 mL 
of a mixture of methanol and 2 M aq. HCl (40:1, 0.05 N) and stirred at room temperature overnight. 
After aqueous workup, the crude was extracted with EtOAc and flash column chromatography 
(EtOAc + 5% NEt3) furnished 33i as colorless solid (20 mg, 90%). 
 
m.p.: 147 °C. 
1H NMR (800 MHz, CDCl3) /ppm: 2.94 (s, 3 H), 7.75 (dd, J=8.1, 4.3 Hz, 1 H), 7.85 (dd, J=8.4, 4.2 Hz, 
1 H), 8.91 (dd, J=8.2, 1.7 Hz, 1 H), 8.94 (dd, J=8.4, 1.4 Hz, 1 H), 9.16 (dd, J=4.2, 1.5 Hz, 1 H), 9.20 (dd, 
J=4.1, 1.5 Hz, 1 H). 
13C NMR (200 MHz, CDCl3) /ppm: 30.0, 119.2, 123.7, 126.1, 129.3, 130.6, 131.7, 139.3, 151.9, 152.2, 
153.0, 162.2, 201.7. 
MS (70 eV, EI) m/z (%): 224 (15), 223 (100), 195 (30), 181 (26), 180 (80), 154 (14), 153 (18), 126 (18), 
43 (16). 
IR ATR  (cm-1): 2928, 2360, 2338, 1714, 1601, 1567, 1455, 1442, 1378, 1346, 1264, 1210, 1152(w), 
904, 789, 700. 
HRMS (EI) for C13H9N3O (223.0746): [M]
+: 223.0740. 
 
Synthesis of 6-butylpyrido[3,2-f][1,7]naphthyridine (33j) according to (TP19/20): 
 
According to TP20, the substituted azaphenanthrene derivative 33j was synthesized from 23a 
(0.1 mmol) with the organolithium reagent 34j (2.43 M, 1.5 equiv, TP19) at -60 °C for 30 min in THF, 
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followed by chloranil-mediated aromatization in DMF overnight. Flash column chromatography 
(EtOAc + 5% NEt3) furnished 33j as colorless solid (18 mg, 76%). 
 
m.p.: 131 °C. 
1H NMR (600 MHz, CDCl3) /ppm: 1.01 (t, J=7.4 Hz, 3 H), 1.59 – 1.53 (m, 2 H), 2.00 - 2.07 (m, 2 H), 
3.64 - 3.69 (m, 2 H), 7.60 (dd, J=8.1, 4.4 Hz, 1 H), 7.79 (dd, J=8.3, 4.3 Hz, 1 H), 8.83 (ddd, J=8.4, 1.6, 
0.2 Hz, 1 H), 8.88 (ddd, J=8.3, 1.6, 0.3 Hz, 1 H), 9.10 (dd, J=4.4, 1.8 Hz, 1 H), 9.12 (dd, J=4.3, 1.6 Hz, 1 
H). 
13C NMR (150 MHz, CDCl3) /ppm: 14.3, 23.2, 30.9, 34.6, 117.7, 122.0, 125.4, 127.9, 130.5, 131.4, 
141.4, 150.7, 152.1, 153.2, 169.7. 
MS (70 eV, EI) m/z (%): 237 (45), 211 (15), 210 (23), 209 (20), 208 (100), 207 (42), 206 (17), 196 (53), 
195 (20), 194 (25), 182 (27), 181 (26), 180 (25), 155 (12), 71 (13), 57 (21), 43 (13). 
IR ATR  (cm-1): 2956, 2943, 2858, 1737, 1729, 1671, 1601, 1569, 1519, 1450(s), 1442, 1359, 1261, 
1058, 792, 712. 
HRMS (EI) for C15H15N3 (237.1266): [M]
+: 237.1274. 
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